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Abstract 
Amyotrophic Lateral Sclerosis is the most common type of motor neuron disease, 
characterized by progressive degeneration of the upper and lower motor neurons. 
Sufferers present with symptoms of muscle weakness and this quickly develops on to 
paralysis and finally death due to respiratory failure within 5 years of disease onset.  
Although the majority of cases are sporadic, about 10% are familial and it is hoped that 
through the investigation of these few cases a greater understanding of the disease 
process, the reasons for its delayed onset and vulnerability of motor neurons will be 
achieved.  Recently a novel mutation linked to ALS was discovered in an evolutionary 
conserved protein named Vesicle associated membrane protein (VAMP) associated 
protein B (VAPB).  VAPB is an integral type II membrane protein localised at the 
Endoplasmic Reticulum and thought to have a role in protein transport.  The orthologue 
in Drosophila has been shown to be involved in the homeostatic regulation of bouton 
formation at the Neuromuscular Junction through an association with the microtubule 
network. To elucidate the mechanism through which this protein causes ALS, Pennetta 
et al have created a Drosophila model of the disease by expressing the mutated 
orthologue in the fly.   To complement this model, I have undertaken a number of 
biochemical experiments to look for potential interactors of the VAP proteins.  The yeast 
two hybrid system utilises the yeast GAL4 transcriptional activator to indicate a protein 
interaction within a yeast cell and can be used to test a cDNA library for interactors.  
Through this technique a number of interesting binding partners have been found that 
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1.1  Neurodegenerative disease 
 
Neurodegeneration is a feature of many devastating diseases and not surprisingly much 
time and research has been spent trying to elucidate the underlying pathomechanisms.  
Unfortunately however, although some major progress has been made there is still little 
known about the pathogenesis of many degenerative diseases.  In particular, there is no 
solid understanding of why only certain subsets of neurons are vulnerable in the various 
diseases, for example, motor neurons in motor neuron disease (MND) and the 
dopaminergic neurons of the substantia nigra in Parkinson’s disease (Bonini and Fortini 
2003; Bruijn et al. 2004) .  There is also much debate as to whether malfunction and 
degeneration of the cell body, axon or synapse is the primary pathological event (Pun et 
al. 2006).  The focus of the work in the Pennetta lab addresses the motor neuron disease 
Amyotrophic Lateral Sclerosis (ALS).  We use Drosophila melanogaster as a model 
system for this disease and harness its genetic potential as a tool to examine the 
contribution of various cellular mechanisms to the onset and progression of disease.  
Synaptic homeostasis and dysfunction, mRNA regulation, transcriptional regulation, 
chaperone and stress pathways, and the proteosome pathway have all been implicated in 
disease and are all vital areas of investigation.  
 
1.2  Bigger is not always better when modeling disease 
 
Drosophila has many advantages over larger model organisms as although it has a 
relatively simple structure, many of the basic components are very similar including 
mechanisms and molecular pathways involved in human disease (St Johnston 2002; 
Bonini and Fortini 2003).  The same is true for other simple organisms including the 
yeast Saccharomyces cerevisiae which has also been used to investigate a number of key 
aspects of disease including Huntington’s Disease (HD) and Parkinson’s Disease (PD).  
A major hallmark of many degenerative diseases is the presence of protein aggregates 
and the cellular response to mis-folded proteins is largely conserved from yeast to man.  
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Outeiro et al (2003) created a fusion protein of the green flurescent protein (GFP) with 
α-synuclein; a protein linked to familial PD and found in the cytoplasmic inclusions 
(Lewy bodies) that are a hallmark of disease.  By doubling the expression of α-synuclein 
in the cell, the protein was observed to relocate away from the plasma membranes and 
form cytoplasmic inclusions and the growth of yeast expressing this fusion protein was 
inhibited (Outeiro and Lindquist 2003). By expressing 5000 individual genes in 
combination with α-synuclein, Gitler et al (2008) screened for genes that modified the 
toxic properties of α-synuclein leading to the discovery of Ypt1p (Gitler 2008).  When 
over-expressed in combination with α-synuclein, Ypt1p allowed a more robust growth of 
yeast and as such was proposed to suppress the toxicity of α-synuclein.  When the 
mammalian orthologue Rab1 was tested in a range of neuronal models including 
Drosophila and C. elegans, a suppression of dopaminergic degeneration was seen, 
adding validity to the original screen in yeast (Cooper et al. 2006; Gitler et al. 2008).  
Screens such as those described here by Gitler et al (2008) are a good example of 
how the simple yeast cell can be a powerful tool for carrying out large scale screens for 
potential therapeutic targets and genetic modifiers of disease. This is further shown in a 
screen for HD, a disease caused by the expansion of a CAG repeat in the gene IT-15 
which encodes huntingtin. (Muchowski et al. 2002; Willingham et al. 2003)  Expression 
of the expanded IT-15 in yeast cells caused an accumulation of the expanded huntingtin 
protein (HD53Q) and the formation of aggregates but with no effect on viability.  A 
screen was thus carried out to find non-lethal gene mutations that when combined with 
huntingtin, enhanced the phenotype so that the combination was toxic to the cells. 
Mutations in chaperone proteins and other genes involved in the cellular stress response 
were found to increase the toxicity of HD53Q (Willingham et al. 2003).  This provides a 
direction for the focus of research in larger more complex systems.   
No system can be perfect for modeling disease and the major drawback of the 
yeast cell is that it is a single celled organism so research into the more complex aspects 
of disease such as why it only affects subsets of neurons is not possible.  Perhaps the 
next step is to use cell culture as a model.  Here it can be possible to grow the specific 
cells affected by disease e.g. motor neurons, in a carefully controlled environment.  The 
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effect of a number of variables can be tested on the cells and observed more easily than 
in the dissection of an organism that would be necessary in vivo.   Cell culture has been 
vitally important in modeling disease and particularly relevant are the studies carried out 
to investigate the affect of mutant SOD1 expression in astrocytes (Julien 2007). 
Mutations in the super oxide dismutase 1 gene (SOD1) are causative for about 20% of 
all familial cases of Amyotrophic Lateral Sclerosis (ALS). Chimeric mice expressing 
mutant SOD1 in some but not all cells were found to exhibit motor neuron degeneration.  
Interestingly, a number of the affected and degenerating motor neurons were not 
themselves expressing mutant SOD1 (Clement et al. 2003).  Cell culture is a good 
technique to further explore the link between SOD1 expression and neuronal 
degeneration.  Different cell types either expressing mutant or wildtype (wt) SOD1 can 
be co-cultured and the results carefully monitered at all time points.  By having better 
control of the conditions and the types of neuronal cells present, cell culture offers 
advantages that no in vivo system can. Nagai et al (2007) found that mutant SOD1 
expressing neurons grown alongside astrocytes expressing mutant SOD1 were 
degenerating faster than those surrounded by wt astrocytes or even other types of cells 
whether or not they expressed mutant SOD1.  They also found that conditioned media 
derived from mutant astroctyes could affect the survival of motor neurons which 
supported the idea of a soluble factor being released from the astrocytes (Nagai et al. 
2007).    
Cell culture may be a good way to dissect individual pathways but to model a 
disease and look at the way a mutated gene or protein acts in a system, with the 
associated stochastic changes and variables, in vivo is the only way.    For a system that 
has many genetic tools available and a fully characterized genome, Drosophila 




1.3  Modeling disease in Drosophila melanogaster 
 
More than 50% of human genes are believed to have a Drosophila homologue with 
some entire pathways being conserved and as many as 75% of disease causing genes are 
believed to be conserved (Fortini et al. 2000; Rubin et al. 2000; Bonini and Fortini 
2003).  The similarity in phenotype between humans and flies expressing a disease 
mutation is evidence of the conservation of the underlying disease pathways. The short 
lifespan of Drosophila means that a new generation can be produced every two weeks 
and flies require a simple diet and few essential requirements so they can be kept 
comparatively cheaply.  Mutants can be easily generated through chemical mutagenesis 
e.g. Ethyl methanesulphonate, or P-element insertional mutagenesis (the disruption of a 
gene by the insertion of a transposable element into the genome). For the ease and 
benefit of the majority of the Drosophila community, stocks of flies carrying carefully 
mapped gene mutations and transposon insertions are readily available to order from 
stock centres.  Finally, it is easy to feed flies pharmacological agents by mixing them 
with the food as larvae are not fussy eaters.      
During the last century, not only has Drosophila become an increasingly 
important tool for genetic studies, in recent years it has also become a very useful model 
for studying neurodegenerative diseases (St Johnston 2002; Driscoll and Gerstbrein 
2003).  A large number of the disease genes in humans have been evolutionary 
conserved and homologues for the majority of human genes can be found in Drosophila 
(Bonini 2001; Bonini and Fortini 2003).  Through the mutation of an endogenous 
homologue or the transgenic expression of the human gene, models have already been 
created for many diseases including Polyglutamine Disease, Parkinson’s Disease and 
Alzheimer’s Disease (AD) (Bonini and Fortini 2003; Driscoll and Gerstbrein 2003; 
O'Kane 2003).  Expression of genes in the fly can be controlled by the utilization of the 




1.4 Drosophila and the GAL4 system 
 
The yeast (Saccharomyces cerevisiae) GAL4 transcription factor binds to a specific 
Upstream Activating Sequence (UAS) to promote the transcription of genes under its 
control (Brand and Perrimon 1993).  In 1993, Brand and Perrimon described the use of 
this method in Drosophila to spatially and temporally target the expression of a gene.  
The approach is bipartite, two separate parental lines express either the GAL4 in a 
particular spatial pattern (driver) or they have the gene of interest under control of a 
UAS (responder), see Figure 1.1.  When the two constructs are separate, the gene is 
silent and the two stocks are phenotypically normal.  When flies are crossed between the 
two lines the offspring will have the UAS-gene x and will produce GAL4 in a tissue and 
time of interest.  This will bring about the expression of gene x but only in the pattern 
dictated by the expression of GAL4 (Brand and Perrimon 1993; Duffy 2002). Driver 
lines are available with a wide array of expression patterns, including ones expressing 
only in motor neurons, those that are pan neural and a number that express only in the 
eye.   
 
 
Figure 1.1: The GAL/UAS system.   
A male carrying the GAL4 driver is crossed with a female carrying the UAS responder (UAS-
gene x).  The resulting progeny contain both elements and express gene x in the pattern dictated 
by the expression of GAL4  
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GAL4 is temperature sensitive and by simply altering the temperature in which 
the flies are raised, a variety of expression levels for the UAS-gene can be achieved.  
This can be particularly useful if low levels of protein expression are necessary to 
overcome an early developmental stage after which a higher expression level can be 
sustained.  Flies are raised at 29oC to ensure optimum GAL4 activity while maintaining 
fly viability.  Since the discovery of the GAL4/UAS system, modifications to further 
optimize the transcription of a gene both temporally and spatially have been created.  
These tend to be tripartite approaches and one such method is the use of hormone 
responsive GAL4 chimeras. By putting GAL4 activity under the control of progesterone 
or estrogen, the ability of GAL4 to induce the expression of the responder is more 
accurately controlled at a temporal level by the exposure of the GAL4-UAS progeny to 
the hormone (Duffy 2002).   
Examining genes linked to degeneration would prove far more difficult if it 
wasn’t possible to limit the expression pattern within the fly as causing widespread 
degeneration may simply lead to premature death before any informative research can be 
carried out.  It is possible to create mosaics in which only certain cells are affected and 
thereby the fly is able to survive whilst still providing insight into the deleterious effects 
of the gene in the affected cells. However, a simpler and more common option in the 
modeling of disease is to drive expression solely in the adult eye. 
 
1.5 Modeling disease in the eye 
 
The insect eye is a complex but uniform structure which has been well characterized 
allowing any modifications to be easily measured and recorded. More importantly it is 
not essential to the survival of the fly so degeneration of the eye can be followed over a 
period of time, important when studying age-dependent diseases.  The compound eye is 
composed of roughly 800 ommatidia and degeneration of a number of these produces a 
rough eye phenotype of varying severity (Bonini and Fortini 2003).  The beauty of the 
GAL4/UAS system in flies allows the spatial expression of genes to be restricted to just 
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the eye and as such the degenerative phenotype of any gene can be looked at solely in 
this organ.  In addition to this, modifier screens can be carried out to examine genes that 
affect a rough eye phenotype in an enhancing or suppressing fashion.  
 Spinocerebellar Ataxia 8 (SCA8) is a triplet expansion-induced 
neurodegeneration which is unique in that the expansion occurs within an entirely non-
coding transcript.  A model of the disease was produced by expressing the human SCA8 
non-coding RNA in the fly eye under the control of the glass multiple reporter (gmr)-
GAL4 driver and the result was a rough eye phenotype with disorganized ommatidia and 
mechano-sensory bristles of the eye (Mutsuddi et al. 2004).  Once this eye phenotype 
was characterized the next step was to look for enhancers or suppressors of the 
phenotype and this was done by crossing these lines with fly stocks containing 
characterized P-element insertions known to disrupt particular genes.  This technique is 
called an enhancer-suppressor screen and the idea is to use a particular phenotype, such 
as a rough eye, to screen for genetic interactors that influence this phenotype. 
Suppression is seen when there is a decrease in the severity of the rough eye or a 
complete reversion to wild type.  An enhancement is an increased severity, greater 
roughness and often a decrease in eye size.  Such a suppression or enhancement suggests 
that the disruption of a particular gene is somehow affecting the phenotype brought 
about by the mutant gene x, or in this case non-coding RNA.  It indicates that there is a 
genetic interaction between the two genes; either they act in the same pathway or in a 
parallel process.  It does not mean that they directly interact physically although that 
may be the case.   The rough eye is an ideal phenotype to easily screen thousands of flies 
making it possible to check for a large number of genetic interactors very quickly.  To 
increase the speed of a screen, there are P-element insertion lines that disrupt one or only 
a few genes at once so a number of genes can be screened for a possible interaction and 
then, if there is a change in the phenotype, the specific gene can be narrowed down by 
obtaining smaller insertions for the chromosomal region.  Such a screen is a good 
compliment to biochemical approaches looking at direct protein interactions. 
Various other triplet repeat expansion induced neurodegenerative diseases have 
been modeled in Drosophila and again the eye has proven to be an ideal organ in which 
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to focus the expression of the disease protein.  In an effort to model HD, Jackson et al 
(1998) expressed fragments of human huntingtin in the Drosophila photoreceptor cells 
under the control of the gmr-GAL4 driver.  Similarly, Bonini (1999) modeled the human 
disease Spinocerebellar ataxia 3 (Machado-Joseph disease)  by expressing the human 
protein containing the disease causing triplet repeat both in the fly eye (gmr-GAL4) and 
pan neurally (elav-GAL4).  In Bonini and Jackson’s eye models, the flies containing the 
mutant form of the protein showed a number of major hallmarks of the disease, most 
notably a late onset degeneration of the photoreceptor neurons and a nuclear 
accumulation of the mutant protein (Jackson et al. 1998; Bonini 1999).  This is in 
contrast to controls expressing wt human protein in which the triplet repeat is within a 
normal range as these flies have no noticeable defects.  Despite this correlation there are 
a few differences between the models and this is attributed to a difference in approach to 
the spatial selection of gene expression.  Bonini used the GAL4/UAS system as 
previously outlined so the expression of the gene is reliant on the production of GAL4 
which in turn is driven by the gmr promoter (Bonini 1999).  Jackson et al. had 
huntingtin under the direct control of the gmr promoter which bypassed the need for 
GAL4 and as such might have seen an earlier production of the protein in the fly 
(Jackson et al. 1998).  This is an example of the flexibility of Drosophila as a model 
system.  A number of different methods are available to bring about a similar goal and 
the choice taken will depend on the type of gene, its function and perhaps simply a time 
and ease factor.  Very slight changes can be made to the expression of genes and a 
number of modifications can be brought together in a single fly fairly easily and 
comparatively quickly.  The benefit of Drosophila has been realized by the community 
of scientists working on degenerative disease as is evident by the number of diseases 








Gene Method Phenotype Author 
Alzheimers 
Disease 
Aβ 42 Expression of 
human Aβ 42 in 
Drosophila eye 
and pan neurally 
Photoreceptor 
degeneration, 
locomotion defects and 
aggregation. 
(Finelli et al. 
2004; Iijima et al. 





Expression of mut 
human tau 
Shortened lifespan, 
degeneration in the adult 
brain 
(Wittmann et al. 
2001) 
ALS SOD1 Expression of 
human mutant 
SOD1 
Locomotion defects (Watson et al. 
2008) 
ALS SOD1 Null cSOD mutant Reduced lifespan, 
reduced fertility and 
increased sensitivity to 
Paraquat 
(Phillips et al. 
1989) 






(Chai et al. 2008) 




of synaptic homeostatis 
and signaling 
(Ratnaparkhi et al. 
2008) 
ALS VAPB Expression of 
mutant 
DVAPP56S 
Aggregate formation, ER 
disruption 
(Tsuda et al. 
2008) 
ALS TDP43 Knock out 
endogenous gene 
Eclosure and locomotion 
defects 
(Feiguin et al. 
2009) 
ALS TDP43 Expression of 
human TDP43 in 
adult eye and 
larvae motor 
neurons 
Disruption of eye 
rhabdomeres and 
locomotion defects in 
larvae leading to death  
(Hanson et al.; Li 
et al.; Lu et al. 
2009) 
ALS TDP43 Expression of 
human TDP43 in 
adult eye and 
larvae CNS 
Disruption of 
Rhadomeres, axonal loss 
and cell death 
(Li et al.) 
ALS TDP43 RNAi of TDP43 
and expression of 
mutant human 
TDP43 
Reduction in dendritic 
branching 







human α synuclein 












human α synuclein 
Dopaminergic neuronal 
degeneration 
(Trinh et al. 2008) 
Parkinson’s 
Disease 





muscle and neuronal 
degeneration 




Parkin Expression of 
mutant human 
Parkin 
Locomotor defects and 
neuronal degeneration 
(Yang et al. 2003; 
Pesah et al. 2004; 
Whitworth et al. 











(Clark et al. 2006; 
Park et al. 2006) 
Parkinson’s 
disease  






(Wang et al. 2006; 
Yang et al. 2006) 
Parkinson’s 
disease 
DJ1 Knock out of 
endogenous 
proteins α and β 
Increased sensitivity to 
oxidative stress. 
(Menzies et al. 
2005; Meulener et 




DJ1 RNAi knock down 
of DJ-1 α 
Loss of photreceptors, 
dopaminergic neuronal 
disruption and increased 
sensitivity to oxidative 
stress 
(Yang et al. 2005) 
Parkinson’s 
disease 





increased sensitivity to 
oxidative stress 







Locomotion defects and 
dopaminergic 
neurodegeneration 








locomotion defects and 
loss of dopaminergic 
neurons 








adult eye and pan 
neurally 
 
Degeneration and NI 
formation. Behavioural 
defects. 
(Warrick et al. 
1998; Bonini 









expression in glia  











(Mutsuddi et al. 
2004) 
PolyQ Huntingtin Expression of 
polyQ expanded 




(Jackson et al. 
1998) 
PolyQ Huntingtin Glial targeted 
expression of 
himan Huntingtin 
Locomotor defects and 
neuronal dysruption 
(Tamura et al. 
2009) 
 
Table 1.1  Summary of Drosophila models of human neurodegenerative disease 
 
 
The second most common human neurodegenerative disease following AD is PD 
(Auluck et al. 2002)  Like the polyglutamine diseases, PD has also been modeled in 
Drosophila and a number of different techniques have been used.  The original model 
used the UAS/GAL4 system to over express the human α-synuclein gene in Drosophila 
(Feany and Bender 2000).  Mutations in α-synuclein were first linked to cases of familial 
PD in a large Italian family (Polymeropoulos et al. 1997). In the same year it was also 
shown to be a major component of the intraneuronal inclusions known as Lewy bodies 
that are a major hallmark of familial and sporadic PD (Spillantini et al. 1997).  The 
function of α-synuclein has not been fully described but it is located in the nucleus and 
at the synapse where it is believed to have a role in synaptic plasticity and 
neurotransmission (Abeliovich et al. 2000; Bonini and Giasson 2005).   
Recently Chandra et al showed that α-synuclein has the ability to rescue the 
lethality associated with the knockout of Cysteine String Protein alpha (CSPα) (Chandra 
et al. 2005).  CSPα is a molecular chaperone necessary for the integrity of synaptic 
nerve terminals. CSPα-deficient mice have a significant reduction in synaptic SNARE 
protein complexes and present with degeneration of the axon terminal at the 
neuromuscular junction (NMJ) which leads to death by 3 months of age. Transgenic 
expression of α-synuclein rescued the degenerative phenotype so that mice lived longer 
than 15 months whereas removal of endogenous α-synuclein accelerated the lethality 
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associated with removal of CSPα (Chandra et al. 2005).  This indicates that α-synuclein 
acts downstream of CSPα and has a protective effect against degeneration.  This is an 
important finding as the toxic form of α-synuclein that is causative for some familial 
cases of PD is thought to be a gain of function mutation as it is an over expression of α-
synuclein that leads to degeneration in the models of PD.  Deletion of α-synuclein has 
little morphological or behavioral effect on otherwise wt mice, without other mutations 
as described by Chandra et al (Gureviciene et al. 2007).   
The mutant forms of α-synuclein that have been identified as causative for PD 
are known as A30P and A53T which relates to the position of the amino acid affected. 
To model the disease both of these mutant human proteins were individually expressed 
in the fly.  A third line was created expressing the wt human protein (Feany and Bender 
2000).  Interestingly in all three cases, there was an age dependent loss of dopaminergic 
neurons when the protein was expressed using a pan neural driver.  A punctuate staining 
pattern for α-synuclein also showed that aggregates were forming that were similar in 
morphology to the Lewy bodies seen in human patients.  These inclusions were present 
only in the nervous system but were in various subsets of neurons and not restricted to 
the dopaminergic cells despite these being the only ones showing degeneration. This is 
similar to the situation we see in human patients (Feany and Bender 2000).  This being 
considered, it is also interesting that expression of α-synuclein in the eye driven by gmr-
GAL4 also caused a degenerative phenotype restricted to the eye.  As this is a stronger 
driver it may be that the eye is not as susceptible to α-synuclein and an increased amount 
of the protein is necessary to induce degeneration as compared to the vulnerable 
dopaminergic neurons.  This is consistent with the fact that wild type and mutant 
proteins gave a comparable phenotype.  It is perhaps the accumulation of the protein due 
to the over expression that drives degeneration.  In humans the wild type protein is also 
present and the mutant protein may resist degradation and thereby accumulate and form 
the aggregates that are a hallmark of this and so many other degenerative diseases.   
Further investigation into PD using mice and Drosophila supports the hypothesis 
that protein accumulation is the key to this disease.  In mice, the overexpression of wt α-
synuclein induces the formation of ubiquitin positive inclusions (Masliah et al. 2000).  
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In Drosophila, the co-expression of Parkin, a ubiquitin ligase that targets proteins for 
degradation, in particular α-synuclein, rescues the phenotypes associated with α-
synuclein expression. Both the motor dysfunction and the eye phenotypes are suppressed 
by an overexpession of the Drosophila Parkin (Haywood and Staveley 2004) and 
similarly with the expression of PTEN-induced putative kinase 1 (Pink1) which is 
thought to act upstream of Parkin (Todd and Staveley 2008).  Pink1 is also known to 
activate chaperones and this may be a further pathway through which it acts because the 
chaperone HSP70 has been shown to suppress many neurodegenerative diseases 
including Parkinson’s  Disease (Auluck et al. 2002). Not only are Parkin and Pink1 
protective but mutations in these proteins are causative for autosomal recessive juvenile 
cases of Parkinson’s Disease.  These cases have an onset between the ages of 20 and 40 
years  but otherwise they are identical to sporadic cases (Kitada et al. 1998; Valente et 
al. 2004; Albanese et al. 2005; Gasser 2009).   
A model of Parkinson’s Disease has been created by knocking out the 
endogenous homologue for Parkin in Drosophila and, in an alternative model, 
expressing human mutant Parkin in a wt background (Greene et al. 2003; Cha et al. 
2005; Whitworth et al. 2005; Wang et al. 2007).  Inactivating the endogenous gene to 
model a disease as in the case of Parkin demonstrates further the flexibility of 
Drosophila as a model system.  Inactivation of Parkin lead to locomotion defects due to 
apoptotic muscle degeneration which was thought to be due to defects in mitochondria 
as seen by the swelling of these organelles and a disintegration of the cristae.  Such 
degeneration of the mitochondrion was seen in flight muscles prior to any other 
morphological changes which suggests this is an early indicator of disease (Greene et al. 
2003).  Interestingly there was select degeneration in the dorsomedial dopaminergic cell 
cluster which is also an area of enhanced toxicity in the Drosophila α-synuclein model 
(Auluck et al. 2002).   
In an attempt to elucidate the mechanisms of the observed phenotype in the 
Parkin mutant, Greene et al. went on to screen for the potential pathways involved by 
microarray and looking for alterations in the level of transcription of about 6000 genes.  
Genes that were significantly up/down regulated were verified by crossing mutants in 
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which the specific gene is knocked out with a homozygous Parkin null fly that shows 
partial lethality.  Enhancement or reduction in the lethality was used to confirm genetic 
interactions and following the success of this screen Greene et al. went on to screen for 
other genetic interactors using a collection of enhancer P (EP) transposon insertion lines. 
(Greene et al. 2005). When P elements are inserted into the Drosophila genome they 
tend to be inserted at the 5’ end of a gene and often upstream of the open reading frame.  
As such although in some cases the gene is disrupted resulting in a loss of function, in 
others the transcription of the gene is possible and a fully functional protein can be 
produced.  The EP lines use a transposon containing a GAL4 responsive promoter and 
the insertion can actually drive the overexpression of the downstream gene when crossed 
with a driver line.  Once a modifier of the Parkin lethality phenotype was observed the 
insertion was then examined to see if it was due to an over expression or loss of 
function.  Two loss of function enhancers that were recovered from this screen were 
Glutathione transferase 1 and thioredoxin, both involved in oxidative stress (Greene et 
al. 2005).  This shows how Drosophila can be used to model a disease by either 
expressing a human mutant disease protein through the incorporation of the gene into the 
fly’s own genome or by removing the endogenous protein.  In the case of Parkin, Greene 
et al. looked at the fly’s endogenous protein and the genetic interactions it formed in 
vivo and now this can be transferred to the human cases to see if similar pathways are 
also affected.  Consistent with these data, patients with Parkinson’s disease have been 
shown to have reduced levels of glutathione (Sian et al. 1994). 
Not only is Drosophila a good model for disease but with all the tools available it 
is easy to screen for modifiers that can affect the disease onset and progression and 
because of the high level of conservation between species, many of the outcomes can be 
directly translated to human patients.  Due to the complex hereditary and variability in 
humans, finding the causative gene for a disease is a much more difficult task.  A 
disease that has been a cause of much research is Amyotrophic Lateral Sclerosis (ALS).  
The majority of cases are sporadic and as such it has been difficult to model ALS.  
However with the discovery of familial cases linked to mutations in SOD1, the 
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possibility arose to model the disease and led the way to finding other contributing 
genes.   
 
1.7 Amyotrophic Lateral Sclerosis 
 
Amyotrophic Lateral Sclerosis (ALS) is the most common type of motor neuron disease, 
characterized by progressive degeneration of the upper and lower motor neurons. 
Sufferers present with symptoms of muscle weakness and this quickly develops on to 
paralysis and finally death due to respiratory failure within 5 years of disease onset 
(Hadano et al. 2001; Farah et al. 2003).  The incidence of the disease is 1-2 per 100,000 
with a lifetime risk of 1 in 2000 and apart from a few exceptions these figures are fairly 
uniform all over the world. The Chamarro population of Guam is one such exception 
that has a higher than average incidence of ALS termed Guam syndrome (Ince and Codd 
2005).  This familial form of disease is linked to a dementia similar to Parkinsonism.  
The cause of this and a few other small areas of high incidence disease populations are 
unknown but there are a number of environmental and genetic hypotheses.  The most 
popular but also largely contested theory is that the disease is a result of toxicity from β- 
methylaminoalanine (BMAA) a product of the symbiotic cyanobacteria which lives in 
Cycad trees (Karamyan and Speth 2008).  The seeds of this tree contain the toxin 
BMAA and are used by the Chamarro population in food and medicine.  It is argued that 
levels ingested are very low but through the consumption of the fruit bat which lives on 
the seeds it is possible that there is a build up of this toxin to a dangerous level. The 
disease presumably has a strong genetic basis also, whether this is a susceptibility to the 
toxin or a direct cause of the disease (Sieh et al. 2009). In the rest of the world the 
majority of cases are sporadic but similar to Guam about 10% are familial (Nishimura et 
al. 2004a).  The most common of these familial cases are those caused by a mutation in 
the Superoxide dismutase (SOD1) gene. 
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SOD1 is a gene encoding the enzyme Superoxide Dismutase that catalyses the 
conversion of the highly reactive oxygen free radical (O2-) into hydrogen peroxide and 
O2 and it is mutations in this gene that have been linked to 20% of all familial cases of 
ALS (Rosen 1993; Takamiya et al. 2005).  There are over one hundred known mutations 
in SOD1 that lead to ALS and the majority are missense mutations producing a shorter 
protein product.  The mutant alleles are dominant and cause the disease in 
heterozygosity despite there being a fully functioning wt protein.  This, in conjunction 
with the evidence from mouse models in which the human mutant transgene causes 
MND despite their own SOD1 being intact, indicates that the mutation is not a loss of 
function.  It is believed that SOD1 takes on a new toxic function possibly quite separate 
from its normal role and thus, despite it being a well characterized protein, there is still 
little known about the pathogenesis of SOD1-linked ALS (Farah et al. 2003; Takamiya 
et al. 2005).   In order to dissect the molecular basis of this disease a number of models 
have been created using transgenic mice and rats expressing mutant SOD1. Gurney et al 
were the first to undertake the challenge of creating an SOD1 mouse by expressing the 
mutant human G93A allele in mice.  The resulting progeny showed an age-dependent 
paralysis in one or more limbs, tremor in the hind limbs and when examined at a 
morphological level showed a decrease in staining for Choline Acetyltransferase 
indicative of neuronal loss.  Gurney et al also found that muscle endplates were multiply 
innervated and single axons formed numerous contacts suggesting that there is a 
sprouting mechanism to compensate for the early degeneration (Gurney et al. 1994).   
A number of models have since been created and used to study all aspects of 
disease onset and progression.  They have proved invaluable tools for increasing our 
understanding of the disease, especially in studying the early pre-symptomatic stages, 
something which, for obvious reasons, is difficult to do in humans. The retardation of 
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slow axonal transport has been reported to occur in SOD1 mutant mice months before 
signs of degeneration and reduced levels of microtubule associated proteins, MAP-1 and 
MAP-2, and an altered level of tau phosphorylation has also been described well before 
the onset of symptoms (Williamson and Cleveland 1999; Farah et al. 2003).  The mutant 
SOD1 protein can associate with actin and is found in the aggregates that form in the 
motor neurons of transgenic mice (Takamiya et al. 2005).   Cytoplasmis inclusions are a 
major hallmark of disease and SOD1 is the main component of these aggregates in 
human patients suffering from type 1 familial ALS.  A closer look at the formation of 
these aggregate has shown there to be two different types; detergent soluble and larger 
in-soluble forms.  In transgenic mice, these larger insoluble forms of mutant SOD1 are 
more prevalent in vulnerable tissue and only when the disease is rapidly progressing.  
This may mean that they play a causative role in the disease but as a number of 
pathologic features are already present prior to their observation it is likely that they are 
more involved in disease progression than onset (Karch et al. 2009).  It is possible that 
very low levels of these insoluble aggregates are necessary to initiate disease or it may 
be that it is the smaller forms that promote the disease and in due course, large 
aggregates form as the cell starts to malfunction.  The appearance of aggregates has been 
implicated as an indication of chaperone and proteasome system malfunction. Under  
normal circumstances, the cell is protected from accumulated proteins by chaperones 
that either aid the normal refolding or target the abnormal proteins to the proteasome for 
degradation (Kabashi and Durham 2006).  As it has been found that proteasome 
inhibitors can induce the formation of SOD1 insoluble inclusions when added to cell 
culture, it is certainly possible that the proteasome system is not working properly in 
ALS patients (Kabashi and Durham 2006).  
A recent and important finding by Clement et al. (2003) was that of the 
protective effect exerted by wild type neurons in chimeric mice expressing mutant 
human SOD1 in a subset of neurons.  The number of mutant SOD1 expressing cells 
degenerating was inversely proportional to the number of wt neurons in the region and 
chimeric mice showed a delayed disease onset and a longer lifespan as compared to 
SOD1G93A littermates (Clement et al. 2003).  Perhaps more interesting is the fact that 
 32
wild type neurons of older chimeras developed ubiquitin-positive aggregates suggesting 
the disease eventually spreads from mutant neurons to healthy ones.  Whether there is a 
soluble factor that could promote degeneration was later confirmed in cell culture by 
Nagai et al (2007) as described previously. 
Despite some interesting research coming from mouse and rat models, the fly 
models have not been so successful.  The most promising is from Watson et al. (2008) in 
which the mutant flies expressed a mutant human SOD1 protein and showed signs of 
motor deficits, synaptic transmission reduction and upregulation of the chaperone heat 
shock protein 70 (Watson et al. 2008).  The expression of the wt protein also gave these 
phenotypes but, as in many disease models discussed earlier, it may be the level of 
protein that is important and it is the overexpression of SOD1 causing the toxic affect on 
the cell.  In this case it may also be due to the difference between the Drosophila SOD1 
and the human protein as there is a variance of 49/153 residues at the amino acid level 
(Watson et al. 2008).  Such a variance from the endogenous protein might cause the fly 
system to treat the human protein as toxic in a similar manner to the mutant protein and 
as such it would be preferable to express a mutated copy of the Drosophila protein.   
Unfortunately this does not recapitulate any of the disease hallmarks.  Lack of any 
visible neuronal loss is also concerning but but there was electrophysiological data 
which suggested synaptic dysfunction. It may be that the primary pathological event 




Another familial linked form of ALS is due to mutations in ALS2.  ALS2 encodes Alsin, 
a 184 kDa protein with three guanine nucleotide exchange factor (GEF) domains and 
mutations in this gene lead to a recessive juvenile form of ALS termed ALS2 (Hadano et 
al. 2001; Hadano et al. 2006). The protein contains regions that are highly homologous 
to RCC1, a GEF for the GTPase Ran that has roles in nuclear transfer and microtubule 
assembly (Yang et al. 2001; Hadano et al. 2006).  Alsin also contains a tandem 
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organization of diffuse B-cell lymphoma (Dbl) homology and pleckstrin homology (PH) 
domains. This is a feature of GEFs for Rho GTPases implicated in signaling cascades, 
neuronal morphogenesis, membrane transport and actin cytoskeleton (Hadano et al. 
2001).  It is hypothesized that mutations disrupt the modulatory function in Ran/Rho-
related GTPases and this in turn causes defects in microtubule assembly, membrane 
organization and trafficking.  Since its discovery, 6 independent groups have created 
ALS2 -/- knockout mice. Results from these models have been rather mixed, with 
varying degrees of motor deficits possibly accountable to the differing recording 
methods and mice with varying genetic backgrounds.   
The first model created by Hadano et al. (2006) developed subclinical deficits of 
spinal motor neurons and showed a significant decrease in cerebellum Purkinje cells but 
it demonstrated normal motor performance, growth and reproductivity (Hadano et al. 
2006).  In all ALS2 models, any visible motor defects are only moderate and lower 
motor neurons are never affected by the disease.  This correlates with the human disease 
as the majority of cases predominantly affect the upper motor neurons but the difference 
in neural organization might mean that mice motor capabilities are less affected.  The 
rodent upper motor neurons always interact with an interneuron in the spinal cord 
whereas human neurons can directly innervate the lower motor neurons to coordinate 
movement.  This being said, in the lateral column, a progressive degeneration of the 
corticospinal tract (CST) neurons was evident in a model created by Yamanaka et al 
(2006).  However, the age-dependent slowly progressive loss of Purkinje cells in the 
cerebellum of the knock out mouse created by Hadana et al was not evident in 
Yamanaka’s model.  (Hadano et al. 2006; Yamanaka et al. 2006)  Cai et al created 
another model and also found no evidence of Purkinje cell loss but they did note a 
decrease in cerebellum-mediated motor learning when the mice were at 20 months of 
age (Cai et al. 2005).   
Despite the discrepancy between some of the results from the different models 
there is some promising data and in particular they are shedding light on the normal 
function of the protein.  As it is a recessive allele the mutation is almost certainly due to 
a loss of function so knowing the role of this protein is vitally important.  Despite Cai et 
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al finding no neuropathological abnormalities they did find a role for Alsin in 
neuroprotection from toxic challenges.  The toxin PQ herbicide produces reactive 
oxygen species which are very harmful to cells and following exposure at a level which 
left wt mice unharmed, 50% of ALS2-/- mice died.  Post mortem showed edema and 
hemorrhage in the lungs.  This led Cai et al to conclude that ALS2 mutations confer a 
susceptibility to oxidative stress and should be classed as a risk factor (Cai et al. 2005).  
 
1.8.3 ALS 4 
 
ALS4 is another rare familial juvenile onset form of ALS which presents with limb 
weakness, severe muscle wasting and pyramidal signs.  There is however an absence of 
overt sensory abnormalities and bulbar and respiratory muscles are not affected.  
Sufferers develop symptoms in childhood but often have a normal lifespan. In 2004 a 
large Maryland family enabled Ying-Zhang et al to map the gene responsible to 
Senataxin (SETX,) a gene encoding a novel DNA/RNA helicase.  These are a family of 
proteins known to be involved in DNA repair, replication, recombination and 
transcription and RNA transcript processing (Chen et al. 2004).  The linkage to this gene 
was verified by a number of other families and the responsible mutations were found to 
be missense and lead to a single amino acid change in the protein product.  
Unfortunately no solid understanding of the function of this protein is known but 
interestingly it has been linked to another degenerative disorder called Ataxia-ocular 
apraxia 2 which presents with cerebellar atrophy, sensory-motor neuropathy and 
oculomotor apraxia (Moreira et al. 2004).  Any increase in our understanding of the role 
of SETX in either of these disorders will be beneficial to both parties and the different 




1.8.4 ALS 11  
 
In 2009 dominant mutations in the FIG4 gene were found be to linked to a number of 
cases of ALS termed ALS11 (Chow et al. 2009).  FIG4 is also known as SAC3 and is a 
phosphoinositide-5-phosphatase. This is one of a family of SAC domain phosphatases 
that catalyses the removal of a phosphate group from the lipid signaling molecules 
phosphoinositide phosphates.  SAC domain proteins have a region of about 400 amino 
acids with a high level of homology to the yeast Sac1p (Hughes et al. 2000).  The gene 
SAC1 (Suppressor of actin) was so-called because yeast mutants suppressed the actin 
phenotype associated with the temperature-sensitive actin mutation act1-1ts (Novick et 
al. 1989).  There are seven highly conserved motifs and in particular a stretch of amino 
acids in the 6th domain that is thought to be the catalytic phosphatase domain.(Hughes et 
al. 2000)  The reversible phosphorylation of phosphatidylinositol at the 3rd, 4th or 5th 
head group position generates different phosphoinositide species (Volpicelli-Daley and 
De Camilli 2007) (See figure 1.2).  A total of 7 Phosphatidylinositol phosphates (PIPs) 
can be created with various combinations of phosphorylation and they are each 
recognized as a different species each with a different cellular localisation and function 
(Volpicelli-Daley and De Camilli 2007).  They have roles in the recruitment of other 
signaling molecules to the cytosolic membrane surface and as such the phosphatases and 
kinases that regulate the levels of the different proteins play an important role in 
ensuring correct levels are maintained.  FIG4 is a lipid phosphatase that removes the 
phosphate group from the 5th head group of PI(3,5)P2 to create PI(3)P. (Volpicelli-Daley 






















Phosphatidylinositol (PtdIns)  
 
Figure 1.2  Basic structure of the Phosphatidylinositol Phosphate (PIP)  
PIPs are created by the addition of a phosphate group onto the inositol ring of 
phosphatidylinositol (Ptdlns) at position 3,4 and/or 5.  Phosphates are added by a PI kinase and 
removed by a PI phosphatase. (Diagram recreated from Hughes et al 2000). 
 
Mutations of the human FIG4 gene have previously been reported to be 
responsible for a recessive severe form of Charcot-Marie-Tooth disease (CMT), a 
peripheral neuropathy that affects both sensory and motor neurons. (Chow et al. 2009)  
The motor neuron dysfunction seen in the CMT patients prompted a screen for cases of 
ALS caused by FIG4 in a candidate gene approach.  In a screen of almost 500 ALS 
patients and more than 400 control individuals, 10 variants of the FIG4 gene were found 
in the patient group that were not present in the control.  Of these, 6 are recognized as 
deleterious due to the incorporation of a premature stop codon before the catalytic 
domain or a deletion within this domain.  All the patients were heterozygous and have a 
wild-type allele as well as the mutated version (Chow et al. 2009).  This might be the 
reason for the difference in disease phenotype of these ALS patients as compared to the 
CMT patients who are homozygous and develop the disease in childhood or early 
adulthood.   
In mice there is a pale tremor phenotype that is caused by mutations in the FIG4 
gene and interestingly studies of the PI(3,5)P2 levels in these mice show that rather than 
being elevated they are actually at a lower level (Chow et al. 2007).  This is also true for 
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yeast that are deficient in FIG4 and the possible explanation is that it is due to the 
disruption of the interaction with the FAB1 activator VAC14.  In yeast FAB1 is the 
kinase responsible for the synthesis of PI(3,5)P2 and it is activated by VAC7 and 
VAC14.  An interaction between VAC14 and FIG4 has been shown and the possibility 
that this plays a role in the maintenance of the PI(3,5)P2 level by controlling the ability 
of VAC14 to activate FAB1 is still being confirmed. In addition to this there are a 
number of PI-5-phosphates that can remove the 5th phosphate group and replace the need 
for FIG4 to produce PI(3,5)P2 (Dove et al. 2002; Gary et al. 2002)  Interestingly 
mutations in VAC14 also cause a neurodegenerative phenotype with neurological 




In 2006 a major component of ubiquitinated aggregates found in many patients with 
sporadic ALS was discovered to be a 43kDa protein called Transactive Response (TAR) 
-DNA binding protein (TDP-43).(Neumann et al. 2006; Kwong et al. 2007)  These 
aggregates, known as ubiquitinated inclusions (UBIs) are found in the cytoplasm and 
nucleus of neural and glial cells of sporadic cases of ALS and a number of familial.  
They are also found in patients with the most common form of fronto-temporal dementia 
(FTLD-U) which is perhaps expected considering ALS is often associated with FTD.  
The mystery of the components of the UBIs was solved by Neumann et al who 
generated mouse antibody probes against insoluble brain tissue material from FTLD-U 
patients and then used liquid chromatography-tandem mass spectrometry to identify the 
positive residues (Neumann et al. 2006).  To date the only exception is the inclusions in 
neurons of familial SOD1 patients as these are negative for TDP-43. Interestingly the 
characteristic inclusions of a wide array of other neurodegenerative diseases including 
Parkinson’s and Trinucleotide repeat diseases are also negative for TDP-43 except for 
30% of Alzheimer’s disease (AD) patients (Kadokura et al. 2009).  
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 TDP-43 is widely expressed in a number of tissues including lungs, heart and 
brain and it is normally found in the nucleus although the formation of aggregates in the 
cytoplasm of disease patients leads to a reduction of the nuclear localization.  It is 414 
amino acids in length and has two RNA recognition motifs (RRM1 and 2) and a glycine-
rich C-terminal sequence.  The original function designated to TDP-43 was as a 
repressor of Tar-DNA transcription which it achieves by binding to the polypyrimidine 
motif but recently it has also been found to affect transcription of other genes including 
ApoA-II and the mouse SP-10 gene (Kwong et al. 2007).  Following the discovery of 
TDP-43 in the inclusions many groups took up the task of finding dominant mutations in 
this gene that might be causative for familial cases of ALS.  There are 6 exons within the 
TDP-43 open reading frame and the majority of disease mutations are dominant 
missense mutations in the sixth exon affecting the C-terminal sequence that is thought to 
be necessary for the interaction with other proteins (Kwong et al. 2007; Lagier-Tourenne 
and Cleveland 2009).  The sequestering of TDP-43 away from the nucleus and into the 
cytoplasm may inhibit its ability to function and as such the mutation might be 
considered as a loss of function. 
 
1.8.6 FUS/TLS – A new causative gene for ALS? 
 
Following the discovery of the link between TDP-43 and ALS two groups independently 
identified mutations in another RNA/DNA binding protein that are also linked to 
familial cases of ALS (Kwiatkowski et al. 2009; Vance et al. 2009).  Kwiatkowski et al 
carried out loss of heterozygosity (LOH) mapping on a family in Cape Verdean who had 
four members with ALS.  The maternal Grandparents were first cousins and the 
population of the small island which they inhabited was only 6000 suggesting a 
recessive pattern of inheritance. A region on chromosome 16 was identified as having 
homozygosity, a region previously identified by Vance et al as linked to cases of ALS in 
a large British family that show a dominant pattern of inheritance (Vance et al. 2009).  
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The two groups narrowed down the culprit gene to FUS/TLS, (fused in 
sarcoma/translocated in liposarcoma).  The dominant mutation R521C was also found in 
four other families and a number of other FUS/TLS mutations have been found in ALS 
patients making it likely that this is a new causative gene for ALS.  FUS/TLS is 526 
amino acids in length and is composed of 15 exons with an N-terminal domain rich in 
Glutamine, Glycine, Serine and Tyrosine, a glycine rich region, an RNA recognition 
motif, multiple RGG repeats implicated in RNA binding, a C-terminal zinc finger motif 
and a highly conserved extreme C-terminal region.  The majority of mutations are 
missense and located in this terminal region (Lagier-Tourenne and Cleveland 2009).  
Similar to TDP-43, the wt protein is localized in the nucleus and is expressed 
almost ubiquitiously.  The disease protein although still found in nuclei is also present in 
cytoplasmic aggregates which is again similar to mutant TDP-43 but interestingly no 
TDP-43 positive aggregates are seen in the FUS cases suggesting that if the mechanism 
of disease pathology is similar, the pathways appear to be independent.  (Vance et al. 
2009) Investigation of FUS/TLS in mice found that it shuttles from the nucleus to 
dendritic spines and in agreement with this, knock out mice showed abnormal spine 
morphology. They hypothesized a role for this RNA/binding protein in synaptic 
plasticity through the regulation of RNA splicing and the transport of mRNA to local 
translationary machinery in the dendritic spine (Fujii et al. 2005).  
 
1.9 VAPB and ALS 
 
Recently a link was discovered between a missense mutation in the human VAPB gene 
(VAMP-associated protein-B) and some cases of ALS and Spinal Muscular Atrophy 
(SMA) (Nishimura et al. 2004a; Nishimura et al. 2004b).  The mutation was a change of 
a proline to a serine at position 56 (P56S) and it was discovered in a large Brazilian 
family with 28 affected members.  The same mutation was also found in another 6 
related families and historical evidence historical evidence pointed to a single common 
ancestor.  With over 200 affected individuals the evidence is strong for the mutant VAPB 
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as the causative agent. The mutation is autosomal dominant with VAPB localized on 
Chromosome 20 at position 20q13.3.  In the original Brazilian family all affected family 
members have the same mutation but there is a wide variance in age of onset and the 
neurons involved so the disease manifested in the 28 individuals has been divided into 
three categories. See Table 1 below.  
First, 8 patients are categorized as having late onset SMA.  The age of onset is, 
on average, 46 years and the progression of disease is such that some individuals had 
suffered with the disease 10-12 years by the time the report was carried out. The disease 
is characterized by selective degeneration of the anterior horn cells in the spinal cord 
leading to muscle paralysis and atrophy but the lack of bulbar or pyramidal involvement 
separates this disease from ALS.  Secondly, 15 affected family members presented with 
symptoms of atypical ALS.  The average age at onset was 38 years and some of the 
affected members had suffered with the disease for 20-30 years indicating a slower 
progression as compared to the typical cases of ALS.  These patients had the bulbar and 
pyramidal involvement of ALS but also a tremor that is atypical.  Finally, 5 members 
had typical ALS and they presented with a late age at onset and a quick disease 


























(exact age not 
disclosed) 
< 5 years 
 
Table 1.2  Summary of the ALS8 affected individuals 
25 family members carried the VAPB P56S mutation and all manifested with forms of motor 
neuron degeneration that has been sub grouped into three categories due to age at onset, 




There is much heterogeneity within these three subdivisions of motor neuron disease 
such that the divisions are becoming blurred and it might be more advantageous to 
consider a spectrum of disease predominantly affecting motor neurons.  The discovery 
of such mutations as VAPB that are causative for all types of MND further reduces the 
divisions.   
 Due to the size of the Brazilian family and number of affected members, the 
P56S mutation is almost certainly causative.  However, when proposing a gene mutation 
as linked to a disease it is important to differentiate between simple polymorphisms and 
true causative mutations and having only one mutation, however large the family is not 
ideal.  Recently however, a second mutation in VAPB has been found to be linked to 
cases of ALS and this greatly adds weight to the argument.   J. de Belleroche identified a 
Threonine to Isoleucine substitution at position 46 (T46I) in a family unrelated to the 
original Brazilian family (personal communication).  This and the original P56S 
mutation both fall within a stretch of amino acids that is highly conserved from yeast to 
man which add further strength to the importance of these VAPB mutations and makes it 
exceedingly unlikely that they are simply harmless polymorphisms. 
 
1.9.1 Vamp Associated Protein of 33kDa (VAP-33)  
 
Importantly in the quest to understand how this protein might lead to cases of ALS, 
some work on the characterization and function of human VAPB (hVAPB) as well as 
the homologues for this protein has already been carried out.  In 1995 Skehel et al 
cloned a 33kDa protein from Aplysia californica and named it VAMP-associated protein 
33 (VAP-33) for its ability to bind to the vesicle associated membrane protein 
synaptobrevin as discovered by yeast two-hybrid (Skehel et al. 1995).  Injections of 
antibodies against this protein blocked neurotransmitter release in cultured neurons 
leading them to conclude that it plays a vital role in neuronal transmitter release.  This 
lead to a number of other studies attempting to find a homologue for this protein in 
mammals and in 1998 Weir et al. identified a human homologue for the Aplysia VAP-33 
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(Weir et al. 1998).  HVAP-33 shared an overall identity of 50% at the amino acid level 
with the highest similarity being at the N terminal with a region of 121 residues sharing 
65% identity.  The C-terminal, despite less comparable on a primary level, has a similar 
structural formation with a hydrophobic C-terminal and coiled-coil domains.   Finally in 
1999 the current knowledge that there are three human homologues was attained by 
Nishimura et al and these have been named VAP A, B and C.  VAP A is the VAP-33 
originally discovered by Weir et al. (1998).  VAP B shares 60% homology to VAP A 
and 48% to a VAP-33. VAP C is a splice variant of VAP B and is missing a region 362 
nucleotides in length. This induces a frame shift so that the transmembrane domain and 
coiled-coil domain present in A and B is not found in VAP C (Nishimura et al. 1999).  
In agreement with Weir, they found VAP A and B to be ubiquitously expressed.   By 
comparing the VAP sequences for humans, Aplysia and rat which also has a VAP A and 
B homologue with a respective 95% and 88% identity to hVAPs, along with a putative 
homologue in C.elegans, Nishimura characterized the proteins and identified three 
conserved domains. 
 
1.9.2 Structural and Phylogenetic Conservation of VAP proteins 
 
All VAP proteins have a characteristic 3 domain structure.  First a highly conserved 
amino acid motif CFKVKTTAPXXYCVRPNSG at position amino acid 41-59 is within 
a well conserved N-terminal region of the protein.  Importantly it is the highly conserved 
proline at position 56 within this motif that is mutated in the ALS8 patients.  The newly 
discovered T46I mutation is also within this conserved stretch of amino acids.  Secondly 
there is a region with a number of conserved hydrophobic residues which make up the 
coiled coil domain and finally the transmembrane domain at the Carboxy terminal 










Figure 1.3 Schematic diagram of the conserved domains in VAP proteins  
There are three conserved domains in the VAP family of proteins. The Major sperm protein 
domain (MSP) at the N-terminal, a coiled coil domain (CC) and the transmembrane domain 
(TM) at the C-terminal.  Within the MSP domain is the highly conserved N-terminal motif 
containing the two mutated residues that have been linked to cases of ALS (highlighted 
in red).  
 
The conserved N-terminal region of about 100 amino acids has been shown to share a 
high identity to the Major sperm protein (MSP) in the nematode Caenorhabditis elegans 
(Weir et al. 1998).  The nematode MSP is found in the sperm cell and is necessary for 
the amoeboid locomotion adopted by these cells.  Unlike the flagellum based swimming 
motion of sperm in other organisms, in nematodes the MSP forms non-polar filaments 
with two helical subfilaments wound round one another and the cyclical 
polymerization/depolymerization acts as a dynamic cytoskeleton that drives the sperm 
cells forward (Tarr and Scott 2005).  In addition to this, the protein is also released from 
the sperm cells through a novel budding mechanism and acts as a signaling molecule to 
promotes oocyte meiotic maturation and gonadal sheath cell contraction (Kuwabara 
2003).  Spermatozoa do not contain the necessary ribosomes, ER and Golgi involved in 
the normal processing and release of proteins so it is believed that the MSP provides the 
force necessary for the protrusion of the membrane during budding (Kosinski et al. 
2005).  The signaling action of MSP is to antagonize the inhibitory somatic gonadal 
sheath cell pathway, in part, by acting on Ephrin (Eph) receptors on the oocyte 
(Kuwabara 2003).  All VAPs in all organisms contain this MSP domain and the link 
between the cytoskeletal and signaling roles of the MSP and possible roles of this 
domain in VAPs has obviously been an area of much interest. So far, a lot of research 
has been done on the VAPs in various organisms and there is a both much similarity and 






1.9.3 Yeast Scs2p 
 
The yeast VAP homologue is called Scs2p.  The gene SCS2 was named for its 
identification as a multicopy suppressor of inositol auxotrophy of the choline sensitive 
mutant CSE1 and hac1/ire mutants (Nikawa et al. 1995; Kagiwada et al. 1998).  
Disruption of SCS2 prevents yeast cells from growing well on plates lacking inositol in 
the medium as compared to various wild-type strains. Scs2p is a type II integral 
membrane protein and under normal conditions it is localized at the endoplasmic 
reticulum (ER).  The protein is 35kDa in length which suggests post-translational 
modification because a direct translation from the transcript would produce a smaller 
peptide. Scs2p has a hydrophobic C-terminal of 16 amino acids corresponding to its 
transmembrane domain but unlike other VAP proteins it does not have a coiled coil 
domain (Kagiwada et al. 1998).  A study looking for genes involved in telomeric 
silencing found SCS2 to be a suppressor.  In yeast, prevention of the transcription of the 
repetitive telomeric sequence at the end of a chromosome is ensured by a number of 
proteins, in particular Mec1p which regulates telomeric length and results in loss of 
telomeric silencing if disrupted.  Overexpression of Scs2p could rescue this phenotype 
and null mutants also show a defect in telomeric silencing (Craven and Petes 2001).   
Unlike the role of VAP-33 in Aplysia, there seems to be no evidence of Scs2p having 
any necessary role in protein release. 
 
1.9.4 Caenorhabditis elegans VPR-1 
 
Not only does C. elegans have the MSP protein but there is also a homologue to the 
VAP-33 protein known as VAP33-related (VPR-1) (Tsuda et al. 2008).  Disruption of 
this gene leads to problems in distal tip cell migration and the ventral hypodermal cell 
migration during enclosure.  VPR-1 may act via a pathway involving Ephrin (Eph) 
receptors as a similar phenotype is seen when the Eph receptor VAB-1 is disrupted as 
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when VPR-1 is disrupted.  As mentioned earlier MSP acts as a signaling molecule in C. 
elegans by binding to VAB-1 receptors on the surface of the oocyte and sheath cell 
plasma membrane.  Interestingly the MSP domain of VPR-1 when removed and purified 
can promote the oocyte maturation and sheath cell contraction to a similar extent as 
MSP.  Similar results were also found for the MSP domain of Drosophila and human 
VAP proteins.  This indicates conservation of the function of VAPs as ligands in the Eph 
pathway (Tsuda et al. 2008).  
 
1.9.5 Drosophila melanogaster DVAP-33A 
 
Prior to the discovery of the role of VAP in ALS, the Drosophila homologue of VAP33 
had already been discovered as DVAP-33A (DVAP).  In Drosophila there are 3 
potential homologues, the first with 39% identity is named farinelli but this is found 
exclusively in the testes.  Second is DVAP-33B, but with only 18% homology it isn’t the 
ideal candidate for the VAP-33 homologue.  Finally there is DVAP with an identity of 
40% and present on the X chromosome with a protein size of 35kDa (Pennetta et al. 
2002).  DVAP is localized both pre- and post- synaptically at the neuromuscular 
junction and is both associated with the membrane and found in the cytoplasm.  It is 
enriched at the periactive zones which surround the active zones in the presynaptic 
boutons and shows an active relocalisation to those neurons undergoing budding 
(Pennetta et al. 2002).  Further investigation into the role of DVAP by the production of 
null mutants and flies over-expressing VAP pre-synaptically found there to be a dosage 
dependent effect on the structure of the synapse.  Loss of DVAP leads to a decrease in 
number of boutons but their size increases such that surface area remains the same.  
Likewise the over-expression of DVAP causes an increase in bouton number but they 
are smaller in size, again maintaining overall surface area. In Drosophila, as in mice, it 
seems that DVAP is associated with microtubules at specific points in the cytoskeleton 
network.  It is proposed that through this interaction it mediates synaptic remodeling by 
changing the cytoskeleton organization at the synapse (Pennetta et al. 2002).  It is 
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notable that in familial cases of ALS linked to SOD1 and Alsin and in these new VAP-
linked cases, there is a common theme of cytoskeletal disruption (Pennetta et al. 2002; 
Takamiya et al. 2005; Hadano et al. 2006).   
 
 
1.10 Drosophila model of ALS 
 
Following the discovery of the link between VAPB and ALS,  we mapped the human 
mutation equivalent in Drosophila to the Proline at position 58 and created a model of 
the disease by expressing the mutant P58S DVAP (DVAPP58S) in wild-type flies also 
expressing endogenous DVAP (Chai et al. 2008).  As DVAP had previously been shown 
to have a role in synaptic homeostasis and considering ALS is a disease of the motor 
neurons, the neuromuscular junction (NMJ) of larvae was chosen as the model system to 
begin the characterization of mutant VAPs.  The larvae musculature is highly stereotypic 
and has a regular pattern of 32 motor neurons per hemisegment that are accessible to 
electrophysiological readings and immunohistochemistry. It has been well characterized 
so any changes can easily be observed and recorded (Collins and DiAntonio 2007).   
Prior to modeling the disease it was important to find out whether the human 
VAP was simply a homologue at the level of amino acid sequence or whether the two 
proteins were functionally interchangeable. We found that by expressing the human 
protein in a null back ground human VAP was able to rescue the mutant phenotype 
which indicates that at least some of the important pathways are conserved between 
species (Chai et al. 2008).  Following on from this we examined whether DVAPP58S 
could also rescue the null phenotype as this would show whether or not the mutation is a 
loss of function.  Interestingly both the Drosophila and human mutant proteins could 
rescue the null phenotype so it is likely that the mutation is either hypermorphic or 
neomorphic.  A neomorphic mutation would mean that the mutant has gained a new 
toxic function unrelated to its normal wt role whereas a hypermorph has an excessive wt 
function.    
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Despite the apparent interchangeable nature of DVAP and hVAP, the Drosophila 
model was created by expressing the Drosophila mutant protein in a wt background.  
This would ensure that all the phenotypes witnessed are due to the mutation and not to a 
previously unseen incompatibility between the hVAP and the Drosophila system.  
Under these circumstances we created a model that recapitulated many of the major 
hallmarks of ALS including muscle wastage, denervation, locomotion defects and 
degeneration.  Aggregates highly immunoreactive for DVAP were present in the nerve 
axons and cell bodies of the brain and this coincided with a decrease in DVAP staining 
at the nerve terminals.  This suggests that the presence of mutant DVAP and the 
formation of aggregates is having a negative impact on the localisation of the wt protein 
and may be causing a situation similar to a dominant negative.  Electrophysiological 
recordings were made at the NMJ and these showed a decrease in mini EJP (evoked 
junctional poteintial) amplitude; the response at the endplate to the release of a synaptic 
vesicle of transmitter.  Possible explanations for this phenotype include a decreased 
sensitivity to the neurotransmitter or a reduction in the packaging of the vesicles. 
Although both are plausible, an observed change in the configuration and distribution of 
glutamate receptors indicates that the sensitivity of the receptors is being affected.  This 
indicates a role for DVAP in the conformation of the post synaptic receptors at the NMJ 
which is very interesting considering mutant DVAP was only expressed pre-synaptically 
in the model.  This implies that DVAP’s effect is not cell autonomous and whether it 
triggers a pathway that crosses the synaptic cleft or VAP itself is secreted requires 
further research (Chai et al. 2008). 
 
1.11 MSP secretion 
 
The secretion of VAP or perhaps only the MSP domain is an intriguing idea considering 
the role of MSP in C.elegans as a signaling molecule. Tsuda et al 2008 found a protein 
cleavage product that compared in size to the MSP domain of DVAP in western blots 
prepared from protein extracts of Drosophila larvae expressing a tagged DVAP 
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transgene.  They also found a similar product to be secreted from cells of the wing 
imaginal disc in cell culture.  By tagging both the N-terminal and C-terminal of DVAP 
and expressing the protein within cell culture it was possible to see that the N-terminal 
was extra cellular and the C-terminal intracellular.  A comparison of staining for the two 
tags showed that the N-terminal flag tag was more diffuse than the C-terminal HA tag 
still inside the cells of origin and only visible when the cells were permeabilised.  This 
led them to conclude that the N-terminal part of the protein is being secreted and is free 
to move away from the cell.  A similar experiment with DVAPP58S did not give the 
same results and showed no secretion suggesting that this mutation prevented the 
cleavage of the MSP domain.  Similar to the results from Chai et al, DVAPP58S was 
found to form insoluble aggregates and they confirmed that they comprised both the 
mutant and wt protein (Tsuda et al. 2008).  This is in keeping with the results from Chai 
et al showing that the expression of the mutant protein removed the wt DVAP from its 
normal localization into these insoluble inclusions.   
The MSP of C.elegans acts through its interaction with the Eph receptor VAB-1.   
Injecting the MSP domain of either of the VAP homologues; VPR-1, hVAP or DVAP, 
into C.elegans all brought about oocyte maturation in a similar manner to endogenous 
MSP.  The interaction with Eph receptor was further confirmed by co-
immunoprecipitation (Tsuda et al. 2008).  Eph pathways are involved in a number of 
cellular functions and this interaction with VAP gives us a new understanding of the 
possible roles played by this conserved family of proteins. Eph receptors in the fly are 
necessary for axon guidance and mutations cause loss of α lobes in the mushroom body.  
Similarly a loss of DVAP and double VAP/ Eph mutants also lack α lobes (Tsuda et al. 
2008).  Studies have found that Eph receptors are involved in the collapse of the growth 
cone through the control of the actin cytoskeleton via a number of Rho GTPases 
(Shamah et al. 2001).  A recent screen looking for genes involved in the homeostasis of 
signaling at the synapse found Ephexin, a Rho-type guanine nucleotide exchange factor, 
to be required for the modulation of transmitter release. Ephexin is a known interactor of 
Ephrin receptors and a homozygous Eph receptor mutant or a heterozygous double 
mutant significantly disrupted synaptic homeostasis (Frank et al. 2009).  Another study 
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found the mammalian EphB receptor and EphrinB to be involved in the formation of the 
synapse and necessary for the recruitment of NMDA receptors post synaptically (Dalva 
et al. 2000).  Considering the involvement of DVAP in synaptic homeostasis and the 
cytoskeleton, the interaction with Eph receptors may hold the key for many of the roles 
played by the VAP proteins.  The Eph receptor interaction shows how much more we 
can learn about a protein once we have an idea of the complexes it might form and the 
pathways in which it might be involved.  As such a number of studies have been carried 
out to find other interactors of VAP proteins. 
 
1.12  Known interactions of VAP and its homologues 
1.12.1 Scs2p and its interacting partners 
 
A comprehensive analysis of protein complexes of the yeast S.cerevisiae was carried out 
through the systematic purification of multiprotein complexes using tandem affinity 
purification (TAP) and mass spectrometry.  589 tagged proteins were purified and of 
these 78% were present with binding partners.  One such protein was Scs2 and within 
the complex the following proteins were found. 
 
 
Fks1 - FK506 sensitive-1 is an integral membrane protein of 215 kDa which is a subunit 
of the 1,3-b-D-glucan synthase (GS) (Mazur et al. 1995).  The glucose polymer 1,3-b-D-
glucan is a key component of the cell wall.  Fks1 is closely related to Fks-2 and the two 
encode alternative catalytic subunits for 1.3-b-D-glucan synthase so there is a degree of 
redundancy.  GS is necessary for cell wall remodeling and synthesis and an Fks1/2 
double mutant completely shuts down cell wall synthesis.  Fks1 localises to the plasma 
membrane at sites of cell wall remodeling and is the predominantly expressed protein of 
the two catalytic subunits (Mazur et al. 1995). 
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Num1 - Nuclear migration 1 is a 313kDa protein involved in coordinating nuclear 
movement into the yeast daughter bud through its interactions with dynein and tubulin.  
It has a Pleckstrin homology domain (PH domain) and is believed to act as an anchoring 
protein for dynein (Heil-Chapdelaine et al. 2000; Schauss and McBride 2007).  In this 
way, a similar interacting protein of DVAP might exist that would account for the ability 
of DVAP to associate with microtubules and mediate synaptic budding.  There is no 
record of a homologue for Num1p in terms of genetic sequence but it is likely that there 
is a functional homologue.  Num1p is also involved in mitochondrial fission and is 
believed to provide a docking site for the dynamin related GTPase (Dmn1p) which is an 
inhibitor of mitochondrial division (Cerveny et al. 2007; Schauss and McBride 2007). 
 
Opi1 – This is a transcription regulator of phospholipid synthesis and it acts by 
repressing the transcription of INO1.  INO1 is recruited to the nuclear membrane for 
transcription to be activated and Opi1 represses this. Scs2 is thought to work in 
conjunction with Hac1 by translocating to the nuclear membrane and stopping the 
reassociation of Opi1 to INO1 (Kagiwada et al. 1998).  An FFAT motif (two 
phenylalanines in an acidic tract) in Opi1 has been shown to be vital for the interaction 
with Scs2 (Loewen and Levine 2005). 
 
Osh1 and Osh2 – Two of the 7 yeast homologues of the mammalian Oxysterol Binding 
protein (OSBP) involved in sterol metabolism.  All 7 of the homologues have a 
conserved OSBP domain but only 1-3 have a Pleckstrin homology domain also found in 
OSBP.  Osh1 and Osh2 also have three Ankyrin repeats at the N-terminal that are not 
present in the mammalian OSBP (Levine and Munro 2001).  In yeast, the Osh family of 
genes have been shown to interact with Cdc42 (cell division cycle 42) which is a 
member of the Rho family of GTPases involved in cell polarity and morphology.  Osh 
proteins also affect the localisation of another Rho GTPase, Rho1p, and are involved in 
the delivery of vesicles to the bud tip for polarized secretion (Kozminski et al. 2006).  
Studies have also shown the Osh family to be necessary for the internalization step of 
endocytosis (Beh and Rine 2004). 
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Rpn10 – Non ATPase base subunit of 19s regulatory particle of the 26s proteosome.  
The yeast Rpn10 is necessary for the targeting of ubiquitinated substrates to the 
proteasome for degradation.  Through the degradation of proteins such as cyclins and 
p53 the proteasome is involved in the control of the cell cycle and proliferation as well 
as in the degradation of damaged proteins by proteolysis (Glickman et al. 1999). There 
is a degree of redundancy for ubiquitin binding factors in yeast as Rpn10 null mutants 
are viable (Madura 2004). 
 
Stt4 – Phosphatidylinositol-4-kinase necessary for the production of PI(4)Ps.  It was 
identified in a screen for hypersensitivity to stauroporine, an inhibitor of Protein Kinase 
C.  Yeast Stt4 mutants present with defects in vacuole morphology, cell wall integrity 
and actin cytoskeleton.  Interaction with Sfk1, an integral membrane protein, is 
necessary for its localisation to the plasma membrane where it controls the levels of 
PI(4)P which are thought to have their own signaling functions as well as act as a 
substrate for PI(4,5)P2 production. PI(4)P levels have been recently shown to have their 
own signaling properties and directly affect vacuole morphology (Foti et al. 2001).  The 
production of PI(45)P2 and activation of the Rho1/PKC1-mediated Map kinase cascade 
are necessary for the other cellular functions affected in the Stt4 mutants (Foti et al. 
2001; Audhya and Emr 2002). 
 
Swh1 –Initially characterized as a single gene the open reading frame for Swh1 is now 
realized to be part of the full open reading frame of Osh1.  It encodes the 5’ region 
which includes the Ankyrin repeats (Levine and Munro 2001). 
 
As the conservation of VAP proteins between species has been so strongly maintained 
so might we expect to find homologues for the interacting proteins described above in 
other more complex organisms.  Already a number of interacting partners of the 
mammalian VAP have also been discovered largely through the appearance of VAP as a 
binding partner of another protein of interest.  A brief account of some of these binding 
partners is given below.  
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1.12.2 Human VAPA interacts with Occludin 
 
The human VAP-33 protein (VAP A) was picked out in a yeast 2-hybrid screen aimed at 
looking for binding partners of Occludin, a transmembrane protein located at tight 
junctions (Lapierre et al. 1999).  These specialized junctions are found between 
epithelial and endothelial cells and they create a tight seal between cells and establish a 
polarity between plasma membrane domains.  Occludin has a role in cell cell adhesion 
and in the formation of the paracellular barrier.  It is also involved in signal transduction 
as it has been shown to activate the small GTPase, RhoA, and alter the actin 
cytoskeleton.  In another study it was shown to inhibit apoptosis via activation of the 
mitogen activated protein kinase (MAPK) and Akt pathways (Chiba et al. 2008).  
Following the identification of VAPA as an interactor, the co-localisation of the two 
proteins was investigated.  There appeared to be two populations of VAP in epithelial 
cells, one being cytoplasmic, the other localized at the tight junction and co-localised 
with Occludin (Lapierre et al. 1999).  It is yet to be determined if this interaction is 
conserved in other species and whether DVAP is also localized at the equivalent of the 
tight junction in flies termed the Septate junction (Woods et al. 1996). 
 
 
1.12.3 The VAP - FFAT interaction and the Golgi membrane  
 
A group of proteins found to interact with VAP are involved in the biosynthesis and 
trafficking of lipids and sterols and are linked by a common motif termed the FFAT 
motif.  This is so called for the presence of two phenylalanines within a conserved acidic 
tract and it is through this domain that these proteins interact with VAP and are localised 
to the ER. The three members of this group are the Oxysterol Binding Protein (OSBP), 
Ceramide Transfer protein (CERT) and Nir2 and they are all located at the Golgi and ER 
and translocate between these two cellular organelles.   The presence of VAP at the ER 
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directly affects the localisation of all these proteins and as such VAP is a key player in 
the roles played by these lipid trafficking and sterol sensing proteins. The current 
knowledge of what these roles are, are outlined below. 
 
1.12.4 Nir2  
 
Nir2 is a phosphatidylinositol/phosphatidylcholine PI/PC transfer protein involved in the 
regulation of Diacylglycerol (DAG) levels at the Golgi apparatus through the inhibition 
of the CDP choline pathway.(Litvak et al. 2005)  DAG is necessary for protein transport 
from the Golgi to the plasma membrane through its crucial role in the fission of transport 
carriers at the trans Golgi network (TGN).  Nir2 has also been implicated in cell 
morphology and is necessary for the completion of cytokinesis through an interaction 
with the small GTPase RhoA. (Litvak et al. 2002)  In mammals there are three Nir 
proteins, Nir1-3, all belonging to a well conserved family Nir/rdgB involved in 
regulating phospholipid trafficking, metabolism and signaling.  The Drosophila 
homologue is the Retinal degradation B (rdgB) protein characterized for its role in 
photo-receptor cell viability and light response.  RdgB, Nir2 and Nir3 contain an N-
terminal PI transfer domain that is necessary for the transfer of PI and PCs between 
membrane bilayers.   Nir2 is predominantly localized at the Golgi apparatus but there is 
some localization at the ER and this is thought to be accountable to the interaction with 
VAP (Litvak et al. 2002; Amarilio et al. 2005).  Amarilio et al discovered the interaction 
of the Nir proteins with VAPB using co-immunoprecipitation and GST pull down 
experiments.  They characterized the interaction as occurring through the conserved 
FFAT motif present in Nir1-3, of the sequence EFFDAXE. Co-expression of VAP and 
Nir2 in HeLa cells lead to changes in the ER structure and the creation of stacked 
membrane arrays which was dependent upon the presence of the FFAT motif and did 
not occur following over expression of either protein alone. The exact mechanism for 
this stacking phenomenon is unknown but a few hypotheses implicate the ability of VAP 
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proteins to oligomerize and bridge between the membranes following a conformational 
change induced by Nir2.  
 
1.12.5 Oxysterol Binding Protein (OSBP) 
 
An interaction between VAP and OSBP has been shown in all organisms from yeast to 
man.  OSPB binds oxysterols, the hydroxylated derivative of cholesterol, and in 
mammals it is believed to play a role in lipid metabolism and inhibition of the 
mevalonate pathway (Alphey et al. 1998; Lehto and Olkkonen 2003).  However, insects 
are unable to biosynthesize sterols and have to take them in as part of their diet so it is 
likely that there is a separate role for OSBP in the insect that is also conserved in 
humans.  A number of studies have focused on the yeast homologues of OSBP, Osh1-7p.  
Interestingly, considering the effect that DVAP has on the morphology of synaptic 
boutons, Osh3p is involved in the control of membrane growth in yeast (Lehto and 
Olkkonen 2003).   
Furthermore the Osh proteins have been shown to interact with Cdc42 (cell 
division cycle 42), a member of the family of Rho GTPases (Kozminski et al. 2006).  
This interaction is important considering that the Rho GTPases play a number of roles in 
the establishment and maintenance of cell polarity and morphology.  In Drosophila 
Cdc42 activity is necessary for the final stages of dorsal closure through the induction of 
filopodia during this morphogenesis (Van Aelst and Symons 2002).  A conservation of 
the interactions of OSBP would be interesting as Cdc42 signaling is also involved in 
microtubule growth and actin filament assembly and the family of Rho GTPases have 
been shown to act on the neuronal cytoskeleton and affect dendrite and spine 
morphology (Newey et al. 2005).   
In yeast the Osh genes were found to affect the localization of Cdc42p and 
Rho1p and as such will affect the various pathways through which these GTPases act 
(Kozminski et al. 2006).  Nothing is known about the role of OSBP at the synapse but if 
it is a significant interactor of DVAP, as concluded from a number of yeast two-hybrid 
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studies, it is likely to be involved in synaptic morphogenesis and it could be a key player 
in the pathways through which DVAP acts (Wyles et al. 2002; Giot et al. 2003).  OSBP 
and its yeast homologues Osh1-3 contain a Pleckstrin Homology (PH) domain which is 
necessary for the localization to the Golgi network by mediating an interaction with 
PI(4)P present in the Golgi membrane (Levine and Munro 2001; Xu et al. 2001).  
Mutations in the PH domain of OSBP increased the interaction with human VAP A as 
evident by the increased localization to the ER.  This might be due to a reduced 
interaction with the Golgi network or may be that the mutation increases the propensity 
for the VAP interaction (Perry and Ridgway 2006).   In the same study, OSBP was also 
found to directly affect the localisation of CERT.  Under conditions which induce an 
upregulation of Sphingomyelin synthesis, including the addition of exogenous 25-
hydroxycholesterol (25OH), a translocation of OSBP and CERT to the Golgi was 
observed where these two proteins then colocalized.  Upon reduction of OSBP, or any of 
its FFAT, PH or Oxysterol binding domains, the translocation of CERT was no longer 
witnessed and as such the transportation of Ceramide is inhibited.   This in turn stopped 
the production of Sphingomyelin and DAG from the substrates Ceramide and PC.  It is 
now believed that OSBP functions as a sterol sensor and is necessary for the activation 
of CERT at the Golgi.  A closer look at CERT by Perretti et al further uncovered the 
interconnecting pathways within this group of VAP interacting proteins. 
 
1.12.6 Ceramide transfer protein (CERT) 
 
ER-Golgi membrane contact sites are required for non-vesicular ceramide transport via 
the ceramide transfer protein CERT (Hanada et al. 2007).  CERT interacts with the 
Golgi network through its PH domain which binds to the Phosphatidylinositol-4-
phosphate (PI4P) present at the Golgi.  It also binds to ER through the FFAT motif and 
this is via VAP A and VAP B (Kawano et al. 2006; Peretti et al. 2008).  Ceramide is 
produced from L serine and Palmitoyl Co A by a number of reactions at the cytosolic 
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surface of the ER.  It is then transported to the Golgi where it can be converted to 
sphingomyelin (SM) and DAG along with other complex glycosphingolipids (Hanada et 
al. 2009).   
Peretti et al examined the role of the VAP-CERT interaction at the ER by 
knocking down the level of VAP through small interfering RNA (siRNA) in HeLa cells.  
SiRNA triggers the degradation of homologous mRNA, in this case VAP, and in doing 
so effectively silences the gene.  Expression and localization of CERT along with Nir2 
and OSBP were recorded and although expression did not alter there was a significant 
increase in cytosolic localization of the VAP interacting proteins and a loss of Golgi 
targeting (Peretti et al. 2008).  The Golgi localization is normally maintained by the 
interaction of PH domain of OSBP and CERT with PI4P and a reduction of VAP was 
found to directly affect the levels of key lipids including PI4P, DAG and SM.  
Interestingly the expression of Nir2 at a high level could compensate for the reduction in 
VAP and restored the localization of OSBP and CERT at the Golgi.  This was accounted 
for by the possibility that over expression of Nir2 at such a high level could bypass the 
need for a binding partner in the form of VAP at the ER. Even without VAP, Nir2 could 
carry out its normal function which is to transport PIs from the ER to the Golgi where 
they are available for production of PI4P.  This then allowed for the re-targeting of 
OSBP and CERT to the Golgi. In this way, all three of the FFAT/VAP interacting 
proteins are linked as illustrated in figure 1.4.  VAPs presence at the ER is necessary for 
the binding of Nir2, CERT and OSBP.  If VAP localises to the ER-Golgi membrane 
contact sites during periods of reduced cholesterol synthesis, Nir2 would too be localised 
here where, through its N-terminal PI/PC transfer domain it exchanges PIs from the ER 
for PCs following the concentration gradient.  This allows for the production of PI(4)P at 
the Golgi which acts as an anchor for OSBP and CERT and through their colocalisation, 
CERT is activated to bring about the transport of ceramide to the Golgi.  This then leads 
to the production of SM and DAG.  The removal of PCs from the Golgi by Nir2 also 






Figure 1.4  Diagram illustrating the possible interacting pathways of 
CERT, Nir2, OSBP and VAP at the ER-Golgi contact sites.   
Vap (in pink) provides an anchor for the FFAT containing proteins at 
the ER. (Peretti et al. 2008) 
 
 
A number of in vivo studies have been carried out to look closer at the function 
of CERT.  A Drosophila DCERT knock out has been created and although the flies are 
viable they have a significantly shortened life span and decreased ceramide and CPE 
(sphingomyelin equivalent) levels (Rao et al. 2007).  The reduction in CPE caused an 
increased fluidity of the plasma membrane and this made the cells more vulnerable to 
oxidative stress as seen by an increase in lipid peroxide products.  Aging flies showed 
metabolic and motor defects but there was no evidence of neuronal degeneration.  The 
overall phenotype was similar to that of accelerated aging (Rao et al. 2007).  In mice 
lacking CERT, homozygous mutants die as embryos at E11.5 (Wang et al. 2009b).  
Similarly to Drosophila they have a decreased level of sphingomyelin but there is no 
difference in membrane fluidity, perhaps because the decrease is only 50% as compared 
to >70% in flies (Rao et al. 2007).  The level of ceramide in the mutant mice was normal 
but the localisation was altered with an increased concentration at the ER.  Examination 
at a cellular level using transmission electron microscope (TEM) found the ER to be 
engorged and also the mitochondria were abnormal, some degenerating.  The change in 
ER morphology taken together with an observed increase in various UPR pathway 
components indicated that the mice were undergoing chronic ER stress. A number of 
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pro-apoptotic factors were also examined but showed no change as compared to wild 
type controls. There was a significant increase in ceramide levels in the mitochondria 
and this had a negative impact on the activity of cytochrome c oxidase, the terminal 
enzyme of oxidative phosphorylation.  The final cause of death in the mice was due to a 
failure to establish a functioning cardiovascular system due to defects in cell cycle and 
differentiation but not as a result of apoptosis (Wang et al. 2009b).   
Despite the apparent lack of apoptosis in the model created by Wang et al 
(2009), ceramide has previously been shown to induce apoptotic cell death when 
expressed in a range of neuronal cell types including motor neurons (Irie and 
Hirabayashi 1998).  At a low level however, it has a protective role against apoptosis.  
Alzheimers patients have shown an increase in ceramide levels along with cholesterol 
and it is believed that it is involved in the activation of degeneration although perhaps 
through a mechanism other than apoptosis as there is a lack of caspase activity (Marks et 
al. 2008).  Ceramide is also thought to be involved in the formation of atherosclerotic 
plaques and is a key signaling molecule in stroke (Adibhatla and Hatcher 2008). There is 
a rare autosomal recessive disease called Farbers disease which is caused by mutations 
in the acid ceremadise gene which results in an accumulation of ceramide in cells.  
Patients suffer with progressively deformed joints, subcutaneous nodules and premature 
death (Levade et al. 1995; Bar et al. 2001).   
Taking all of the above into account, the interactors of VAP have a number of 
important cellular functions requiring a tight regulation of their localisation and 
production. Mutations affecting VAP, a key player in regulating the localisation of these 
proteins, will presumably have a number of negative effects on the cell and this may be 
involved in the phenotypes associated with ALS8.  There is still much to learn about the 
overall role played by VAP proteins in the cell and the aim of this project is to move a 
few more steps towards a clearer picture of what that might be. 
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1.13 Aims  
 
Through the described interactions, VAP has a number of important roles in the cell 
including membrane lipid composition, cytokinesis and cell morphology.  Add to this 
the data from Drosophila implicating DVAP in the formation of boutons and the 
glutamate receptor configuration, it is obvious that the VAP proteins are key integral 
membrane molecules.  It is no wonder that the mutation discovered has a serious effect 
on the cell but what is still not clear is why it is the motor neurons that are affected in the 
ALS 8 patients and why there is a late onset degenerative phenotype.  For this reason, 
research into the function of VAP proteins is still vitally important as the more 
knowledge gained, the greater will be our understanding of the problems that might arise 
when the mutation is present.  The aims of my thesis are all geared towards increasing 
our understanding of VAP and discovering how the mutation might affect the normal 
functioning of this protein. 
  
Aim 1. Characterisation of the VAPT46I mutation.  In order to characterize the new 
mutant protein the equivalent mutation will be mapped in DVAP and a mutant transgene 
expressed in Drosophila. The resulting phenotype will be compared to the DVAPP56S 
model of disease.  
 
Aim 2.  Verification of the homodimerization of VAP proteins and the effect of the 
mutations.  The Drosophila VAP protein is known to homodimerise and as the human 
homologue VAPB is similar in structure and has the ability to rescue the knock-out fly, 
it would be expected that it has many of the same biochemical properties.  This will be 
tested by yeast two-hybrid screening to examine the interaction between the VAP 
proteins.   
 
Aim 3.  Confirmation of VAP-SAC Interactions. Sac1 was shown to be a potential 
interactor of DVAP in a large scale yeast-two hybrid screen of the protein interactions of 
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Drosophila (Giot et al. 2003).  Considering that FIG4, also known as SAC3, has been 
linked to cases of ALS and it too is a lipid phosphatase this is potentially a very 
important interaction. This interaction will be verified by small scale yeast two-hybrid 
looking at the binary interaction of Drosophila VAP and the Drosphila Sac1.  As a 
functional homologue, human VAP should also be able to form the same complexes as 
its Drosophila counterpart.  Therefore, if the interaction is important, this could mean 
that the interaction with Sac1 is conserved despite the species difference. 
 
Aim 4.  Examining the role of Sac1 in the fly.  After studying the biochemical 
properties of Sac1, an investigation of the protein in the fly will be examined in two 
ways.  Overexpression of the protein by utilizing the GAL4/UAS system or removal of 
the gene to create a knock out will hopefully produce some interesting phenotypes that 
will expose the pathways in which it is involved.  Already Wei et al. (2003) have shown 
that Sac1 is involved in the closure of the amnioserosa during gastrulation as a full null 
mutant is reported as embryonic lethal (Wei et al. 2003a).  If this is the case a 
hypomorphic allele may be used to overcome this lethality whilst still giving a 
phenotype that will allow the characterization of Sac1 at the synapse. 
 
Aim 5. Confirmation of VAP/CERT interactions.  The interaction of VAPs with the 
FFAT domain proteins is potentially very important to understanding the pathogenesis 
of disease in ALS8.  Confirmation of the interaction with dCERT, a known FFAT 
domain protein in Drosophila, and the effect of the mutation on this interaction will 
increase our underatanding of the impact of VAP mutations on downstream pathways 
 
Aim 6. The identification of DVAP interactions by a library scale yeast two-hybrid 
screen.  Using a Drosophila embryonic cDNA library the Drosphila genome will be 
screened for potential interactors of DVAP using the yeast two-hybrid system.  The 
interacting genes will be identified by sequencing and then the interaction verified by 
small scale yeast two hybrid using full length cDNAs as many of the library cDNAs are 











Chapter 2: Material and Methods 
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2.1 Drosophila melanogaster stocks 
 
Strain Source 
Canton S Bloomington Drosophila  Stock Center 
elavC155-Gal4/elavC155-Gal4;+/+ Bloomington Drosophila  Stock Center 
yw/Y; +/+; ey-Gal4/ey-Gal4 Bloomington Drosophila  Stock Center 
BG57-Gal4 (Budnik et al. 1996)  







yw/yw; UAS-Sac1RNAi/UAS-Sac1 RNAi; 
+/+ 
Bloomington Drosophila Stock Center 
yw/yw; UAS-SAC1/UAS-SAC1;+/+ G. Pennetta 
 
Table 2.1 Drosophila Stocks 
 
2.2 Primary Antibodies 
 
Primary Antibody Source 
AffiniPure Rabbit α-HRP Jackson ImmunoResearch 
Guinea Pig α-DVAP G. Pennetta 
Rabbit α-hVAPB Sima Lev 
Rabbit α –c-Myc Sigma 
Mouse α -Flag Sigma 
Rabbit α –SERCA Sanyal et al 2005 
Mouse α -KDEL Stressgen 
Mouse α –HSP70 Affinity Reagents 
 
Table 2.2 Primary Antibodies 
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2.3 Secondary Antibodies 
 
Antibody Source 
Goat α-rabbit Biotinylated IgG Vector Laboratories 
Goat α-rabbit FITC (Flourescein 
isothiocyanate) 
Jackson ImmunoResearch 
Goat α-rabbit HRP Jackson ImmunoResearch 
Goat α-guinea pig HRP IgG Jackson ImmunoResearch 
Goat α – mouse Cy3 (Cyanine) Jackson ImmunoResearch 
Goat α –rabbit Cy3 Jackson ImmunoResearch 
Goat α –guinea pig Cy3 Jackson ImmunoResearch 
 
Table 2.3 Secondary Antibodies 
 
 
2.4 General Cloning Procedure 
2.4.1 Polymerase Chain Reaction (PCR) 
 
The following reagents were mixed in a 0.5ml PCR tube on ice; 5μl Pfu 10x reaction 
buffer (Stratagene), 3μl template DNA (300ng), 5μl forward primer (10μM stock), 5μl 
reverse primer (10μM stock), 5μl dNTP (10mM stock), 26μl ddH2O and 1μl Pfu 
polymerase enzyme (Stratagene).  The reaction mixture was overlaid with 50μl mineral 
oil and the tube inserted in a thermocycler set with the following program. 1) One cycle 
of 95oC denaturation for 2 min, 2) 30 cycles of 95oC denaturation for 30 sec, 60oC 
annealing for 50 sec and 68oC extension for 2 min, 3) Final cycle of 68oC extension for 
10 min.  When complete, the DNA solution was removed from below the mineral oil 
and cleaned by phenol extraction (200μl Phenol Chloroform/ 200μl Tris EDTA (TE, 
pH8.0) and precipitated (20μl 3M NaAc/ 500μl 100% Ethanol) overnight at -20oC or for 
1 hour at -80oC.   
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2.4.2 Restriction Digest  
 
Precipitated DNA was resuspended in TE pH 8.0.  Restriction enzymes (New England 
Biolab), specific for restriction sites within the primers (see table 2.4) and the multiple 
cloning site of the vector, were either used sequentially or combined depending upon 
their compatibility.  If individual digestions are required the DNA was resuspended in 
23μl TE and the reaction set up as follows in a single ependorf; 23μl DNA, 3μl 10x 
BSA, 3μl 10x restriction buffer and 1μl restriction enzyme (all solutions from New 
England Biolab).  The reaction was then incubated at 37oC for 2 hours. The same 
digestions are carried out for the vector DNA.  If two enzymes are compatible the total 
volume is increased to 40μl and the 2 enzymes added together (30μl DNA, 4μl BSA, 4μl 
buffer, 1ul enzyme1 and 1μl enzyme 2) and incubated for 4 hours at 37oC.  Following 




2.4.3  Ligation 
 
Prior to ligation the precipitated insert DNA was resuspended in 17μl TE (pH8.0) and 
the vector resuspended in 10ul.  1ul from each is then run on a 0.8% agarose gel so that a 
rough estimate of DNA ratio can be made.  If necessary the vector DNA was further 
diluted to optimize the probability of insert being taken up by the vector.  The following 
reaction is then set up and put at 14oC overnight. 16μl insert (resuspended in TE pH8.0), 
1μl vector, 2μl l0x ligase buffer, 1μl DNA ligase (Promega) 
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2.4.4  Transformation 
Chemically competent bacterial cells XL1-blue (Stratagene) were used and transformed 
with the ligated DNA constructs.  To 100μl cells 1.7ul B-ME was added and the cells 
incubated on ice for 10 minutes. Then 10μl of DNA ligation mixture was added to the 
cells and incubated for a further 30min on ice.  Mean while the SOC broth was prepared 
and preheated and then the reaction was heatpulsed at 42oC for 45 seconds and then 
incubated on ice for 2 min.  1ml SOC broth was added to the cells followed by a 60 min 
recovery incubation at 37oC with shaking. 200ul of mixture was added per plate 
containing the necessary antibiotic, Kanamycin, Ampicillin of Chloramphenicol 
depending on the resistance conveyed by the vector.  Plates were incubated overnight at 
37oC. 
 
2.4.5  Amplification/extraction of DNA by mini prep (boiling 
method) 
 
DNA was harvested by transferring single bacterial colonies into 2ml of LB medium 
containing the appropriate antibiotic in a 5ml bijou tube incubated overnight at 37oC 
with shaking.  1.5ml of the culture was then transferred into a microcentrifuge tube and 
centrifuged at 12,000g for 2 min.  The supernatant was removed by aspiration and the 
bacterial pellet resuspended in 350ul STET, mixed by vortexing and then 25ul of freshly 
made lysozyme (10mg/ml in 10mM Tris Cl, pH8.0) added.  The microcentrifuge tubes 
are placed in a boiling waterbath for 1min then centrifuged for 10 min at 12,000g.  The 
pellet of bacterial debris was removed using a toothpick and to the remaining 
supernatant 40ul NaAC (2.5M, pH5.5) and 420ul Isopropanol was added to precipitate 
the DNA.  The reaction was mixed by vortexing briefly, storing at room temperature for 
5 min and then centrifuging for 10min at 12,000g.  The supernatant was removed by 
aspiration and the pellet of DNA washed in 70% Ethanol.  This was again centrifuged 
 66
for 2 min at 12,000g and then the supernatant removed by aspiration.  Once dry, the 
pellet was resuspended in 50ul TE pH8.0.  
 
2.4.6 Clean preparation of DNA 
 
Restriction digests were carried out to identify clones carrying the correct insert and 
200ul of the corresponding bacterial culture used to inoculate 150ml LB and incubated 
in a 500ml conical flask overnight at 37oC with shaking.  The DNA was extracted using 
a Qiagen maxiprep kit which uses anion-exchange resin in QIAGEN-tips to selectively 
bind plasmid DNA and allow contaminating impurities to be washed away leaving the 
ultrapure plasmid DNA to be eluted in high salt buffer. The resulting DNA pellet was 
resuspended in 300ul TE (pH8.0). 
 
 
2.5 Site directed mutagenesis  
 
In vitro site-directed mutagenesis was carried out using the QuikChange II XL site-
directed mutagenesis kit from Stratagene. CDNA was obtained for SAC1 from the 
Drosophila Genomics Resource Centre (DGRC) in the form of clone GH08349 in pOT2 
vector.  This was first subcloned into the smaller vector pBluescript SK+ using primers 
aligning to the sequence upstream and downstream of the open reading frame to amplify 
the Sac1 cDNA by PCR. 5’Sac1 (5’-TATTGGATCCCCATCCCTATCACACACG) 
3’Sac1(5’GAGCGGTACCCTAGCA ATGCGTAAAATA) following the general 
cloning procedure outline above and using BamH1 and Kpn1 restriction enzymes. The 
following primers were then used in order to carry out the deletion and substitution (D to 
N) mutagenesis of SAC1.  
Deletion  5’ (5’-GCAGACTGGTGTCTTCGTCGTGCAGAGCATGC) 
3’ (5’-GCATGCTCTGCACGACGAAGACACCAGTCTGC) 
D to N 5’ (5’-CTTCCGAACGAATTGTATCAATTGTCTCGATAGGACGAACG) 
3’ (5’-CGTTCGTCCTATCGAGACAATTGATACAATTCGTTCGGAAG) 
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For DVAPT48I mutagenesis the DNA template was in the form of LD06870 also 
obtained from the DGRC, which is already in a pBluescript vector.  The primers were as 
follows; 
DVAPT48I sense (5’-TCTGGTCTTCAAGATCAAGATAACCGCCCCGAA) 
DVAPT48I antisense (5’-TTTCGGGGCGGTTATCTTGATCTTGAAGACCAGA) 
 
The QuikChange II XL site-directed mutagenesis kit from Stratagene uses PCR to 
replicate the whole plasmid while adding the desired mutation.  In the case of the 
deletion, the primers span the deleted region and because a large fragment was to be 
removed, an extra step of PCR had to be carried out to ensure that the primers anneal to 
the template DNA and not to each other.  The primers for the single Sac1 D to N 
mutation and the DVAPT48I mutagenesis complement the template enough to make this 
extra step unnecessary. 
For the deletion mutagenesis the following reaction was first set up with two 
tubes, one for each primer (sense and antisense). 5ul of 10x reaction buffer, 3ul of DNA 
template (50-200ng), 1ul primer (5’ or 3’), 1ul dNTP, 3ul Quik solution, 37ul of H2O 
and 1ul Pfu DNA polymerase. The reaction was overlaid with 50ul mineral oil and 
placed in the thermocycler for the following program; 1) One cycle of 95oC denaturation 
for 30 sec, 2) Ten cycles of 95oC denaturation for 30 sec, 55oC annealing for 1 min and   
68oC  extension for 8 min.  25ul was then removed from below the mineral oil of each of 
the two reactions and added together in a separate tube.  The second step and the only 
necessary step for the other constructs are as follows.  After mixing together all the 
reaction solutions including both primers and 1ul of Pfu polymerase, the PCR was 
carried out with the following program. 1) 95oC denaturation for 1 min 2) 18 cycles of 
95oC denaturation for 50 sec, 60oC annealing for 50 sec and 68oC extension for 6 min, 3) 
One cycle of 68oC extension for 7 min. 
  To remove the template DNA 1ul Dpn I was added to the reaction mixture 
below the mineral oil and the reaction incubated for 1 hour at 37oC.  This should digest 
all non mutated supercoiled DNA as Dpn I is an enzyme specific to methylated DNA.  
The PCR product is not methylated and as such is not digested.  The next step was to 
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transform supercompetent cells with the mutant DNA.  XL10 Gold ultracompetent cells 
are provided with the kit and are made competent by the addition of B mercaptoethanol 
(B-ME).  To 45ul cells 2ul B-ME was added and incubated on ice for 10 minutes.  Then 
5ul of mutant DNA mixture was added to the cells taking care to remove residual 
mineral oil and incubated for a further 30min on ice.  Meanwhile NZY+ broth was 
preheated and the reaction then heat pulsed at 42oC for 30 seconds followed by 2 min 
incubation on ice.  0.5ml NZY+ broth was added followed by a 60 min recovery period 
at 37oC with shaking. The mixture was then divided into two and plated on LB agar 
medium containing Ampicillin.   After an incubation of 16 hours, a number of colonies 
were picked and cultures prepared and grown overnight in LB broth containing 
Ampicillin to amplify the DNA. Qiagen miniprep was carried out following 
manufacturer instructions to obtain clean DNA suitable for sequencing by the Dundee 
Sequencing Service.  
 Positive clones were obtained and the final step was to subclone the mutated Sac1 
and DVAP into the Drosophila transformation vector pUAST for injection into the fly.  
The desired Sac1 fragment was removed from pBluescript by restriction digest using 
BamH1 and Kpn1 (NEB) sequentially.  The fragment of DNA was then separated and 
purified by running the DNA on an agarose gel and carrying out a Qiagen gel extraction 
following manufacturers guidelines.  The recovered insert DNA was then ligated into the 
multiple cloning site of pUAST cut with BglII and Kpn1 which provided the necessary 
overhanging ends for the ligation. DVAPT48I insert was amplified and removed from 
pBluescript by PCR and then ligated into pUAST.   
 
2.6 UAS-SAC1 Cloning Strategy 
 
The GAL4/UAS system is used in Drosophila to target the expression of genes and the 
pUAST vector is used to insert a UAS-gene into the Drosophila genome.  This is a 
vector into which genes can be subcloned downstream of a tandem array of five 
optimized GAL4 binding sites (Upstream Activation Sequence, UAS), and an Hsp70 
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TATA box and transcriptional start.  The polylinker contains 6 unique sites and is 
followed by a SV40 small-t intron transcriptional terminator and polyA site.  The vector 
was created by inserting this fragment into the P-element vector pCaSpeR3 which 
contains P element ends (P3' and P5') and the white gene thus enabling the insertion of 
the UAS-gene into the genome.  The UAS-gene remains silent unless the fly is crossed 
with a fly expressing GAL4 (Enhancer trap GAL4) and then it is only expressed in those 
cells expressing the GAL4. 
The full length transcript for Sac1 was cloned into pUAST from the GH08349 
clone.  The following primers were used to remove and amplify the sequence from the 
pOT2 vector by PCR following the procedure described in section 2.4 
5’Sac1  (5’-GATCAGATCTCCATCCCTATCACACACG)  
3’Sac1  (5’-GAGCGGTACCCTAGCAATGCGTAAAATA)  
 In the above oligonucleotides the 5’ primer introduced a unique BglII site upstream of 
the sequence, the 3’ primer introduced a unique Kpn1 site at the end of the sequence.  
Once a positive clone was obtained and a clean maxiprep stock made the vector was 
injected in Drosophila.   
 
2.7 Injection Protocol 
 
The injection of clones into flies was carried out in our lab by Andrea Chai following the 
basic protocol outlined here.  Delta 2-3 flies were amplified on grape juice plates with 
yeast paste and on the morning of injection, the plates were changed every 30 minutes. 
3ul of the DNA diluted in TE was loaded into the needle of the injection microscope and 
the compensation pressure set to ensure that during injection, medium will not flow into 
the needle from the cell.  Once there are enough embryos laid during the 30 minute 
period the embryos are carefully washed from the plate into a mesh basket using milliQ 
water and then they are dechorionated using a 50% bleach solution. The basket was held 
in this solution for 3 minutes with agitation then washed clean with milliQ water and 
spread onto a piece of red grape juice agar.  The embryos were carefully aligned against 
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the edge of the agar with the micropile facing outwards and then stuck carefully onto a 
coverslip wrapped in double sided tape. The coverslip was placed onto a slide and the 
embryos desiccated by placing in a chamber with silica gel for approximately 4 minutes 
depending on room humidity.  The embryos were then covered in a drop of heavy oil 
and were ready to be injected into the germ-line precursor cells which must be done 
before cellurization occurs.  The resulting surviving larvae were carefully placed in a 
vial of food and the resulting flies crossed as virgins to yw (yellow white) flies.  The F0 
are phenotypically normal but the resulting F1 from these crosses may be transgenic.  
Pigmentation in the eye indicates the single or multiple insertion of the transgene 
because of the presence of the linked mini-white reporter gene. 
 
2.8 Immunohistochemistry 
2.8.1 DVAP staining of third instar larval NMJs 
 
Wandering third instar larvae were selected and dissected in 1xPBS (phosphate buffered 
solution) and then fixed in Bouin’s fixative (15:5:1 saturated picric acid, 37% 
formaldehyde and glacial acetic acid) for 5 minutes.  The samples were washed in 0.1% 
PBT (PBS + 0.1% TritonX-100) and then blocked with NGS for 30 minutes under 
rotation.  The antibodies; Affinipure rabbit α-HRP (Horseradish peroxidase) (Jackson 
ImmunoResearch) and guinea pig α-DVAP (GP33) (Pennetta et al., 2002) were then 
added in 5% NGS (normal goat serum) and 0.1% PBT at a concentration of 1:500 and 
1:1000 respectively and the samples put at 4oC to rotate overnight.  The samples were 
washed for 2 hours in 0.1%PBT, changing the solution every 15 minutes, and then 
incubated with the secondary antibodies; α rabbit FITC (flourescein isothiocyanate) 
(Jackson ImmunoResearch) and α GP-Cy3 (cyanine) at 1:1000 and 1:500 respectively in 
5% NGS and O.1% PBT.  After 2 hours incubation at room temperature the samples 
were again washed for 2 hours in 0.1% PBT and then mounted on a slide with 
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Vectashield (Vector Laboratories).  Larval NMJs were imaged using an Axiovert Zeiss 
microscope. 
2.8.2 Staining of third instar larval brains 
 
Larvae were dissected in 1x PBS and fixed in Bouin’s fixative for 5 minutes.  After 
washing with 0.1% PBT they were blocked in 10% NGS for one hour and then 
incubated at 4oC overnight with primary antibodies in 5% NGS and 0.1% PBT. Samples 
were then washed in 0.1% PBT for 2 hours and then incubated with secondary 
antibodies in 5% NGS and O.1% PBT.  After 2 hours incubation at room temperature 
the samples were again washed for 2 hours in 0.1% PBT and then mounted on a slide 
with Vectashield.   Primary antibodies used were as follows: Affinipure rabbit α-HRP 
(1:500, Jackson ImmunoReseach), guinea pig α-DVAP (1:1000, Pennetta et al., 2002), 
Mouse α KDEL (1:50, Stressgen), mouse α HSP70 (1:200, Affinity BioReagents) 
Secondary antibodies were all from Jackson Immuno Research and were as follows: 
Goat α-rabbit FITC (1:100), goat α-GP Cy3 (1:500) and goat α-mouse cy3 (1:500)  
 
2.8.3 Larval body wall staining 
 
Wandering third instar larvae were selected and dissected in 1xPBS (phosphate buffered 
solution) and then fixed in Bouin’s fixative (15:5:1 saturated picric acid, 37% 
formaldehyde and glacial acetic acid) for 5 minutes.  The samples were washed in 0.1% 
PBT (PBS + 0.1% TritonX-100) and then blocked in 10% NGS in PBT for 1 hour under 
rotation. Samples were then incubated with the primary antibodies in 5% NGS in PBT at 
room temperature for 2 hours or at 4oC overnight.  After 2 hours of washing in PBT 
changing solution every 15 minutes the larvae were incubated for 2 hours with the 
secondary antibodies in 5% NGS in PBT  and then washed for another 2 hours in PBT.  
Larvae were mounted on slides in VectaShield.  The primary antibodies used were as 
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follows; rabbit polyclonal anti HRP (1:200, Jackson ImmunoResearch), mouse 
monoclonal anti KDEL (1:50, Stressgene), guinea pig polyclonal anti DVAP (1:1000, 
Pennetta et al 2002), mouse monoclonal anti HSP70 (1:200, Affinity Bioreagents), 
rabbit polyclonal anti-SERCA (1:1000, Sanyal et al, 2005), guinea pig polyclonal anti-
Boca (1:1000, Culi and Mann, 2003)  Co-staining with anti Boca required a different 
DVAP antibody so rat polyclonal anti-DVAP was used (1:1000, Pennetta et al 2002). 
Secondary antibodies were all used at a concentration of 1:500 (Jackson 
ImmunoResearch). 
 
2.9 COS 7 cell transfections and immunohistochemistry 
 
 
The open reading frame of DVAPT48I and wt DVAP were amplified from their 
pBluescript vectors by PCR using the following primers; 
 pCMV-Flag DVAP 5’ (5’-CGAGTCGACCGTTCGTTTATGGCA) and  pCMV-Flag 
DVAP 3’ (5’-GCGGGAATTCGCCACAATGAGCAAATC)      
 pCMV-c-Myc T48I 5’ (5’-CGCGGAATTCCCACAATGAGCAAATCA)  and pCMV-
myc 3’ (5’-ATACGGTACCGGCGTTCGTTTATGGCA)   
The amplified inserts were cloned into c-Myc- and Flag-tagged pCMV expression 
vectors.  DCERT was also cloned into pCMV-c-Myc and Flag expression vectors by 
amplifying the ORF using the following  primers: 
pCMV DCERT Flag 5’  (5’-CTGGCAGAATTCAAGAAGATG) and      
3’(5’ATTAGGGCCCTCAGAACATGA) 
pCMV DCERT c-Myc 5’ CACTGGTACCTCAGAACATGATCGGCT) and 3’ (5’-
GCTAGAATTCGGAAGAGGATGGACACG)  
 
COS-7 cells were cultured in DMEM medium containing 10% FCS and 1% 
penicillin/streptomycin. COS-7 cells were seeded on Poly-D-Lysine Coated glass 
coverslips (BD BioCoat) at a concentration of 150,000 cells/ml. The following day, cells 
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were transfected with Fugene 6 Transfection Reagent (Roche) according to 
manufacturer's instructions (see section 2.11).  After 24 h the cells were fixed in 4% 
paraformaldehyde for 20 min and blocked in PBT containing 10% normal goat serum. 
Stainings with the relevant antibodies were performed accordingly to the procedure 
described above. The following primary antibodies were used: Rabbit anti-myc (Sigma) 
and mouse anti-Flag (Sigma) at a concentration of 1:500 and 1:200 respectively. 
Secondary antibodies (Jackson ImmunoResearch) were all used at a concentration of 
1:500.      
 
2.10 Scanning Electron Microscopy of the Drosophila eye 
 
To observe the degenerative phenotype of the adult eye, Drosophila were decapitated 
under CO2 and immediately fixed with 3% Glutaraldehyde in 0.1M Sodium Cacodylate 
Buffer (pH 7.4) for more than 3 hours.  They were then washed in 0.1M Sodium 
Cacodylate buffer (pH7.4) for 1 hour changing every 20 minutes and incubated in 1% 
Osmium Tetroxide in 0.1M Sodium Cacodylate buffer for 1-2 hours.  The samples were 
then washed in distilled water for 30 minutes, dehydrated in 50%, 70%, 90% acetone for 
10 minutes each and then 3 times in 100% acetone and finally after drying with CO2 in a 
Polaron E3000 SII CPD the samples are sputter coated with 20nm Gold/Palladium 
(60/40) in an EMSCOPE SC500 Sputter Coater.  The samples were scanned with a 
Phillips 505 scanning eletron microscope  (SEM).  Fixing and preparation of the samples 





COS-7 cells were cultured in DMEM medium containing 10% FCS and 1% 
penicillin/streptomycin.  100,000-300,000 cells were plated in 2 ml of medium (50,000-
150,000 cells/ml) in one well of a 6 well plate.  The DNA for transfection was diluted to 
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a concentration of 0.5ug/ul meanwhile the Fugene 6 reagent (Roche) and serum free 
DMEM medium (Sigma) were warmed at room temperature.  6ul of Fugene was added 
to 94ul of DMEM in a sterile eppendorf, tapped to mix and then incubated for 5 minutes.  
2ul of the diluted DNA was added to the reaction mixture, mixed and incubated for at 
least 15 minutes. The complex was then added dropwise to the cells, 100ul reaction per 
well and the cells incubated at 37oC for 3 days.  Cells were then trypsinized and 
resuspended in 1ml DMEM.  The cells were lysed using Hepes-lysis buffer containing 
1% Digitonin following the following protocol.  A 2x stock solution of Hepes-Lysis 
buffer was made containing 100mM Hepes-NaOH buffer (pH7.4), 2mM EDTA and 
100mM NaCl.  To 5ml of this buffer the following were added; 5ml H2O, 20μl DTT 
(0.5M), 100μl 100mM PMSF and 1 tablet protease inhibitor.  Finally to 500μl, 5mg of 
Digitonin was added.  The transfected cells were spun down at 2000 rpm for 5 minutes, 
washed by resuspending in 1 ml PBS, centrifuged again and resuspended in 160ul of the 
freshly prepared lysis buffer.  The samples were incubated for 45 minutes on ice and 
after removing 10μl as input, the cell lysate was centrifuged at 13,000 rpm for 20min at 
4oC.  The supernatant was incubated with 10ul of myc-beads (Pierce-c-myc IP/CO-IP 
kit) overnight at 4oC in columns provided with the kit.  The following morning the 
columns were centrifuged and the supernatant collected as it flowed from the column 
leaving only the beads and any interacting proteins behind.  The column was washed 3 
times in a 0.1% Digitonin wash buffer (as for lysis buffer but 10x less Digitonin) and 
then the myc tagged proteins eluted by incubating samples at 95oC with 40ul non-
reducing sample buffer.  Samples from the beads, supernatant and initial input cell lysate 
were then run on a 12% SDS-PAGE gel for Western blot analysis. 
 
 
2.12 Western Blot 
 
The electrophoresis module (Biorad laboratories) was assembled and the protein 
samples and molecular weight marker (Molecular Probes) were loaded into each well of 
an 12% SDS-PAGE gel.  Electrophoresis was carried out at 100 volts for 90 minutes.  
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The gels were removed and the protein transferred onto Hybond-P PVDF membranes 
(Amersham Biosciences) at 120V for 2 hours.  The membranes were incubated in 
blocking solution which contains 2% ECL Advance Blocking Agent  (Amersham 
Biosciences) diluted in TBST (Tris buffered solution with Tween)-0.1% Tween 20 
(Sigma) in TBS (8 grams NaCl, 20ml 1M Tris at pH 7.6 brought up to 1 litre volume 
with distilled water).  The following morning, the membranes were rinsed briefly in 
TBST and then incubated with primary antibodies in blocking solution for 2 hours with 
gentle agitation.  Membranes were then washed vigorously for 2 hours in TBST 
changing solution every 15 minutes.  The membranes were then incubated for two hours 
with the secondary antibodies with gentle agitation.  Following this final incubation the 
membranes were again washed for 2 hours in TBST.  Signals were detected on the 
membranes using the ECL Advance Western Blotting Detection Kit (Amersham 
Biosciences). Soutions A and B in the kit were mixed at a 1:1 ratio and then pipetted 
onto membrane in a thin layer and left for 1 minute.  Excess was removed by blotting on 
a paper towel and then the membrane wrapped in cling film.  In a dark room the 
membranes were placed in an X ray film cassette and exposed to autoradiography film 
(HyperfilmTMECL) for 60 seconds.  The film was then submerged in developer for 30-
60 seconds, rinsed in water and then submerged in fixer. 
The antibodies used for the Western were as follows. Primary antibodies: Guinea 
pig anti DVAP (GP33, 1:40,000) and rabbit anti c-myc (Sigma, 1:10,000) Secondary 
antibodies were all from Jackson ImmunoResearch and were as follows. Goat anti rabbit 
HRP (1:30,000) and goat anti guinea pig HRP (1:60,000)  
 
2.13 The yeast two-hybrid System 
 
We used the MATCHMAKER GAL4 Two-Hybrid System 3 for our yeast two-hybrid 
and the Drosophila wild-type VAP as the bait protein to screen a Drosophila embryonic 
library provided by Clontech. This system incorporates a number of features that reduce 
the incidence of false positive results.  The yeast strain used is AH109, (MATa, trp1-901, 
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leu2-3, 112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2 : : GAL1UAS-GAL1TATA-HIS3, 
GAL2UAS-GAL2TATA-ADE2, URA3 : : MEL1UAS-MEL1 TATA-lacZ)(Clontech) which 
virtually eliminates false positives through the incorporation of three reporters; ADE2, 
HIS3, and MEL1 (or LacZ), all under the control of distinct GAL4 upstream activating 
sequences (UASs) and TATA boxes.  These promoters yield strong and specific 
responses to GAL4 which means that false positives caused by proteins interacting 
directly with the sequences flanking the GAL4 binding site and those that interact with 
transcription factors bound to specific TATA boxes should not occur.  The ADE2 
reporter allows yeast to grow on medium lacking Adenine and this alone provides strong 
nutritional selection.  Using HIS3 selection (media lacking in Histidine) reduces the 
incidence of false positives and increases the stringency of selection.  There is also the 
option of using either MEL1 or LacZ, which encode α-galactosidase and β-galactosidase, 
respectively. In this screen we are using MEL1 because α-galactosidase is a secreted 
enzyme so it can easily be assayed directly on plates containing X-α-Gal.  In the 
occurrence of an interaction, not only will the yeast be able to grow on plates lacking 
Adenine and Histidine but the colonies will be blue in colour due to the secretion of α-
galactosidase. Provided in this kit are two types of cloning vectors pGBKT7 contains the 
GAL4 binding domain and pGADT7 contains the activation domain.  Full length and 
truncated forms of DVAP bait constructs were generated by cloning cDNA fragments in 
frame alongside the Gal4 binding domain coding sequence in pGBKT7 vector. The 
oligonucleotides listed in Table 2.4 were used to amplify the various fragments from the 
full length cDNA clone LD06780 for DVAP and GH08349 for SAC1 (received from the 
DGRC) by PCR using Pfu turbo polymerase (Stratagene).   The same oligonucleotides 
could be used to clone the ORF of these genes into pGADT7 in frame downstream of 
the GAL4 activation domain coding sequence to produce a target fusion protein. 
 
2.13.1 The Drosophila embryonic library 
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A Drosophila 0-24 hour embryonic library was obtained from Clontech.  This is a 
library of cDNA inserted into pACT2 vectors. Like pGADT7, this vector contains a 
GAL4 activation domain and will initiate transcription when brought into close 
proximity to a bait protein containing the GAL4 binding domain.  During construction 
of the library cDNA is initially inserted into the lambda phage ACT2 and then released 
into E.coli.  The average size of the cDNA inserted into the pACT2 vectors is 1.4kb and 




Primer Sequence 5’-3’ 
DVAP 5’ EcoR1 GCCAGCGAATTCGCCACAATGAGCAAATCA 
DVAP 3’ BamH1 TAGTGTGGATCCTAGCATGTTGCTGGCGTT 
C-term DVAP EcoR1 GCAGGAATTCGCAAATGCTGAGAACACC 
N-term DVAP BamH1 GAATGGATCCGGTGTTCTCAGCATTTGC 
Sac1 5’ Nde1 TGCACATATGATCATGGACAGCAGGGAG 
Sac1 3’ BamH1 TTACGGATCCACGACACTAACGTCATGG 
C term Sac1 Nde1 GCAGCATATGGAGTCTTTCGACTTCCAC 
N-term Sac1 BamH1 GATTGGATCCGATGAGTATGTTCAGCCG 
Short Sac1 3’ Kpn1 GAGCGGTACCTACATTGCAGTTAATCG 
hVAP 5’ EcoR1 TTGAGTGAATTCATGGCGAAGGTGGAGCAG 
hVAP 3’ BamH1 GTAGAAGGATCCATGCTACCTCTACAAGGC 
Pio 5’ EcoR1 TGCCGAATTCACCATGAAGACAGGCACT 
Pio 3’ BamH1 TGTAGGATCCTCCATCCTCCTCATCTTC 




Table 2.4  Primers from the yeast two hybrid 
 
 
2.13.2 Titration and amplification of the Library 
The library of cDNA clones was obtained from Clontech and, upon arrival, the first step 
was to titer the library.  Various dilutions of a library aliquot were plated on LB plates 
containing Ampicillin and incubated at 30oC for 24 hours.  The titer (cfu/ml) was then 
calculated by counting the number of colonies. 
(Initial dilution ½) Dilution: 10-6  No. of colonies: 177   Amount plated: 100μl 
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177 x 1/100 x 106 = 1.77 x 106 = 1.77 x 109 colonies per ml.     x 2 = 3.2 x 109 cfu 
(colony forming units) 
It is suggested that 2-3 times no. of independent colonies should be plated = 9 x 106 at a 
concentration such that the colonies are almost confluent on the 150mm plates ~ 20,000 
9,000,000/20,000 =  450 plates. 
The plates were incubated at 30oC to avoid any plaques due to phage contamination as a 
by-product of the library construction in the lambda phage.  Plates were incubated for 36 
hours.  To remove the colonies, 5 ml of LB media was pipetted onto each plate and then 
the bacteria scraped into the solution using a bent Pasteur pipette and then removed and 
pooled together.  The resulting 2.25 litres of bacteria culture was then left shaking at 
30oC for 3 hours to help the bacteria recover and then sterile glycerol added to a final 
concentration of 25% and the solution aliquoted and put at -80oC.  A third of the culture 
was set aside for plasmid preparation and this was divided between 6 Beckman 
centrifuge flasks and pelleted down by centrifuging at 6000rpm for storage at –20oC.  
The plasmids were purified using a QIAGEN Plasmid Giga kit that follows a protocol 
based on a modified alkaline lysis procedure followed by binding of plasmid DNA to 
QIAGEN Anion-Exchange Resin in a column.   
 
2.13.3 AH109 Stock 
 
The AH109 yeast strain is provided in the kit as a frozen glycerol stock.  This must first 
be streaked onto YPDA plates before a colony picked and the yeast plated onto selective 
SD plates missing the vital nutrients Methionine and Uracil.  The yeast colonies are 
allowed to grow for 1-2 weeks until the colonies are about 2mm in size and then the 
plates sealed and stored in a fridge for a maximum of 2 months before they should be 
replated.  For use to inoculate a liquid culture the yeast colonies should be about 1 week 
old and ideally incubated at a constant temperature of 30oC and if the colonies are less 
than 2mm in size, a number of colonies should be picked.  
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2.13.4 Transfection protocol 
 
Initially 50ml of YPDA is inoculated and incubated overnight for 16-18 hours at 30oC 
until the OD600 is greater than 1.5.  The culture is then diluted into a culture of 300ml 
YPDA so that the OD600 is 0.2-0.3 and again incubated at 30oC for at least 3 hours until 
the OD600 is 0.5±0.1.  The yeast culture is then pelleted down in sterile falcon tubes 
using a tabletop centrifuge at 1000 x g for 5 minutes.  The pellets are resuspended in 
sterile ddH2O and combined into a total volume of 20-50 ml.  Recentrifuge, remove 
supernatant and resuspend in a total volume of 1.5ml 1xTE/LiAC.  The cells are now 
competent and ready for transfection.  Herring testes carrier DNA provided by clontech 
is mixed with the vector DNA to be transfected and the cells added along with a 
polyethylene glycol/LiAC/TE solution.  PEG is necessary for inducing the binding of 
DNA to the yeast cell and Li+ permeabilises the cell wall allowing the DNA to enter and 
bind to the cell membrane. Finally with the addition of Dimethyl sulfoxide (DMSO) and 
a 15 minute heat shock the integrity of the plasma membrane is damaged and it is 
permeabilised for the entry of vector DNA.  The preps are put on ice for two minutes 
after the heat shock and then pelleted down briefly and resuspended in 500ul TE pH 7.5 
or YPDA.  200μl is plated onto the selective SD Drop out plates, -Leu,Trp to select for 
the presence of both vectors  and -Adenine, Histidine, Leucine, Tryptophan (AHLT) for 
an interaction. 
 
2.13.5 Library Scale Yeast two Hybrid Screen  
 
A Drosophila 0-24 hour embryonic library containing a library of cDNA inserted into 
the pACT2 vector containing the GAL4 activation domain was obtained from 
Clonetech.  Following amplification and titering of the library as described above yeast 
strain AH109 was cotransfected with the full length DVAP BAIT plasmid and library 
plasmids following the protocol outlined previously but with an initial culture of 150ml 
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diluted into 1 litre. A final volume of 10ml transfected yeast is obtained which is plated 
on 50 large 150mm AHLT plates.  
 
2. 14  Reagent Stocks 
 
EDTA (0.5M) pH 8.  Add 186.1g disodium EDTA.2H2O to 800ml of H2O, adjust the 
pH to 8.0 with NaOH and bring up the volume to 1 litre 
 
 
SOB Per liter: 20g Tryptone, 5g Yeast extract, 0.5g NaCl. Add dd H2O to a final 
volume of 1liter and autoclave.  Then add 10ml filter sterilized 1M MgCl2 and 10ml 
filter sterilized 1M MgSO4 prior to use. Store at –20oC or –80oC in 50ml aliquots 
 
SOC Per 100ml: Add 2ml filter sterilized 20% glucose or 1ml filter sterilized 2M 
glucose.  Bring up to 100ml with SOB (autoclaved) 
 
Sodium Acetate (3M, pH5.3): Dissolve 408.3g of Sodium Acetate.3H20 in 800ml of 
H2O. Adjust pH to 5.3 with glacial acetic acid and adjust volume to 1 liter with H2O. 
 
STET: 10mM Tris-Cl pH 8.0, 0.1M NaCl, 1 mM EDTA pH 8.0 and 5% (v/v) Triton X-
100 
 
Tris-Cl (1M): Dissolve 121.1g of Tris base in 800ml of H2O.  Adjust pH to desired 
value by adding concentrated HCl.  For pH 8.0 add 42ml HCl.  Bring up the volume to 1 
litre.  Sterilize by autoclaving 
 
10 x Tris EDTA (TE) pH 8: 100mM Tris-Cl (pH8) and 10mM EDTA (pH8) 
 
50x TAE: 242g Tris base, 57.1ml glacial acetic acid, 100ml of 0.5M EDTA (pH8.0) 





 Stock concentration Working Conc. In 100ml 
Ampicillin 100mg/ml 100ug/ml 100ul 
Kanamycin   10mg/ml   50ug/ml 500ul 












Chapter 3: Results 
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3.1 Characterization of the T46I mutation using Drosophila 
 
 
As described earlier, there has recently been a discovery by the lab of Prof. Jaqueline de 
Belloroche of Imperial College London of a new mutation in VAPB (T46I) that is also 
believed to be causative for ALS.  Such a discovery adds weight to the role played by 
VAPB in ALS as despite there being a large number of VAPP56S affected individuals, 
the fact that they are all related and carry the same mutation still provides room for 
argument against the worth of this mutant protein in ALS research.  The T46I mutation 
has been identified in a completely unrelated family and is also within the MSP domain 
of VAP which is highly conserved from yeast to man. Two mutations linked to ALS and 
both affecting residues of such a conserved domain make the case much stronger for the 
necessity of research into VAP proteins with respect to ALS and perhaps other 
degenerative diseases.  It is now necessary to characterize the VAPT46I mutant protein 
and Drosophila is the ideal model system for this.   
The mutation in humans was mapped to the corresponding residues in 
Drosophila by aligning the primary sequences for these two proteins.  The 
corresponding Threonine mutated in Drosophila is at position 48 (T48I) and site 
directed mutagenesis on the wt cDNA clone of DVAP (LD06878) was carried out to 
generate mutated cDNA which was then subcloned into a Drosophila transformation 
vector (UAS-DVAPT48I). The construct was injected into Drosophila embryos and the 
P element transposase recognition sites within the pUAST vector, enables the insertion 
of DNA into the Drosophila genome when transposase is present.  A number of 
transgenic lines were established and the transgene expressed using the GAL4 UAS 
system as described in Chapter 1.4 (Brand and Perrimon 1993).  A number of 
experiments have been carried out to observe the effect of this mutation on DVAP in 
vivo as compared to the wild type and original P58S mutation.   
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HVAPB 1   MAK--VEQVLSLEPQHELKFRGPFTDVVTTNLKLGNPTDRNVCFKVKTTA     48 
          |:|  .:..|::||:|||:|.||||..|.|.:.|.|.:...:.||:||||  
DVAP  1   MSKSLFDLPLTIEPEHELRFVGPFTRPVVTIMTLRNNSALPLVFKIKTTA     50 
 
      49  PRRYCVRPNSGIIDAGASINVSVMLQPFDYDPNEKSKHKFMVQSMFAP--     96 
          |:|||||||.|.|....|..|.:.||||.||..||:||||||||:.||   
      51  PKRYCVRPNIGKIIPFRSTQVEICLQPFVYDQQEKNKHKFMVQSVLAPMD    100 
 
      97  TDTSDMEAVWKEAKPEDLMDSKLRCVFELPAENDKPHDVEINKII-----    141 
          .|.||:..:||:.:||.|||:||:||||:|.......:......:      
      101 ADLSDLNKLWKDLEPEQLMDAKLKCVFEMPTAEANAENTSGGGAVGGGTG    150 
 
      142 --------STTASKTETPIVSKSLSSSLDDTEVKKVMEECKR---LQGEV    180 
                  :.|:|.:...:.||...||.|..:...::|..:.   |.||: 
      151 AAGGGSAGANTSSASAEALESKPKLSSEDKFKPSNLLETSESLDLLSGEI    200 
 
      181 QRLREENKQFKEEDGLRMRKTV----------QSNSPISALAPTGKEEGL    220 
          :.|||.|.:.:.|: |.::..:          |.|.|   .||...|:.: 
      201 KALRECNIELRREN-LHLKDQITRFRSSPAVKQVNEP---YAPVLAEKQI    246 
 
      221 STRLLALVVLFFIVGVIIGKIAL    243 
          ....:|:.:...||.:::||..| 
      247 PVFYIAVAIAAAIVSLLLGKFFL    269 
 
B 
Yeast  FKVRTSAPTKYCVRPN 
Aplysia  FKVKTTAPKRYCVRPN 
Drosophila FKIKTTAPKRYCVRPN 
Mouse  FKVKTTVPRRYCVRPN 
Human  FKVKTTAPRRYCVRPN 
 
   
Figure 3.1 Comparison of VAP sequences 
A) Alignment of the human and Drosophila VAP protein sequence.  Lines joining two letters 
indicate complete conservation, dots indicate moderate conservation (: more so than a single 
dot).  The MSP domain is boxed and spans 100 amino acids in Drosophila, 96 in humans. The 
two mutated residues that have been linked to ALS are the P56S and T46I in humans shown by 
the green highlight.  These correspond to P58S and T48I in Drosophila.  They both fall within 
the 16 amino acid sequence (highlighted in pink) which is highly conserved from yeast to man as 
shown in panel B.  The yellow region is the coiled coil domain and the blue region is the 
transmembrane domain.  Figure is adapted from Chai et al 2008. Sequences are from Flybase 




3.3 Neuronal over-expression of DVAPT48I in Drosophila larvae 
induces aggregate formation  
 
Previous work looked at the effect of over-expressing DVAPP58S in Drosophila larvae 
under the control of the pan neural elav-gal4 driver and found that the mutant protein 
formed large aggregates in the nerve fibers and cell bodies of the larva brain when 
expressed together with the endogenous wt protein (Chai et al. 2008).  In wt larvae the 
localisation of DVAP is homogeneous along the length of the nerve fiber and in the 
membrane and cytoplasm of the cell bodies but this is lost and replaced by bright 
punctate staining upon transgenic expression of the pathogenic mutant protein.  This 
suggests that the presence of DVAPP56S leads to the formation of aggregates and 
sequesters DVAP away from its normal localisation. See figure 3.2. 
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Figure 3.2 Transgenic DVAPP58S expression induces aggregate formation in the larval 
brain and nerve fibers 
Nerve fibers and brains of third instar larvae stained with antibodies for DVAP (red) and the cell 
surface marker anti-HRP (green). A) Wt (Canton S) larvae show faint but uniform DVAP 
staining along the length of the nerve fiber. B) Larvae expressing transgenic DVAPP58S under 
the control of the elav-GAL4 pan neural driver present with concentrated spots highly 
immunoreactive  for DVAP marking the presence of aggregates along the nerve fiber in regions 
just prior to the brain or the muscle endplate but not in between these regions (C). D) Brains of 
wt larvae show uniform staining of the plasma membrane around the cell bodies and similarly to 
the nerve fibers this is reduced to punctate staining in the brains of larvae expressing transgenic 
DVAPP58S (E).  In (D) and (E), single sections of confocal images are shown. Scale bars are 20 




Following the creation of the DVAPT48I transgene it is important to see if it too induces 
the formation of aggregates in the Drosophila nervous system. Similarly to the previous 
experiment (Chai et al. 2008), DVAPT48I was expressed under the control of elav-GAL4 
and the localisation of DVAP examined in the larva nerve fibers and cell bodies using 
antibodies specific for DVAP (GP33) and the neuronal cell surface marker (HRP).  Wt 
(Canton S) and transgenic third instar larvae were dissected and stained with the two 




Figure 3.3 Transgenic DVAPT48I expression induces aggregate formation in the larval 
brain and nerve fibers  
Brains and nerve fibers of third instar larvae were stained with antibodies against DVAP (red) 
and the neuronal cell surface marker anti-HRP (green).  A) Control wt larvae (Canton S) have 
uniform staining for DVAP around the cell bodies of the nerve. B) In DVAPT48I larval brains 
DVAP staining is reduced to bright punctuate, suggestive of aggregates. C)  Nerve fibers from 
wt larvae present with a faint and uniform staining for DVAP while in T48I transgenic nerves, 
large aggregates that are strongly immunoreactive for DVAP accumulate along the nerves (D). 
Scale bars are 10µm.    
 
The results from the transgenic larvae expressing DVAPT48I in a wt background showed 
that in the presence of the endogenous protein, aggregates formed that are brightly 
immunoreactive for DVAP and there is a reduction in staining for DVAP in other areas 
of the nerve (figure 3.3).  The data are identical to those seen with the previous mutation, 
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P58S (figure 3.2), and are suggestive of a similar disease mechanism.  If the hypothesis 
is correct that the formation of aggregates sequesters wt DVAP away from its normal 
localisation then the composition of the inclusions would be of both mutant and wt 
protein.  In the previous experiments this could not be proven as the DVAP antibody 
detected both forms of the protein.  To further analyse the aggregates, COS7 cells were 
utilized to examine the composition of such inclusions following the expression of 
tagged wt and mutant DVAP proteins. 
 
3.4 Composition of aggregates following expression of 
DVAPT48I 
 
In order to differentiate between the mutant and wild type DVAP, Flag- and c-Myc- 
tagged fusion proteins were created by subcloning the cDNA into pCMV vectors 
containing the tag sequence upstream of the multiple cloning site.  The resulting N-
terminally tagged DVAP-Flag and DVAPT48I-Myc were expressed in pCMV under the 
control of the cytomegalovirus promoter in COS7 cells following the co-transformation 
of the two plasmids into this cell line.  Anti-c-Myc and anti-Flag staining allowed for the 




Figure 3.4 Cotransfection of COS7 cells with DVAP and DVAPT48I  induces aggregate 
formation composed of both wt and mutant protein 
COS7 cells transfected with DVAP-Flag and DVAPT48I-c-Myc under the control of the 
cytomegalovirus promoter and stained with antibodies specific for the two tags.  A) Staining 
against Flag in control cells expressing DVAP-Flag alone show a uniform staining throughout 
the cytoplasm in a reticulum pattern that is consistent with an ER-associated protein. B-G) Cells 
co-transfected with wt and mutant DVAP show a staining pattern suggesttive of aggregate 
formation. D and G) Anti-Flag and Anti-c-Myc staining show colocalisation suggesting that the 
aggregates are composed of both wt and mutant DVAP. 
 
Anti-flag staining of the COS-7 cells transfected with DVAP alone is of a uniform 
perinuclear reticular staining pattern as would be expected for an ER-associated protein 
(figure 3.4).  However when the COS-7 cells are cotransfected with both wt and mutant 
protein the staining becomes more diffuse with punctuate staining highly 
immunoreactive for both Flag and c-Myc tags.  This staining is very similar to that seen 
in the cell bodies of Drosophila larvae and is suggestive of the formation of aggregates 
in the cells.  The colocalisation of the staining shows that the aggregates are indeed 
composed of both wt and mutant protein.  
 
3.5 DVAPT48I induces aggregate formation and sequesters wt 
DVAP away from its normal localisation 
 
The experiments described here have clearly shown that the T48I mutation in DVAP 
brings about a similar phenotype at a cellular level to that seen when DVAPP58S is 
expressed in the Drosophila larval nervous system (Chai et al. 2008). In the nervous 
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system DVAP is faintly but uniformly expressed along the nerves and at the synapse.  
Following the addition of mutant transgene (T48I or P58S), DVAP accumulates into 
aggregates which mainly concentrate at the proximal and distal ends of the nerve.  A 
lack of staining between these points suggests a sequestering of DVAP away from these 
areas of the nerve.  Previously we did not answer the question of whether the 
DVAPP58S induced aggregates contained both wt and mutant protein but now, using 
cell culture, we have shown for DVAPT48I that the inclusions, which only occur when 
both proteins are present, do indeed contain both wt and mutant DVAP.  Following the 
work presented on the Drosophila model of ALS which used DVAPP58S to induce 
many major hallmarks of ALS including the neuronal inclusions as well as muscle 
wasting, neuronal degeneration and locomotion defects, a number of groups looked at 
the possible mode of action for the phenotypes witnessed.  We put forward a dominant 
negative action in the belief that the mutant protein would interfere with the localisation 
of the wt protein.  This is despite it having the ability to rescue the null phenotype and 
retaining a number of its essential functions.  This is perhaps due to an excessive wt 
function so the mutant protein is in fact a hypermorphic allele which causes it to bind 
strongly to wt DVAP and induce aggregation.  This then inhibits the action of the wt 
protein and therefore the final outcome is that of a dominant negative mechanism.  
Following our initial model, other groups supported this hypothesis and have shown in 
both cultured motor neurons and in Drosophila larva muscles that wt DVAP is brought 
into aggregates when DVAPP58S is expressed (Ratnaparkhi et al. 2008; Tsuda et al. 
2008).  Using COS7 cells and GST pull-down Teuling et al have also shown that 
endogenous hVAPB is brought into insoluble aggregates in the presence of hVAPP56S  
(Teuling et al. 2007).  The results that we report here are suggestive of a similar story for 
DVAP in the presence of the mutant protein DVAPT48I.  If this is indeed true, it may 
well be a similar case for VAPBT46I in humans.  
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3.6 Effect of DVAPT48I expression on the ER and chaperone 
HSP70 
 
VAP proteins are type II integral membrane proteins and have been shown to localise to 
the ER in yeast and mammals (Kagiwada et al. 1998; Soussan et al. 1999).  The wt 
staining of DVAP has a pattern that is conducive to an ER localised protein and the 
question to be answered now is whether, following the expression of DVAPT48I, are the 
resulting cytoplamic aggregates linked to a change in the structure of the ER?  Teuling et 
al describe the formation of aggregates in DVAPP56S expressing HeLa cells which they 
reported to contain tubular structures of ER origin (Teuling et al. 2007).  Co-expression 
of VAP along with Nir2 has also been shown to affect the structural integrity of the ER 
in HeLa cells (Amarilio et al. 2005) and removal of CERT, another interactor of VAP 
proteins, causes ER stress as seen by engorgement of this organelle (Wang et al. 2009b).  
DVAP acts as the ER anchor for both these FFAT containing proteins and so, following 
the aggregation and sequestering of wt DVAP it may be expected that there will be a 
direct effect on the structure of the ER.  To investigate the cytoplasmic localisation of 
DVAP in Drosophila, larval brains were stained with antibodies against DVAP and the 
ER marker KDEL.  The ER was also observed following the expression of DVAPT48I 
transgene.  
 Along with changes in the ER, it would be expected that in conjunction with the 
formation of aggregates there will be a change in the pattern and level of heat shock 
proteins in the cell.  Under wt conditions, these chaperones normally prevent the 
accumulation of misfolded proteins by aiding their refolding or facilitating degradation 
by the proteasome (Shinder et al. 2001).  Chaperones are upregulated in response to 
cellular stress and in the SOD1G93A model of ALS, an upregulation of HSP70 has been 
observed (Liu et al. 2005).  The benefit of such a response is still under debate as unlike 
the results seen in primary culture and other degenerative disease, an increase in 
endogenous HSP70 did not extend the lifespan of the SOD1 mice and HSP70 was 
actually reported to be sequestered into the SOD1 aggregates (Shinder et al. 2001; Liu et 
al. 2005).  However in another study the addition of exogenous recombinant HSP70 was 
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found to extend the lifespan and delay disease onset in the SOD1G93A  mouse 
(Gifondorwa et al. 2007).  Some reports suggest that motor neurons have an intrinsic 
inability to respond to cellular stress and have a higher threshold for the induction of the 
heat shock protein response making these neurons more vulnerable to cellular stress 
(Batulan et al. 2003)  The involvement of HSP70 in our Drosophila model of ALS is 
obviously very interesting and as such we stained brains of DVAPT48I transgenic larvae 







Figure 3.5 Expression of DVAPT48I in the larval brain is associated with fragmentation of 
the ER and an upregulation of HSP70 
Brains from wt (Canton S) larvae (A-C, G-I) and transgenic lines expressing DVAPT48I (D-F, 
J-L). A-F) Brains are stained with antibodies specific for DVAP (red) and the ER marker KDEL 
(green).  Fragmentation of the ER accompanied by DVAP aggregates is seen in the brains of 
transgenic larvae. G-L) Brains are stained with antibodies specific for DVAP (green) and HSP70 
(red).  In wt neuronal cell bodies, HSP70 staining is faint but uniform.  In transgenic larvae, 
there is an up-regulation of HSP 70 and some aggregation is seen close to but not overlapping 
with those of DVAP. Scale bars are 10 µm. 
 
Results from the co-staining of Drosophila larval brains with antibodies against DVAP 
and KDEL are suggestive of a good colocalisation of DVAP with the ER in the 
cytoplasm of the brains.  In transgenic flies expressing the pathogenic mutation, DVAP 
forms aggregates and the ER staining is nolonger uniform with some areas of 
colocalisation within the inclusions.  A possible explanation is that the structure of the 
ER has been altered and become fragmented although it may also be linked to a 
redistribution of the KDEL marker.  For this reason the phenotype was also confirmed 
using an antibody specific for the Boca protein (data no shown), another independent ER 
marker (Culi and Mann 2003).  Other ER markers that could have been used are 
Calnexin and Protein Disulphide Isomerase (PDI). The change in staining for ER and its 
apparent fragmentation should be examined further at an ultrastructural level by TEM.  
Whether this is a direct result of the removal of DVAP or due to an indirect effect on the 
change in localisation of interacting proteins such as Nir2 and CERT is something to be 
considered.  If the removal of DVAP into aggregates is causing ER stress, perhaps by an 
increase in the level of Ceramide in this organelle, this opens up a possible pathway that 
might lead to the death and degeneration of the cell. This will be elaborated upon in the 
Discussion. 
 The results from the staining observed for HSP70 in wt larva brains is uniform 
throughout the cytoplasm of the cell bodies. (figure 3.5 G-I).  The staining in the brains 
of DVAPT48I transgenic larvae is indicative of an upregulation of HSP70 with the 
formation of some aggregates that are highly immunoreactive for HSP70.  Although 
these aggregates are closely associated with the DVAP inclusions present in these cells, 
they do not overlap.     
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 The results reported here are possibly suggesting that following the pan neural 
transgenic expression of DVAPT48I, the neuronal cells become stressed as seen by the 
accumulation of aggregates, the upregulation of heat shock protein 70 and the alteration 
of the structure of the ER.  This is highly suggestive of the pathomechanism of the 
disease in VAP-linked ALS and perhaps other forms of ALS and degenerative disease. 
The next step is to look at the effect of the transgene when expression is localised to the 
muscles as muscle wastage is a key hallmark of ALS and it is unknown whether this is a 
direct effect of the mutant protein or due to the loss of nerve input following neuronal 
degeneration. 
 
3.7 Effect of DVAPT48I expression when targeted in the muscle 
 
One of the early signs of ALS is muscle weakness and atrophy of the skeletal muscles.  
However, as the understanding of ALS has increased it is becoming increasingly 
obvious that ALS is not a disease solely affecting the motor neurons. It is important to 
consider whether the observed atrophy at the muscle is secondary to a loss of nervous 
input or indeed as a direct result of toxicity within the muscle.  A study using the mutant 
SOD1 mouse model of ALS found that localised expression of SOD1G93A in the muscle 
causes muscle atrophy in mice as young as 4 weeks old. Ultrastructural analysis showed 
misalignment of sarcomeres, disorganization of the sarcotubular system and a disruption 
of the mitochondrial morphology (Dobrowolny et al. 2008).  A few other studies have 
also used the SOD1 mice to show that muscle targeted variation in gene expression can 
affect disease progression.  Muscle localised expression of insulin like growth factor 
(Igf) -1 delayed the progression of disease (Dobrowolny et al. 2005) and Nogo-A, a 
neurite outgrowth inhibitor shows increased expression in the skeletal muscle of SOD1 
mice and ablation increased the lifespan of the mice whereas overexpression in the 
muscle fibers caused a reduction in the NMJ size (Dupuis and Loeffler 2009). 
To examine whether mutant VAP is directly toxic to the muscle fibers in 
Drosophila, expression of the DVAPT48I transgene was driven in the muscles using a 
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BG57-GAL4 line in which GAL4 expression is under the control of a muscle-specific 
enhancer (Budnik et al. 1996). Both wt and BG57-GAL4; UAS-DVAPT48I lines were 
dissected and the NMJs stained with antibodies specific for DVAP and a range of 
muscle specific markers in order to assess the sub-cellular localisation of DVAP and the 
effect that mutant VAP might exert on the muscle.  Similar to the larval brains, the effect 
of DVAPT48I expression on HSP70 was also examined at the larval NMJ using 



















Figure 3.6 Targeted DVAPT48I expression in the muscles induces aggregate formation, ER 
fragmentation and an upregulation of HSP70 
Larval muscles from wt (Canton S) larvae (A-F, J-L) and transgenic larvae expressing UAS-
DVAPT48I in the muscles under the control of BG57-Gal4 driver (G-I, M-O).  
A-C) Control muscles stained for DVAP (red)  and SERCA, an ER/Sarcoplasmic Reticulum 
marker (Sanyal et al. 2005) (green) shows a good co-localisation.  
D-F) Wt larval muscle stained with anti-Boca (green), specific for the ER (Culi and Mann 2003), 
reveals intense immunoreactivity around the nucleus and throughout the cytoplasm with again a 
good degree of colocalisation with DVAP (red).  
G-I) DVAPT48I transgenic muscles stained with anti Boca (green) and DVAP antibody (red) 
shows brightly immunoreactive ER fragments which colocalize with DVAP-positive aggregates.  
J-L) Control muscles stained with anti-Hsp70 (green) and anti-DVAP (red).  The HSP70 
immunoreactivity is under the detection limit of our antibody (J).  
M-O) DVAPT48I transgenic muscles stained with anti HSP70 (green) and anti-DVAP (red).  In 
these muscles there is an increased intensity of HSP70 staining, localised mainly to the nuclei, 
suggestive of an upregulation of HSP in the muscles of transgenic larva. Relocation of HSPs to 
the nucleus has been linked to cellular stress. Scale bars are 10 µm. 
 
In wt Drosophila larva, DVAP immunoreactivity is distributed throughout the cytosol of 
the muscle with areas of increased intensity evident particularly around the nuclei of the 
muscle.  There is a high degree of colocalisation with SERCA, a Calcium ATPase that is 
localised at the sarco-endoplamsic reticulum in Drosophila muscles and Boca, an ER 
marker.  Similar to the expression of DVAPT48I in neuronal cells, in muscles expressing 
the mutant transgene, aggregates are present and the staining for Boca is disrupted, 
which could be indicative of fragmentation of the ER.   Similar to the previous staining 
in the larval brain, there is extensive colocalisation of the Boca Staining with the DVAP 
inclusions (See figure 3.6).  Transmission Electron Microscopy should be carried out to 
confirm the exact effect of DVAPT48I on the ultrastructure of the cell and show whether 
the ER is truly fragmented. For now, the staining is consistent with the findings in a 
number of SOD1 models in which targeted expression of the mutant protein has a direct 
toxic effect on the muscle.  This conclusion is supported by the evidence of an 
upregulation of HSP70 seen in the transgenic lines.  Here there appears to be a re-
localisation of HSP70 into the nucleus which is a phenomenon linked to cellular stress 
giving further evidence that muscles cells are stressed following the expression of 
DVAPT48I.   
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Research in ALS is finding more and more evidence to suggest that this is not 
simply a disease of the motor neurons but a multi-systemic disorder and my findings 
here support this hypothesis as the muscle of ALS patients will be undergoing cellular 
stress and possible degeneration in addition to the degeneration occurring in the motor 
neurons.  The primary pathological event in ALS is yet to be discovered but such 
findings as we have here shed some light on the events that might be leading up to cell 
death. 
 
3.8 Effect of DVAPT48I over expression in the adult eye 
 
 
DVAPT48I has the ability to induce aggregate formation and disrupt the ER but it is 
unknown whether this also brings about degeneration in a manner similar to DVAPP58S.  
If human VAPBT46I is a true causative allele for ALS it would be expected to 
recapitulate a number of the major hallmarks of the disease when modeled in the fly and 
considering ALS, degeneration within the nervous system is obviously key to the disease 
process.  For this reason, DVAPT48I expression was localised to the adult eye. Use of 
the Drosophila eye to model disease is a common technique that has proved a valuable 
tool in the understanding of degenerative disease (See section 1.5 for more information).  
Expression of the DVAPT48I transgene was driven by the eye specific driver eyeless-






Figure 3.7 Targeted expression of DVAPT48I in the Drosophila eye causes a rough eye 
phenotype 
Scanning electron micrographs of wt (A) and transgenic (B) adult fly eyes expressing the UAS-
DVAPT48I transgene under the control of eyeless-Gal4. (C) and (D) are higher magnifications of 
(A) and (B) respectively.  A decrease in size accompanied with missing bristles (black 
arrowhead) and fused ommatidia (white arrowhead) are seen when the DVAPT48I transgene is 
expressed in the eye. 
 
The eye of the Drosophila adult is composed of an array of ommatidia with individual 
bristles arranged in an ordered and highly conserved pattern that can be easily screened 
under light microscope for changes.  In flies expressing DVAPT48I the eye is much 
reduced in size and the neat ordered arrangement is lost to a rough eye appearance with 
missing bristles and fused ommatidia (see figure 3.7).  Such a phenotype is consistent 
with neurodegeneration and a similar phenotype was also evident when the P58S 
transgene was expressed in the Drosophila eye (data not shown).  This goes further to 
support the hypothesis that the DVAPT48I mutant allele is indeed causative for ALS and 
it is possible to speculate that the mutation affects DVAP in an identical way to the P58S 
mutation.  To further support this idea, further analysis of the mutations on a 













Chapter 4: Biochemical properties of mutant VAP vs wt 
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4.1 Homodimerisation of VAP proteins 
 
To understand the role played by the mutant VAP proteins in ALS, an appreciation of 
the effect that the mutation has on the protein must be fully recognized.  To begin such a 
characterization I focused upon the biochemical property of VAP proteins to interact 
with one another and form dimers, a process termed homodimerisation. The Yeast two 
hybrid system was used to investigate the deimerisation properties of VAP proteins 




Figure 4.1  Yeast two hybrid system 
The binding domain (BD) of the yeast GAL4 protein binds to the GAL4 UAS upstream of the 
reporter genes and the activation domain (AD) activates transcription of reporter genes.  These 
two domains can be separated and fused to other proteins while maintaining their functionality. 
If brought into close enough proximity through the interaction of the proteins to which they have 
been fused they will activate the transcription of reporter genes thereby signaling an interaction 
within the yeast colony. Diagram taken from the MATCHMAKER GAL4 Two Hybrid System 3 
and Libraries User Manual. (Clontech) 
 
To investigate the ability of DVAP and human VAP to homodimerise, a number of 
small scale yeast two-hybrid experiments were carried out. The open reading frame for 
DVAP and hVAP were inserted into the yeast tranfection vectors pGBKT7 and 
pGADT7 which contain the sequence for the GAL4 binding domain and activation 
domain respectively.  The resulting fusion proteins translated within the cell consist of 
VAP fused to an active domain of GAL4 and if a cell is cotransfected with genes 
inserted into both vectors then if the two resulting proteins interact, the two GAL4 
domains are brought together to initiate transcription of reporter genes.  The yeast cells 
were simultaneously transformed using the polyethylene glycol/lithium acetate 
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(PEG/LiAc)- mediated transformation protocol as outlined in the MATCHMAKER 
Two-Hybrid System 3 handbook and described briefly in Chapter 2.12.  Following the 
transformation, cultures were plated on SD plates that are a combination of a Minimal 
SD Base and a Drop Out Supplement.  This is a synthetic, defined minimal medium 
lacking one or more specific nutrients.  Cells containing the pGADT7 vector alone can 
grow upon media lacking Leucine, Cells with pGBKT-7 can grow on media lacking 
Tryptophan and a cell that has been transformed with both vectors can grow on SD-Leu, 
-Trp plates.  If the proteins expressed within a cell interact, the transcription of reporter 
genes means that the cells can grow on plates lacking Adenine and Histidine as well as 
Leucine and Tryptophan.  Colonies will also be blue in colour due to the activity of α-
galactosidase under the control of the MEL1 reporter gene.  In parallel with the 
experimental test transformations, yeast cells were also inoculated with control plasmids 
supplied by Clontech.  PGADT7-T and pGBKT-53 contain the known interacting 
proteins SV40 large T-antigen and murine p53 respectively and act as the positive 
control.  PGADT7-T and pGBKT7-Lamin C are known to not interact and act as a 
negative control. 
 
The experimental set up was as follows: 
 
pGADT7 wt DVAP and pGBKT7 wt DVAP 
pGADT7 mut P58S DVAP and pGBKT7 mut P58S DVAP  
pGADT7 mut DVAP and pGBKT wt DVAP 
pGADT7 wt VAPB and pGBKT wt VAPB 
pGADT7 mut P56S hVAPB and pGBKT7 mut P56S hVAPB 
pGADT7 mut P56S hVAPB and pGBKT7 wt hVAP B 
pGADT7 mut T48I DVAP and pGBKT7 wt DVAP 
pGADT7 mut T48I DVAP and pGBKT7 mut T48I DVAP 
 
Finally, the human protein VAPB was extensively studied in Drosophila by expressing 
the wt and mutant VAPB in a wt background and when considering the phenotypic 















by the inter-species differences in sequence.  The human protein had the ability to rescue 
the phenotype of a DVAP null mutant so the two proteins are functionally 
interchangeable as well as homologous on the level of genetic sequence but this does not 
necessarily mean they will act in the same manner when in the presence of the 
endogenous wt protein. For this reason the following binary interactions were also 
carried out. 
pGAD-hVAP and pGBKT7 DVAP 
pGAD-Mut hVAP and pGBKT7 DVAP 
4.2 Results from the binary Yeast two-hybrid interactions 
 



















Figure 4.2  Homodimerisation of VAP proteins is not affected by the mutations 
Plates A, B and C show co transformed yeast taken from low stringency plates lacking 
Leucine and Tryptophan and re-plated onto high stringency plates also lacking Adenine 
and Histidine in addition to Leucine and Tryptophan (SD-AHLT).  Yeast co-transformed 
with pGADT7 and pGBKT7 empty cloning vectors act as a negative control as do yeast 
co-transformed with pGAD-VAP and pGBKT-Lamin.  PGBKT-53/pGADT7-T acts as a 
positive control and shows good growth on the high stringency plates. A and B) Mutant 
proteins carry the original P56S/P58S mutation. C). The examination of the ability of 
DVAPT48I to interact with wt DVAP and homodimerise.  This plate also shows the 




        
 
Table 4.1,2,3 and 4. Summary of VAP homodimerisation results 
Summary of the results from a number of small scale yeast 2-hybrid experiments looking at the 
binary interactions of the Drosophila and human VAP proteins.  + shows an interaction, - no 
interaction was observed.  
 
 
4.3 Homodimerisation is not affected by P58S/T48I mutations 
 
Results from these experiments indicate that DVAP has the ability to homodimerize 
(Figure 4.1). Yeast containing pGADT7-DVAP and pGBKT-DVAP grew well on the 
high stringency plates that lacked Adenine, Histidine, Leucine and Tryptophan (SD-
AHLT) and the colonies were blue in colour.  Dimerisation is likely to be crucial for the 
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P58S mut 
DVAP-33A 
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P56S mut 
Hum VAPB 





DVAP-33A       +             + 




DVAP-33A          - 
 
          - 
 104
homodimerise as it demonstrates that the mutation does not interfere negatively on this 
biochemical property.  The aggregates seen in the Drosophila model of ALS8 are 
believed to be composed of both wild type and mutant protein and the interaction 
between these two proteins will be necessary for the aggregate formation.  Consistent 
with this, yeast co-transformed with either DVAP mutant and wild type DVAP show 
good growth on the SD-AHLT plates. 
The ability of human VAPB to rescue the phenotype of a null Drosophila mutant 
indicates that the two proteins are functionally interchangeable.  If dimerisation is key to 
the function of DVAP it is very likely to be conserved in the human homologue and the 
results of this yeast two-hybrid show this to indeed be the case for both wild type and 
mutant hVAPP56S.   
In contrast to these positive results, when the ability of hVAPB to interact with 
DVAP was examined, no interaction was evident and nothing grew on the high 
stringency plates despite the presence of colonies on the low stringency plates selecting 
for co-transformation. The lack of interaction, especially of the mutant hVAPB with 
DVAP, is particularly intriguing considering the decision to model the disease in 
Drosophila by expressing a mutated form of the endogenous DVAP protein rather than 
the human VAPB.  Expression of VAPBP56S in a Drosophila wild type background 
gives rise to a similar phenotype as that seen by the overexpression of wt DVAP and 
does not show the extensive hallmarks of disease that our DVAPP58S Drosophila model 
presents with.  One such hallmark is the presence of aggregates and we believe that the 
formation of these large insoluble inclusions, incorporating both wt and mutant VAP, 
sequester the wt endogenous protein away from its normal localisation.  This gives rise 
to a dominant negative situation and the mutant protein causes a loss of function 
phenotype despite it having the ability to rescue the phenotype of a null mutant in which 
no endogenous DVAP is present.  The interaction between the mutant and wt protein is 
key to this aggregation and the inability of hVAP and DVAP to interact would account 
for the lack of this hallmark and others present in the model.  This warns of the potential 
problems that might arise when modeling any disease in Drosophila through the 
expression of a human protein.  This is a common practice that has produced many 
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invaluable models for studying human disease but it is certainly worthy of note as in this 
case the human protein appears to be functionally interchangeable with DVAP in a null 
fly but is incapable of modeling the disease when expressed with wt endogenous protein 
of Drosophila.  Co-immunoprecipitation is currently being carried out in the lab to 
confirm the yeast two hybrid results and preliminary results are in support of the data 


























Chapter 5: Effect of the VAP mutations on complex 
formation 
 107
5.1 Interaction of VAP with Sac1 
 
 
Another potential effect of the pathogenic mutation is to disrupt the interaction of VAP 
with other proteins in the cell and therefore affect the complex formation of VAP.  An 
interactor of DVAP as noted in a large scale genome wide screen by Giot et al  is Sac1 
(Giot et al. 2003).  Sac1 is a lipid phosphastase that is necessary for the regulation of a 
pool of PI(4,5)Ps and is thought to play a role in a number of functions including cell 
morphology and the organization of the cytoskeleton (Foti et al. 2001; Wei et al. 2003a; 
Liu et al. 2008a).  Considering the observed role of DVAP in homeostatic control of the 
NMJ with regard to the size and number of synaptic boutons (Pennetta et al. 2002), an 
interaction with Sac1, that too elicits changes in cell morphology, makes this an 
interesting interaction. To verify this interaction and look at the ability of Sac1 to 
interact with the wild type and mutant forms of DVAP a small scale yeast two-hybrid 
was carried out.  It is important to understand the effect of the mutation on the 
interactions formed by VAP proteins as a loss of an interaction will affect the normal 
function of such proteins and will extend our knowledge of the pathways affected.  
Maintenance of an interaction could mean that the protein is incorporated into the 
aggregates and similar to the reduction in endogenous VAP from its original location, it 
might also sequester the interacting protein. The ability of hVAPB to interact with Sac1 
was also investigated as human VAP is functionally interchangeable with DVAP, so if 
this is an important interaction it might be maintained despite Sac1 being a Drosophila 
protein.  The cDNA for Sac1 was obtained from the DGRC and the open reading frame 
subcloned in frame into the yeast transformation vector pGBKT7. Yeast was co-
transfected with pGADT7-DVAP and pGBKT7-Sac and the transformed yeast plated 
onto medium lacking Adenine, Histidine, Leucine and Tryptophan.  Growth on these 










Figure 5.1  Interaction of VAP and Sac1 is not affected by the mutation 
Plate showing co transformed yeast taken from low stringency plates lacking Leucine and 
Tryptophan and re-plated onto a high stringency plate also lacking Adenine and Histidine in 
addition to Leucine and Tryptophan (SD-AHLT).  Yeast co-transformed with pGADT7 and 
pGBKT7-Lamin act as a negative control.  pGBKT-53/pGADT7-T acts as a positive control and 
shows good growth on the high stringency plates. 













         +         +           +            +           + 
 
Table 5.1  Summary of the VAP-Sac1 yeast two hybrid results 
Summary of the results from a small scale yeast 2-hybrid looking at the binary interactions of the 
DVAP and hVAP with the Drosophila SAC1 protein. 
 
 
 Yeast co-transformed with either wt or mutant DVAP and Sac1 grew well on the high 
stringency AHLT plates which indicates that despite the mutation or species of origin, 
VAP proteins are able to interact with the lipid phosphatase Sac1 (figure 5.1 and figure 
4.1 for the plates showing the DVAPT48I/Sac1 interaction).  A confirmation of this 
interaction for wt DVAP and DVAPP58S was carried out by Co-IP.  The cDNA for 
Sac1 was obtained from the DGRC and subcloned into pCMV-myc in order to express 














the cells were lysed and the lysate incubated with α-Myc beads overnight.  A wash 
buffer containing Digitonin was used to remove non-specific binding to the beads and 
the presence of interacting proteins was detected by Western blot (see figure 5.2 below).  
It should be noted that these are preliminary data and experiments are ongoing in the lab 
to improve the technical quality of these results.  However these preliminary data show a 
good interaction of DVAP with Sac1 which is maintained despite the disease mutation in 
DVAP. 





Figure 5.2  Confirmation of DVAP-Sac1 interaction by Co-IP 
Western blots from a co-immunoprecipitation carried out with COS7 cells co-transfected with 
either wtDVAP (A and B) or mutant DVAPP58S (C and D) and Myc tagged Sac1 Anti Myc 
agarose beads were used to bind the Myc tagged Sac1 and any other interacting proteins. A and 
B) Anti DVAP staining for the presence of wt DVAP in the input (I) and a strong clear band in 
the test lane (Pellet PdVAP Sac1) confirms that wt DVAP can interact with Sac1.  In these western 
blots the Input from the two control samples was not run but the supernatant shows any 
remaining protein that did not bind to the beads.  B) Anti-Myc staining for the presence of Sac1-
Myc in the input (IdVAP Sac 1) and attached to the beads (P dVAP Sac1 and P Sac1).  There is no protein 
staining visible in the supernatant lane as all Sac1-Myc is attached to the beads. C and D) Anti 
DVAP again shows a strong band in the test lane Pellet PP58S Sac1 indicating that in agreement 
with the Yeast two hybrid results, mutant DVAP retains its interaction with Sac1.  D) Anti-Myc 
staining for the presence of Sac1-Myc in input (I P58S Sac1) is very faint but there is a very strong 
band showing the attachment to the beads (P P58S Sac1 and P Sac1).  
I       PP58S Sac1  S P58S Sac      IP58S   P P58S    S P58S            I Sac1         P Sac1     S Sac1 
I       PP58S Sac1  S P58S Sac      IP58S   P P58S    S P58S            I Sac1         P Sac1     S Sac1 
   α DVAP 
 α myc-Sac1 





5.3 Interaction with SAC1 is not affected by mutation 
 
Both human and Drosophila VAP can interact with the Drosophila Sac1 protein.   Yeast 
transfected with pGBKT-SAC1 and either wt or  mutant P56S/P58S VAPB or DVAP 
grew well on the high stringency plates that lacked Adenine, Histidine, Leucine and 
Tryptophan and the colonies were blue in colour. This was also true for yeast transfected 
with DVAPT48I and Sac1 (as shown in earlier figure 4 plate).  The Co-IPs further 
confirm these results.  Sac1 proteins have 7 highly conserved domains that are evident in 
all species from yeast to man and if the interaction utilizes one or more of these 
conserved domains the ability of this Drosophila protein to interact with the human 
VAPB is understandable.  As the mutant forms of DVAP and VAPB can rescue the 
phenotype associated with a knock out of the endogenous protein, the important 
complexes may still be maintained and these results are consistent with this.  The Sac 
domain is present in a number of proteins including SAC3, described previously as the 
causative gene for ALS11.  The ability of VAP to interact with other SAC domain 
proteins is an important avenue for further investigation that could answer many 
questions about the role of VAPs and shed light on how the P56S/T46I mutation causes 
neurodegeneration. It should be considered that the mutation may cause an increase in 
the strength of interaction.  The data reported here are not quantitative and both for the 
Sac1 interaction and the homodimerisation of VAP, there may be an increased 
propensity to interact with the mutant protein.  The result from this might be the 
formation of aggregates as seen following the expression of DVAPP56S/DVAPT48I in 
the fly and COS7 cells 
The next intriguing question is whether Sac1 is directly involved in the 
degenerative phenotype associated with mutant VAP.   This could be due to Sac1 being 
sequestered away within the aggregates and away from its wt localisation or with the 
formation of aggregates, DVAP may be unable to localize with SAC1 and despite 
mutant VAP having the ability to interact, spatial parameters prevents this.  Before 
continuing with such investigations, an examination of the domains necessary for the 
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VAP-SAC interaction was carried out to see whether the residues necessary for 
interaction are affected by the mutation. 
 
5.4 Narrowing down the interacting domains for VAP1 and Sac1  
  
In order to deduce the regions necessary for the interactions reported earlier, constructs 
were designed and cloned which contained shorter sequences of Sac1 and DVAP.  By 
removing domains from each protein and looking at the ability of these truncated 
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Figure 5.3 Truncated proteins used in yeast two hybrid 
Diagrammatic representation of the truncated proteins used in the binary yeast two hybrid aimed 
at narrowing down the regions necessary for interaction. Pink represents the LZ domain of Sac1. 
Blue the Sac domains. Yellow: ER targeting motif.  Purple: the MSP domain of DVAP.  Red: 
coiled coil domain and green: TM domain. 
  
 
Nterm DVAP. First 417 base pairs of the DVAP open reading frame ligated into the 
pGADT7 vector. Resulting protein contains 139 amino acids and includes the MSP 
domain.  
 
    LZ motif 
ER retrieval 
motif 
Conserved Sac1 domains 
CC MSP 
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Cterm DVAP.  Final 411 base pairs of the DVAP open reading frame ligated into the 
pGADT7 vector.  Resulting protein contains 137 amino acids and includes the predicted 
coiled-coiled domain and the transmembrane domain (Chai et al. 2008).  
 
Nterm Sac1.  First 1050 base pairs of Sac1 open reading frame ligated into the 
pGBKT7 vector.  Resulting protein contains 500 amino acids and includes the predicted 
LZ motif and the first 5 of the 7 conserved Sac1 domains (Hughes et al. 2000). 
 
Cterm Sac1.  Final 774 base pairs of Sac1 open reading frame ligated into the pGBKT7 
vector.  Resulting protein contains 358 amino acids and includes the final 2 conserved 
Sac1 domains, the transmembrane domain and the C terminal ER retrieval motif. 
 
The cDNA for these subfragments were amplified by PCR and cloned into the yeast two 
hybrid transformation vectors PGBKT and pGADT7 and a small scale Yeast two hybrid 
carried out.  There is some discrepancy in literature as to which regions are necessary for 
homodimerisation.  Investigating which of these truncated DVAP proteins will be able 
to interact with full length DVAP or Sac1 will be interesting when considering the 
function played by the mutations in the MSP domain 
 
5.3.1 Results for the truncated protein yeast two hybrid 
interactions 












   Table 5.3 DVAP 
N-SAC1       - 
C-SAC1       - 
Table 5.2 DVAP SAC1 
N-DVAP     -     - 
C-DVAP     +     + 
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Table 5.2 and 5.3. Summary of the yeast two hybrid results looking at the interaction with 
truncated proteins 
Tables summarising the ability for the shortened DVAP and SAC1 constructs to interact with the 




























Figure 5.4.  Plates from yeast two hybrid looking at the interaction of truncated proteins  
Plates show co transformed yeast taken from low stringency plates lacking Leucine and 
Tryptophan and re-plated onto high stringency SD-AHLT plates.  Yeast co-transformed with 
pGADT7 and pGBKT-Lamin constructs act as a negative control as do yeast co-transformed 
with pGAD-VAP and pGBKT-Lamin.  PGBKT-53/pGADT7-T acts as a positive control and 
shows good growth on the high stringency plates. 
 
5.3.2 MSP domain is not necessary for homodimerisation or 
interaction with Sac1 
 
 
Results from these experiments indicate that only the final 136 amino acids of DVAP-33 
are required both for the interaction with Sac1 and itself.  Yeast transfected with C-
DVAP and either full length DVAP or Sac1 grew well on the high stringency plates that 
lacked Adenine, Histidine, Leucine and Tryptophan and the colonies were blue in 
colour.  As controls in this experiment PGADT7-T and pGBKT-53 also showed an 
interaction as did the full length DVAP and Sac1.  Similar to the negative control of 
Lamin C and T antigen, neither of the shortened Sac1 constructs interacted with DVAP 
nor did the N-DVAP construct interact with Sac1.   
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The division of the Sac1 domains in both the Sac1 constructs designed above 
may be the cause of a lack of interaction. It is possible that all seven domains are 
important for protein interactions. As such, another Sac1 construct was designed 
containing all seven of the conserved Sac1 domains and missing only the 
Transmembrane domain and the ER motif.  At a  length of 1455 base pairs, the transcript 









Figure 5.5. Diagram of Sac1 truncated protein containing all 7 conserved Sac1 domains 
 
 
The above fragment was cloned into pGBKT7 and transfected into yeast along with 
pGADT7-DVAP but again no interaction was observed suggesting that the whole of the 
protein is necessary for interaction or at least for stability. It is possible that the truncated 
protein is being degraded by the yeast cell and this should be tested either by western 
blot or repeating the experiment in another system such as cell culture.  
 
    LZ motif 













Chapter 6: Investigation of Sac1 in the Nervous System  
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6.1 VAP interacts with Sac1 
 
 
Data has been presented that verifies the interaction of DVAP and hVAPB with Sac1.  
This has the potential to be a very important interaction considering the identified role of 
Sac1p in yeast in cytoskeletal organization and cellular morphology.  Wei et al have 
shown that Sac1 is vital for dorsal closure which involves the migration of the lateral 
epidermal flanks over the amnioserosa driven by the actomyosin contractile apparatus 
(Wei et al. 2003a).  There is a dramatic morphological change in the shape of the cells 
during this process and a link with Sac1 means that this protein could be a key player in 
regulating the changes observed at the synaptic boutons of DVAP mutants.  The down 
stream effectors of Sac1 may also be responsible for the changes in synaptic bouton 
morphology in reponse to dosage of VAP at the NMJ. In addition to this, mutations in 
SAC1 have been found to enhance the degenerative eye phenotype seen in the fly model 
of spinocerebellar ataxia 8 (SCA8) (Mutsuddi et al. 2004) (see introduction for a more 
detailed description of this model).  Further analysis of the role played by Sac1 in the fly 
is required in order to elucidate the involvement in the mutant phenotype associated with 
DVAP. 
There are already a number of mutants available for Sac1 in Drosophila but 
unfortunately due to the requirement in dorsal closure, null mutants are embryonic lethal 
which makes a functional analysis of the neuromuscular junction impossible.  The 





Figure 6.1 Genomic region of Sac1  
Sac1 is present on chromosome 3. This diagram indicates the position of available P-
element inserts available within this region. (Flybase). 
 
 
The three mutations available from the Drosophila stock centre are 1) 
P(GT1)Sac1[BG02228], 2) PBac(PB)c01078 and 3) (EPgy2)Sac1[EY02269]. The 
PBac(PB)c01078 (2)  is inserted in the first intron of the 5’ untranslated region, 60 base 
pairs upstream of the AUG and mutant flies survive to adulthood.  
P(GT1)Sac1[BG02228] (1) is in the first exon, 234 base pairs upstream of the AUG and 
is the mutant line used by Wei et al and is embryonic lethal. Finally   
P(EPgy2)Sac1[EY02269] (3)n is in the first exon of the 5’ UTR, 242 bp upstream of the 
AUG and the few escapers in this stock die at the first instar larval stage due to problems 
of dorsal closure (Wei et al. 2003a). Attempts were made to rear these larvae to a later 
stage as it has previously been shown that larvae carrying apparently embryonic lethal 
mutations in synaptotagmin can be reared to adulthood by optimizing the conditions of 
culture (Loewen et al. 2001).  By removing the homozygous larvae from competitive 
heterozygous siblings and providing a thinner yeast paste that is easier for them to 
consume, the problems in mobility are overcome. Such conditions were of little help to 
the EY02269 flies as they have severe developmental problems underlying death.  Wei 
et al had a hypomorphic allele that promoted defective eye development but this has 
unfortunately been lost (Wei et al. 2003a) . 
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Following the identification of Sac1 as an interactor of DVAP the function of 
this protein in the fly deserves to be further investigated.  Unfortunately these mutant 
stocks are not ideal for investigation as they are embryonic lethal or as in the case of 
PBac (PB)c01078 have little evident phenotype other than a potential sterility problem.  
This PBac stock has further problems in that a few flies always have white eye which 
indicates a loss of the transgene.  Considering all this the first step is to characterize the 
phenotype associated with an over-expression of the protein  This was achieved through 
the creation of UAS-SAC1 transgenic lines that express the SAC1 gene under the control 
of the  pan neural elav-Gal4 driver.  The cDNA for SAC1 was obtained from the BDGP 
gold cDNA collection from Drosophila resource centre and this was subcloned into the 
pUAST. The construct was injected into Drosophila embryos and a number of 
transgenic lines were established. Third instar larvae from the transgenic lines 
(elav;UAS-SAC1) were dissected and neuromuscular junctions stained with the HRP 
antibody.  
As the Sac1 null flies created by Wei et al. were shown to be lethal due to the 
necessity of Sac1 in dorsal closure our ability to look at the nervous system by dissection 
was greatly impeded.  To overcome this problem we undertook the task of creating a 
loss-of-function mutation as a dominant negative which will act as a functional null in 
the areas of expression i.e. the larval nervous system, meanwhile leaving wt Sac1 levels 
unchanged in other tissue (thereby bypassing the first requirement for the gene).   The 
production of a dominant negative was proposed by the removal of a suspected vital 
region of the Sac1 sequence necessary for its function.  The resulting mutant protein 
would compete with the wild type and inhibit its action thereby producing a hypomorph. 
An RNAi stock was also procured from the Vienna Drosophila Resource Centre 
(VDRC).   Utilising the spatial and temporal control provided by the UAS/GAL4 system 
makes it possible to drive the Sac1 dominant negative allele and RNAi solely in the 
larval nervous system.  This will overcome the lethality due to the necessity of Sac1 in 
embryonic gastrulation as only where the mutant protein is driven will the wild type 
Sac1 be affected. This may give a phenotype suggestive of Sac1’s role at the synapse. 
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6.2 Creation of a SAC1 Dominant Negative 
 
A number of proteins contain a Sac domain comprising of seven highly conserved 
motifs (see Figure 6.2 below).  The sequence RTNCIDCLDRTN is particularly highly 
conserved and contains the CX5R(T/S) motif  present in a variety of metal-independent 
protein and inositide phosphatases that have been well characterized.  This conserved 
motif is believed to cradle the phosphate moiety necessary for the catalytic action of 
these proteins and perhaps the Sac1 proteins as well (Guo et al. 1999; Hughes et al. 
2000).  The yeast proteins Sac1p, Inp52p, Inp53p, and synaptojanin are all active 
phosphatases whereas Inp51p, which differs only by three residues in this putative 
catalytic motif, has no phosphatase activity adding weight to this hypothesis (Hughes et 
al. 2000).  Finally there are a number of mutant yeast strains for Sac1p that lack the 
phosphatase activity, one being sac1-8 in which the first Aspartate residue is mutated in 
the CX5R(T/S) motif (Nemoto et al. 2000).  
 The coding region of the Sac1 gene was obtained from Flybase and was aligned 
with the yeast Sac1p (NCBI) and the catalytic motif was found to be conserved in the 
Drosophila Sac1.  This is a good candidate region to mutate to produce a dominant 
negative mutant and two options were considered. First a deletion of the entire DNA 
sequence encoding the motif RTNCIDCLDRTN.  Second was to change only the first 
Aspartate residue in this sequence found to be important both in yeast and also in rat 
(Hughes et al. 2000; Nemoto et al. 2000).  The change of a negatively charged Aspartate 
residue  to a positive Asparagine should be enough to disrupt the catalytic activity whilst 
maintaining the normal folding such that it successfully competes with the wild type 
protein.  Site directed mutagenesis was carried out to remove/ change the necessary 
sequence and the resulting cDNA subcloned into the transformation vector pUAST 





Figure 6.2  Alignment of the Drosophila Sac1 gene with the yeast Sac1p.   
There are 7 conserved SAC1 motifs and the 6th is the predicted catalytic domain.  Adapted from 
Hughs et al 2000. 
  
 
6.3 Effect of Sac1 dosage at the neuromuscular junction 
 
The role of Sac1 at the NMJ has never been investigated and considering the 
aforementioned role of Sac1 in cellular morphology, a good starting point in the 
investigation of Sac1 and VAP is to look at the effect that Sac1 overexpression and 
under expression has at the NMJ.  Larvae expressing Sac1 RNAi driven pan-neurally by 
the elav-GAL4 driver (Yao and White 1994)  (elav; SAC1RNAi)   were dissected and the 
NMJ stained for the neuronal cell surface marker HRP.  Transgenic larvae 
overexpressing the wt SAC1 under the control of elav-GAL4 (elav; UAS SAC1) were 
also dissected and the pattern of staining in these two lines, as compared to controls, was 









Figure 6.3 Effect of Sac1 dosage on bouton formation at the NMJ  
Effect of dosage of Sac1 was examined at muscle 12 and 13 of flies injected with a UAS-SAC1 
construct and the transgene expression driven by the pan neural elav-GAL4 driver.  The UAS-
Sac1 RNAi flies were also crossed with an elav-GAL4 driver to express the transgene and 




An over-expression of Sac1 at the NMJ of third instar larvae is associated with a 
decrease in bouton size and an increase in bouton number. Similarly, a decrease in Sac1 
level by the expression of a UAS-Sac1 RNAi leads to an increased bouton size with an 
apparent decrease in number.  Preliminary observations of flies expressing the dominant 
negative Sac1 suggests that results are similar in these flies too.  A statistical analysis is 
yet be carried out but the observed changes are dramatic and parallel those seen for 
DVAP in which significant changes in bouton size and number are observed following 
the over expression or knock- out of DVAP in the nervous system of larvae (see Figure 
6.4 below (Chai et al. 2008).  In conjuction with the yeast two-hybrid data the results 
point towards a common pathway for Sac1 and DVAP in their ability to affect the 










Figure 6.4 Dosage dependent effect of DVAP at the NMJ 
Dosage dependent effect of DVAP on the synaptic boutons of muscles 12 and 13 at the larval 
NMJ stained with anti HRP. (A-C) Wt  controls. B) DVAP∆166 null mutant has fewer boutons 
that are of a larger size as compared to wt.  D) UAS-DVAP over expressing larval NMJs have 
many more boutons that are reduced in size. Images from Chai et al 2008. 
 
6.4 Effect of Sac1 on the Drosophila eye 
 
A Sac1 mutation has previously been shown to enhance the degenerative phenotype of 
SCA8 in a Drosophila model of the disease which utilizes the eye as a model.  To further 
investigate the role played by SAC1 in degeneration, the effect of a reduction in SAC1 
expression on the formation of the eye was investigated.  Flies from the pan neural 
expression of RNAi SAC1 transgene showed necrotic patches in the eye (Figure 7.5). 
Interestingly, because the elav-gal4 driver is inserted on the X chromosome, it is 
possible to see that Sac1 has a dosage dependent effect on neurodegeneration because 
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males have a stronger phenotype.  This is linked to an upregulation due to the dosage 
compensation of the X chromosome in males which leads to an increased expression of 
GAL4 in the males flies.  In the females, although milder, there is a degenerative 
phenotype characterized by depigmentation and roughness. Necrotic patches are seen in 
the eye of l(3)2107 mutant species which also disrupt the SAC1 gene (Wei et al. 2003b). 
Unfortunately this fly line is no longer available.  Necrotic patches are indicative of cell 
death and this provides a tentative link between Sac1 and the neuronal death seen in our 
fly model of ALS which should be further investigated. 
 
Figure 6.5  Necrotic patches in the eye of UAS-SAC1 RNAi flies. 
Flies expressing UAS-SAC1 RNAi under the control of a pan neural driver show a dosage 
dependent development of necrotic patches in the eye. A) wild type eye. B) Eye of a female 
expressing RNAi SAC1. C) Male eye expressing RNAi SAC1.  The driver regulating the 
expression of the transgene is on the X chromosome which means that the expression is 
influenced by the dosage compensation seen in males. 
 
The eye phenotype was investigated further by the eye specific reduction of Sac1 which 
was established by expressing the RNAi Sac lines under the control of the driver elav-
Gal4.  The morphology of the surface of the eye was observed using scanning electron 
microscopy (SEM) See Figure 6.6.  The eye specific reduction in SAC1 causes a 
reduction in eye size, a severe rough eye phenotype with a reduction in eye size, fused 
ommatidia and missing bristles.  This is all indicative of degeneration of the photo 




Figure 6.6  Eye specific expression of SAC1 RNAi (panel B and D) show a severe rough eye 
phenotype  
B and D) Eye specific expression of SAC1 RNAi induces a severe rough eye phenotype 
accompanied by a decrease in the size and a disruption of the ommatidia as compared to the wild 
type eye (panel A and C).  Arrowheads pinpoint areas of fused ommatidia and missing bristles. 
 
As previously hypothesized, a potential explanation for the link between mutant DVAP 
and the resultant phenotypes with relation to Sac1 is that this interacting protein is also 
captured by the formation of aggregates and as such is removed from its normal 
localisation.  Another hypothesis is that the aggregation of VAP removes the ability to 
form a complex that is necessary for Sac1 to function, perhaps in particular affecting its 
localisation at the ER and as such causing a similar effect as the reduction in Sac1 levels 
by RNAi.  Regardless of the mechanism, a decrease in Sac1 protein levels recapitulates 
some of the phenotypic hallmarks of the mutant DVAP model which makes this a very 
attractive gene for further study with regard to degenerative disease.  The maintenance 














Chapter 7: Investigation of VAP-CERT interaction 
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7.1 VAP mutation affects interaction with CERT 
 
Human VAP has been shown to interact with a group of proteins containing a FFAT 
motif and one such protein is the Ceramide transport protein, CERT, as described in 
chapter 1.  Considering that VAPB is functionally interchangeable for DVAP and the 
SAC1 interaction is maintained between the two species I hypothesised that the 
Drosophila homologue for CERT will interact with DVAP.    This was initially 
examined by co-localisation in cell culture using COS7 cells.  The cDNA for Drosophila 
CERT was obtained from the DGRC and subcloned into the pCMV-c-Myc vector 
containing the sequence for the c-Myc tag upstream of the multiple cloning site which 
will produce an N-terminally tagged fusion protein expressed under the control of the 
cytomegalovirus promoter.  The pCMV DVAP-Flag construct cloned previously was 
again used and antibodies against the c-Myc and Flag tags were used to analyse the 




Figure 7.1 Colocalisation of DCERT and DVAP in COS7 cell 
COS7 cells expressing DVAP-Flag and DCERT-Myc driven under the control of the 
cytomegalovirus promoter.  Antibodies against Flag (red) and Myc (green) show extensive 
colocalisation which could indicate a physical interaction as present in other species. 
  
Analysis of the localisation of DVAP and CERT when expressed in COS-7 cell culture 
shows a clear overlap which is suggestive of a physical interaction (figure 8.1).  As 
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CERT is believed to interact with VAP via the FFAT domain it is likely that many other 
FFAT domain proteins shown previously to interact with VAPB will also show a 
conserved interaction with DVAP including Nir2 and OSBP.  Considering the observed 
fragmentation of the ER following the transgenic expression of DVAPT48I, a loss of 
FFAT interaction would be fitting as it would recapitulate a DVAP null situation.  To 
this end, Co IP’s were carried out to test for the interaction of DCERT and DVAP and 
analyse the effect of the T48I mutation.  A yeast two hybrid screen is currently 
underway to confirm the results from the Co-IP. 
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7.2 Co-IP of DVAP and DCERT shows an interaction that is lost 








Figure 7.2 CoIP showing the loss of DVAP-DCERT interaction following the DVAPT48I 
mutation. 
Western blots from a co-immunoprecipitation carried out with COS7 cells co-transfected with 
either wtDVAP (A and B) or mutant DVAPT48I (C and D) and DCERT.  When testing the 
interaction of wt DVAP with DCERT, anti c-Myc agarose beads were used to bind the Myc 
tagged DCERT to act as bait for the any other interacting proteins.   For DVAPT48I, a Myc 
tagged form of this mutant protein was used.  The results heve been confirmed with the 
alternative arrangement of tagging.  
A and B) Anti DVAP staining for the presence of wt DVAP in the input (I) and a  faint but 
visible band in the test lane (PdVAP dcert) confirms that wt DVAP can interact with DCERT.  No 
band is present in the test lane of the single transformation controls. B) Anti-c-Myc staining for 
the presence of DCERT-c-Myc in the input (I) and attached to the beads (P dVAP dcert and P dcert).  
There is no protein staining visible in the supernatant lane as all DCERT-c-Myc is attached to 
the beads. 
C and D) Anti DVAP (GP33) shows a strong band in the test lane  indicating that it has bound 
well to the beads but despite this there is no staining visible against flag in the test lane 
indicating that DCERT does not interact with mutant VAP.  The T48I mutation disrupts the site 
necessary for the FFAT –VAP interact to occur.  
 
The results from the Co-IP (Figure 7.2) confirm that the interaction between DCERT 
and VAP is lost following a mutation linked to ALS which gives a potential mechanism 
for the disease, especially considering that it probably means that none of the 
I        PT48I CERT  S T48I CERT   P T48I    S T48I   P CERT  S CERT 
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30kDa - 






interactions with the FFAT-containing proteins, Nir2, OSBP and CERT, will be 
possible.  Removal of VAP was shown to lead to the relocalisation of FFAT containing 
proteins away from the ER into the cytoplasm and this might lead to an increase in 
Ceramide levels at the ER which has been shown to cause stress at this organelle (Peretti 
et al. 2008).    The implications of the loss of this interaction could have serious effects 
on the cell and be a major part of the disease pathomechanism. 
 
 
The potential breadth of knowledge to be gained by obtaining a better understanding of 
the role played by these few interacting proteins in the phenotypes seen following the 
transgenic expression of mutant VAP is very exciting.  Only when all the pathways 
affected by the mutant proteins are realized can we truly hope to grasp what mechanisms 
lead to the degeneration observed both in our fly model and in human patients.   For this 






















8.1  Screening the Drosophila embryonic library 
 
Following the successful results obtained in the small scale binary experiments the yeast 
GAL4 matchmaker 2 hybrid kit was used to carry out a library scale yeast two hybrid 
and screen a whole library of possible interactors.  To be optimised at least 1x106 clones 
should be screened and the transformation efficiency was calculated in order to 
determine the efficacy of the screen. 
In total two screens were performed.  The first, 3 different types of plates were 
used. Low stringency, medium and high. Colonies growing on the low stringency were 
collected and re-plated onto the high stringency plates.  This extra step allows an initial 
phase of growth that increases the plasmid copy number and thereby increases the 
chance of finding proteins that may interact only weakly or transiently.  In the second 
screen due to the high excess of interactors picked up from the first screen all 




Co-transformation efficiency:        cfu x total suspension volume  
 Vol. plated x dilution factor x ug DNA 
= 633cfu/ug   
The ideal co-transformation efficiency for a library scale experiment is 103-104 so this 
first screen is a little low. 
 
No. of independent clones screened: co transformation efficiency x ug library DNA 
= 633 x 300 =  189,900 independent clones have been screened. Ideally at least 106 
clones should be screened so the amount of DNA used must be adjusted accordingly. 




Gene number Name Role 
CG3564 CHOp24 Protein transport 
Egg laying and embryogenesis 
CG4264 Heat shock protein 
cognate 70 
Molecular chaperone, ATPase 
BT028801 - Mitochondrial DNA 
CG11949 Coracle Gluatamate receptor anchoring 
CG5185 Twin of M4 Antagonist of Notch signaling 
CG3365 Drongo ARF GTPase 
CG6206 - Alpha mannosidase activity 
CG14206 Ribosomal protein s10b Structural constituent of ribosome 
CG4027 Actin 5c Actin isoform. Component of 
cytoskeleton 
CG11590 - Cation transport acivity 
CG17618 - Unknown 
CG8177 - Anion exchange 
CG7434 Ribosomal protein L22 structural constituent of ribosome 
CG6444 - unknown 
CG17921 HMG Protein Z DNA binding 
CG5596 Myosin alkali light chain 
1 
Microfilament motor activity. ATPase 
activity 
CG5014 Vap-33-1 Synaptic remodelling 
CG8465 Lethal (1)G0222 unknown 
CG4046 Ribosomal protein s16 Constituent of ribosome 
CG5826 Peroxiredoxin 5037 Cell redox homeostasis 
CG17903 Cytochrome C (proximal) Electron carrier activity 
CG10671 FIT2 Accumulation of lipid 
CG5495 Thioredoxin-like Cell redox homeostasis 
CG32701 Lethal (l)G0320 Signal sequence binding 
CG4005 Yorkie Transcriptional co-activator, Negative 
regulator of apoptosis 
CG18815 Acyl protein thioesterase1 Palmitoyl hydrolase activity 
CG10718 nebbish Chromatin binding kinesis-like protein
CG2163 Pabp2 mRNA binding 
CG7533 Charybde Negative regulator of growth. Head 
involution 
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CG10756 TBP associated factor 13 Transcription factor 
CG40191 - Water channel activity 
CG8258 - Protein folding 
CG7326 Mek 1  Histone deacetylase 
CG11164 - unknown 
CG3153 - unknown 
CG1782 Ubiquitin activating 
enzyme 
Neuron remodeling, Protein 
modification 
CG1783 dSLIP Potassium channel regulator 
CG7088 Bangles and beads gliogenesis 
CG3576 Longevity assurance  
gene 1 
Transcription factor 
CG5634 Distracted unknown 
CG7173 - unknown 
CG5226 - Transporter activity 
CG17521 Qm  Constituent of ribosome. 
CG5703 NADH dehydrogenase NAD binding. Electron transporter. 
CG10364 Msb1l  Unknown 
CG10385 Msl-1 Chromatin binding. Dosage 
compensation. 
CG6944 Lamin Nervous system development, 
morphogenesis. 
CG9568 - Unknown 
CG4038 - rRNA pseudouridylation guide 
CG2198 Amalgam Antigen binding 
CG5780 - unknown 
CG10203 X 16 Protein binding/mRNA splicing 
CG6370 - N-linked glycosylation 
 
Table 8.1 Summary of interactions from Library Screen 1.   
PGBKT DVAP was used as the bait protein to look for interactions in an embryonic library 
containing CDNA in the pACT2 vector.  A number of the interacting partners have never been 
characterized and are known only as a gene number (CG).  The activity in these cases is inferred 









Due to the large number of interactors found in the first screen the level of stringency 
was increased for the second screen so all colonies were plated straight onto medium or 
high stringency plates. 
 
Co transformation efficiency = 4 x 103 
Number of clones screened 3.7 x 106  
 
The efficiency of this screen was within the desired parameters.  The list of interactors is 
far fewer for screen two due to the increased stringency and also because a number of 
the clones found were repeated.   Prior to sequencing, digestions are carried out in an 
attempt to avoid sending the same clones for sequencing but as was seen in the case of 
DVAP, in this second screen six different clones were sequenced and found to be DVAP 




Gene number Name Role 
CG5014 VAP-33-1 NMJ development/synaptic remodeling 
CG4264 HSC 70-4 Molecular chaperone 
CG3541 Pio Tracheal development 
CG6198 CHORD Unknown 
CG1516 - Pyruvate Carboxylase activity/ 
Gluconeogenesis 
CG32666 - Protein threonine/serone kinase activity 
CG5899 - ATP-dependent DNA helicase activity 
CG5146 - Unknown 
 
Table 8.2 Summary of interactions from Library Screen 2.   
PGBKT DVAP was used as the bait protein to look for interactions in an embryonic 
library containing CDNA in the pACT2 vector.   
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Potentially interesting interactors were considered on a basis of previous 
characterization and tools available.  A known role in cell morphology, 
neurodegeneration or any phenotypic changes possibly relating to ALS caused the 
following proteins to be picked as candidates for further investigation.  
 
8.2 Interesting Interactions 
 
1. Coracle 
Table 1 - Coracle is the Drosophila homologue of the human erythrocyte protein 4.1.  
Originally characterized for its role at the septate junction where they link 
transmembrane proteins to the spectrin-actin- cytoskeleton (Fehon et al. 1994).  The 
homologue in Drosophila  has since been shown to be required for the localisation of 
Type A glutamate receptors by anchoring them to the actin cytoskelton in the 
postsynaptic bouton (Chen et al. 2005).  The cDNA retrieved from the screen only 
contained the last 50 base pairs at the C-terminal of the coracle gene and the rest of the 
3’ UTR.  The C-terminus is the domain that interacts with the glutamate subunits so this 
is still a feasible interaction.  Unfortunately however, reproducing the interaction with 
the full length cDNA obtained from the Drosophila Genomics Resource Centre (DGRC) 
has not been possible.  
 
2. Pio 
Table 2 - Pio was identified for its mutant phenotype in Drosophila which includes a 
disintegrated tracheal system. Pio encodes a 462 aa long transmembrane protein with an 
N terminal signal perptide, a Zona Pellucida (ZP) domain, a putative furin cleavage site 
and a cytoplamic tail (Jazwinska et al. 2003).  Pio is necessary for the formation of the 
tracheal system, possibly through the assembly of an apical extracellular matrix (aECM) 
(Paul and Beitel 2005).  It is thought that it acts with another ZP domain protein known 
as Dumpy and that both proteins are cleaved at the furin site.  This would leave the N-
terminal portions containing the ZP domains free to interact and aid in the formation of 
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the aECM thereby providing the structure necessary to support the elongation and 
‘zipping up’ of the endothelial cells of the tracheal system. Pio and Dumpy are also key 
to the formation of the inner layer of the aECM that forms as the outer layer of the wing.  
Flies that have had Pio or Dp disrupted have a blistered wing phenotype as the layers 
separate (Bokel et al. 2005).  Again problems were encountered when trying to recreate 
the interaction with the full length cDNA received from the DGRC. A number of splice 
variants were constructed including removal of the transmembrane domain and the 
removal of the N terminal signaling peptide. Despite this there was still no interaction 





Table 1 - Yorkie is a transcriptional co-activator that positively regulates the growth of 
cells and is a downstream effector of Warts in the Salvador/warts/hippo tumor 
suppressor pathway.   Yorkie interacts with the Drosophila consistency Scalloped (Sd) 
transcription factor which has the DNA binding capabilities that Yorkie does not and it 
promotes the nuclear localisation (Zhang et al. 2009).  Warts phosphorylates Yorkie and 
inhibits the interaction with Sd and the nuclear localisation.  The targets activated by 
Yorkie include CycE and Diap but there are likely to be many more that are in involved 
in organ growth (Pan 2007).  The mammalian orthologue of Yorkie is Yes associated 
protein YAP and this is also the final target of a Hippo-like pathway that has been 
conserved from fly to man (Wang et al. 2009a).  Further investigation of this interaction 
has not been continued but the interacting cDNA was complete for the open reading 
frame so it is likely to be a true interaction. 
 
 
4. HSP 70 
Table 1 and 2.  An interaction found repeatedly is the heat shock cognate protein 70-4. 
Hsc70-4, a homologue of the human HSP70.  Unlike other heat shock proteins Hsc70-4 
is a constitutively expressed member of the HSP-70 family of chaperones which are 
necessary for the correct folding of new peptides, prevention of aggregates and the 
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refolding or degradation of damaged proteins (Broadley and Hartl 2009). Recently 
Hsc70-4 was found to be protective from hyperoxia induced neurodegeneration as it 
extended the lifespan of hyperoxia treated flies (Gruenewald et al. 2009). This 
interaction has not been verified but in the Drosophila model of ALS8, Hsp70 was 
found to be upregulated and relocalise to the aggregates.  This may be a key player in 
the disease mechanism.  
 
5. CHOp24 
Table 1 - CHOp24 (CG3564) is one of 9 genes in the Drosophila p24 family that are 
homologous to the gene first discovered in Chinese hamster ovary cells (CHO) p24 
(Stamnes et al. 1995; Blum et al. 1996).  P24 proteins are type 1 integral membrane 
proteins located at the ER and Golgi and have been localised to both COPI- and COPII-
vesicles (Wieland and Harter 1999).  There are a number of hypothesized roles for the 
members of the P24 family including the formation of vesicles and regulating protein 
transport from the ER (Stamnes et al. 1995; Blum et al. 1996; Springer et al. 2000). The 
localisation of VAP at the ER means that an interaction with CHOp24 is feasible and the 




Table 1 - This Drosopila homologue of Fat inducing transcript 2 (FIT2) is a member of 
a highly conserved group of proteins initially described in mice for their role in fat 
storage (Kadereit et al. 2008).  Located at the ER, overexpression of FIT in mice and 
cell culture has been shown to cause an accumulation of lipid droplets rich in 
triglycerides.  We have preliminary data indicating that DVAP is also located at fat 
droplets in Drosophila (data not shown) and, in cojunction with the localisation at the 
ER, this could be a very interesting interaction.  ALS patients often present with 
hyperlipidemia which also provides a link between this gene and the disease (Dupuis et 




8.3 Interaction of DVAP with full length Piopio 
 
 
The interacting cDNA of Pio consisted of the final 2 and a half exons of about 720 base 
pairs in length.  This would be translated as a peptide of 240 amino acids in length (just 
over half of the full length protein of 462aa) and consisting of the transmembrane 










Figure 8.1 Dagramatic representation of Pio  
Pio has the 3 different domains, N-terminal signal perptide, a ZP domain and a C-terminal TM 
domain.  There is also a putative furin cleavage site.  The C terminal protein sequence would be 
positioned within the cytosol of a cell and the N terminal outside in the extra cellular matrix. 
 
When the interaction was tested with the full length protein, clone GH04558 from the 
DGRC, no interaction could be found with DVAP.  It was hypothesized that the 
interaction could be interfered by the presence of the N-terminal signaling peptide, 
antagonizing the localisation to the nucleus so a clone was constructed missing the first 
30 amino acids of the protein.  It was also possible that it is the transmembrane domain 
that interacts with VAP and because the protein is normally cleaved at the furin site, 
when the whole protein is present it is cleaved and only the N terminus will remain 
attached to the GAL4 activation domain.  This would mean that any interaction of the C 
terminus with DVAP would not be seen as an activation of reporter genes.  For this 
reason a construct was also made with just the C terminal amino acids of Pio in the 
pGADT7 vector.  Unfortunately neither of the shortened Pio constructs showed any 

























Amyotrophic Lateral Sclerosis is a devastating disease of which only a limited 
understanding of the causes and mechanisms is known. The majority of cases appear to 
be sporadic but a few have known genetic causes. Much of the current research is 
focused on these few genetically linked cases and aimed at trying to get a clearer 
understanding of the role played by the mutated protein in the ensuing degeneration and 
progression of the disease. It is reasonable to believe that the pathways affected in the 
sporadic and genetic cases are similar if not identical and therefore any advancement 
made in these rare genetic forms is greatly beneficial to all.  VAPB is a recent addition to 
the group of genes linked to ALS and as such, current research investigating the function 
of this protein has the potential to greatly increase our knowledge and understanding of 
ALS (Nishimura et al. 2004a).  The aim of this project was to get an insight into the 
biochemical properties of VAP proteins and look at the complexes formed by the wild 
type protein to see which interactions are affected by the disease causing P56S mutation 
and the newly identified T46I mutation.  Using a variety of model systems the effect of 
these two mutations has been examined and compared.  The implication of all the results 
and the relevance to current published research will be discussed. 
 
9.2 DVAPT48I recapitulates the phenotypic hallmarks of the 
DVAPP58S model of ALS   
 
The first task was to examine the effect of the newly discovered T46I mutation on VAP 
proteins and compare the resulting phenotype following expression of this mutant 
protein with that of the original P56S mutation.  The results from a number of 
experiments examining the Drosophila protein carrying the equivalent mutation showed 
that, consistent with DVAPP58S, the pan-neural expression of DVAPT48I leads to the 
formation of aggregates both along the nerve axon and in the cell body, see figure 3.2 
(Chai et al. 2008) and figure 3.3.  These aggregates are composed of both wt and mutant 
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protein as has been confirmed for the composition of P56S/P58S induced aggregates 
(Tsuda et al. 2008). Again in agreement with previous experiments the expression of 
DVAPT48I in the Drosophila eye caused a degenerative phenotype (figure 3.7) and the 
similarity in this range of mutant phenotypes indicates a similar pathomechanism for 
these two mutations.  As more unrelated families suffering from ALS are found to carry 
a mutant VAP allele the justification for researching VAP proteins in relation to this 
disease increases. Although currently only a few cases of ALS have been attributed to 
VAP it is likely that many more will be found, perhaps in the upstream regulatory 
sequences that could disrupt the proper translation of VAP (Scheper et al. 2007).  Such 
regions are rarely analysed during large scale screening of ALS patients (Conforti et al. 
2006) so these mutations have yet to be found.  With the identification of another VAP 
mutation linked to ALS and the lack of progress in the SOD1 mutant models, hopefully 
more resources will be put into the discovery of more VAP mutations in ALS patients. 
 
9.3 Unfolded proteins and ER Stress 
 
A significant finding in our model of ALS, following the over expression of DVAPT48I 
either pan neurally or in the muscle, is the fragmentation of the ER and the upregulation 
of HSP70 (see figures 3.5 and 3.6).  Under normal conditions, proteins destined for 
secretory pathways are translated at the ribosomes of the rough ER and are moved into 
the ER lumen where they undergo proper folding and post translational modifications 
before translocating to the Golgi (Bukau et al. 2006; Szegezdi et al. 2006).  ER 
chaperones are required for the correct folding and organisation of protein subunits and 
the internal climate of the ER is carefully maintained in order to prevent mis-folding and 
the formation of aggregates (Boot-Handford and Briggs; Bukau et al. 2006; Szegezdi et 
al. 2006).  However, when mis-folding occurs, chaperones are in place to aid the correct 
refolding or if necessary, the removal of proteins to ER associated degradation (ERAD) 
by way of the 26S proteasome (Bukau et al. 2006). The careful environmental control 
necessary in the ER means that it is vulnerable to a number of environmental insults 
 142
including energy deprivation, altered Calcium levels, redox status, gene mutations, 
elevated protein traffic and altered post translational modifications (Szegezdi et al. 
2006). In response to the accumulation of misfolded proteins (ER stress) the unfolded 
protein response (UPR) is activated which initiates a cascade of events designed to 
regain control of the system.  The three ER stress sensors are Inositol requiring enzyme 
1 (IRE1), Protein kinase-like ER kinase (PERK) and Activating transcription factor 6 
(ATF6) (Boot-Handford and Briggs; Malhotra and Kaufman 2007). Together these 
proteins bring about a reduction in protein synthesis, an increase in chaperone levels and 
an increase in transcription of genes involved in ERAD.   This all helps bring about the 
removal of the accumulated unfolded proteins but if in cases of an inability to solve the 
defect, prolonged UPR induces programmed cell death (apoptosis).   The mutation in 
VAP and the formation of aggregates is understandably associated with an increased 
HSP70 level and fragmentation of the ER.  The impact that the sequestering of wt VAP 
has on its interacting proteins must also impact upon the ER as an increase in Ceramide 
levels in the ER will disrupt the homeostatis of this organelle also (Wang et al. 2009b).  
The upregulation of HSP70 has been shown in a number of disease models to delay 
onset of disease symptoms by stabilizing mutated proteins and allowing some wt 
function (Mayer and Bukau 2005).  As part of the aging process however, the ability of a 
cell to respond to ER stress is reduced and this might explain the late age of onset in a 
number of neurodegenerative diseases (Calderwood et al. 2009).  If ER stress has a 
major role in such diseases, the age-related decline in UPR will lead to cells being 
overwhelmed by aggregating proteins and any other environmental insults on the ER 
bringing about cell death. 
 The reasoning behind the aggregation seen in our VAP model of ALS is possibly 
due to an increased propensity of the mutant protein to dimerise, especially with the wild 
type protein.  We utilized the ability of VAP to homodimerise in an attempt to 
understand how the mutation affects the biochemical properties of both the Drosophila 
and human proteins by yeast two-hybrid.  
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9.4 Yeast two hybrid binary interactions 
9.4.1 Homodimerisation of VAP 
 
By yeast two-hybrid I have confirmed that DVAP has the ability to homodimerize and 
can interact both with wild type and mutant DVAP (figure 4.1).  Homodimerisation is 
likely to be a necessary action for this protein to function and in agreement with this I 
and others have shown that the human and other mammalian proteins can also form 
dimers (Kanekura et al. 2006; Teuling et al. 2007).  Previous studies have yet to find the 
yeast homologue Scs2p in dimeric form so this is perhaps an evolutionary advancement 
in the protein and a comparison of structural composition can give a clue as to the 
domains responsible for this interaction, as discussed below (Loewen and Levine 2005).  
The ability of the mutant proteins to homodimerise fits with theories about the 
implication of the mutation as rather than being a loss of function it is likely to cause the 
protein to gain a new function or be a hypermorphic allele.  The current hypothesis 
adopted by our lab is that the mutation increases the strength of interaction, in particular 
with the wt protein and brings this into aggregates, thereby removing DVAP from its 
normal localisation.  This mode of action is similar to a dominant negative mutation as 
despite the mutant protein retaining some of its wt functions, its presence disrupts the 
cells by decreasing the activity of the wt DVAP.   
Following the creation of our Drosophila model for ALS using DVAPP58S a 
number of groups have supported our hypothesis and present a dominant negative role 
(Teuling et al. 2007; Ratnaparkhi et al. 2008; Tsuda et al. 2008).  All report the 
sequestering of wt VAP into aggregates in the presence of the mutant protein.   Perhaps 
the pioneering research into the implication of the disease mutation was reported prior to 
our model in 2006 by a group looking at the affect of the mutation on the interaction of 
VAP proteins using cell culture and GST pull down (Kanekura et al. 2006).  Their 
findings are consistent with those reported here as they too found that the VAPBP56S 
mutant protein retained its ability to be homodimerized and proposed that the P56S 
mutation enhances the propensity for this interaction as seen by an increase in signal by 
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GST pull down.  In a truncated protein missing the transmembrane domain Kanekura et 
al report a weak interaction with a full length protein and this is greatly enhanced by the 
P56S mutation.  No such interaction was seen in the truncated protein of my yeast two 
hybrid but this is perhaps due to the size of the region removed and the different system 
used as the pull-down reported here is only very slight when the wt protein is truncated 
(Kanekura et al. 2006).  If the MSP domain has a slight ability to homodimerise it might 
affect the dimerisation of the whole protein when mutated and increase the propensity 
for the wt and mutant protein to interact.  Of course the C.elegans major sperm protein 
dimerises to form the actin like structures that propel the sperm forward and some of this 
ability may be retained in the domain of VAP (Tarr and Scott 2005).  Our data however 
implicates the C-terminal portion of the protein as being ultimately responsible for the 
homodimerization and the decrease in pull down in the wt VAP∆TM protein supports 
this (Kanekura et al. 2006).    
A study in 2000 looked at various transmembrane domain motifs and found the 
sequence GxxxG to be particularly common with reference to the ability of a protein to 
homodimerise (Russ and Engelman 2000).  Table 2 of the report by Russ and Engelman 
(2000) identifies various amino acid combinations which have a strong association with 
dimerisation and of particular interest is the sequence featuring the large side chain 
residues of Valine, Leucine and Isoleucine alongside Glycine as this is exactly what is 
present in the human transmembrane domain and similar to the Drosophila.  In 
Drosophila the homologous first Glycine residue is replaced by a Serine and both these 
amino acids are small in size (Figure 9.1).  Whether it is this slight difference of the 
motif between these two species that causes a lack of interaction or the inability for the 
two regions to join as a consequence of an overall incompatibility in size and shape of 
the proteins as a whole is something unanswered here but it is evident that this slight 






MSP Domain CCD TMD
hVAPB    FKVK  T TAP--YCVR P NSG 
DVAP      FKI K   T TAP--YCVR P NIG 
SCS2        FKVK  T TAP--YCVR P NAA 
MSP78     YGI K  TTNM--LGVD P PCG  
hVAPB    FFIVGVI I GKIAL 
DVAP      AAIVSLLLGKFFL 
SCS2        ILVLGWFYR- - - - 












Figure 9.1  Primary organization of VAP 
Diagram showing the primary organization of VAP homologues from human, Drosophila, and 
yeast.  The MSP domain shows a high degree of conservation between species and compared to 
the original Major sperm protein of C. elegans (MSP78).  Highlighted in red are the two current 
mutated residues, T46/48 and P56/58.  The transmembrane domain contains the GxxxG motif in 
blue. Adapted from (Lev et al. 2008). 
 
 
Many Drosophila models of disease have utilized the ability to express human genes in 
the fly and have proved invaluable in the progression of research in these diseases 
(Bonini and Fortini 2003; Cha et al. 2005; Greene et al. 2005).  However the data 
presented here highlights a potential problem.  If the possibility to express a mutation 
form of the endogenous Drosophila gene is available it may often be preferable as the 
foreign protein may not be able to recapitulate all the hallmarks of a disease due to an 
incompatibility within the system.  Here we have previously shown that hVAP can 
rescue the null mutant which would indicate a full functional interchangeability but for 
such a disease model where an interaction with wt endogenous protein is so important, 
the human protein could not have been used in the model.  Of course when the 
homologue in flies is unknown or perhaps has a very different primary sequence the use 
of human transgenes will always continue but it is a potential pitfall that should be 
acknowledged both in the fly world and other model organisms.  Certainly in our case, 
the model expressing DVAPP58S has recapitulated the major hallmarks of ALS 
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remarkable well and provided a good example against which to test the new T48I 
mutation and any other mutations that may later be found. 
In support of a growing amount of research, we find that the two mutations do 
not negatively interfere with the interaction of VAP with itself (figure 4.1). It is possible 
that the interaction is actually strengthened which may be tested in the future by 
methods such as GST pull down that provides results that can be quantitatively 
measured.   However, perhaps more importantly is the effect of the mutations on the 
interaction with other proteins.  Initially in agreement with the finding that DVAPP58S 
can rescue the null DVAP mutant fly was the finding that mutant VAP can still interact 
with the lipid phosphatase Sac1 (Figure 5.1).  The C terminus of DVAP retains this 
interaction which is perhaps expected if the necessary domain for interaction is away 
from the site of mutation in the MSP domain.  An understanding of the domains 
involved in various interactions with respect to the position of the mutated residues will 
give us some idea as to the impact the mutation should have on the interactions the 
protein forms. 
 
9.5 Implication of VAP mutation on the function of Sac1 
 
The exact domain of DVAP that interacts with Sac1 is currently being investigated by 
further yeast two hybrid studies.  As described previously however, the potential effect 
of the maintenance of interaction following aggregation is of two categories both leading 
to a similar conclusion.  Firstly Sac1 might be sequestered into the aggregates and 
removed from its site of action. Secondly, due to the removal of VAP away from the ER 
despite the ability to bind to VAP, the spatial barrier will mean that Sac1 will lose its 
binding partner and as such will have a reduction in function as a consequence of the 
loss of wt VAP.  Both these scenarios will have a similar effect as both might be likened 
to a Sac1 loss of function and only by understanding the role of Sac1 can the potential 
effect of this on the cell be fully appreciated.  Co-staining of cells expressing mutant 
VAP and Sac1 will need to be undertaken in order to examine the localisation of Sac1 in 
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mutant cells.  An antibody is currently being created in order to look at the localisation 
of endogenous Sac1 in wt and mutant cells. 
 
9.5.1 Current research of the role of Sac1 
 
Sac 1 is a lipid phosphatase that dephosphorylates Phosphoinositide Phosphates (PIPs) 
to produce PIs  that have been implicated in various roles including cytoskeletal 
organization, vesicle trafficking and apoptosis (Liu et al. 2008a).   In Drosophila Sac1 
plays a key role in dorsal closure (DC) and is a negative regulator of JNK activity (Wei 
et al. 2003a). The JNK MAPK cascade in Drosophila is necessary for the assembly of 
actomysin contractile apparatus and controls cell shape change and the transcription of a 
number of genes including members of the transforming growth factor (TGFβ) family 
(Noselli and Agnes 1999).  Null mutations in Drospohila Sac1 results in defects in cell 
shape change with a premature morphogenesis of amnioserosa cells during DC (Wei et 
al. 2003a).   In rats the activation of the JNK cascade has been linked to a decrease in 
glutamate release and an impairment of Long Term Potentiation (LTP) as well as cell 
death in the hippocampus (Minogue et al. 2003).  JNK activation is believed to be the 
downstream effector of Aβ in rat models of Alzheimers disease and degenerating 
neurons of patients have been found to have increased JNK activation.  As a negative 
regulator of JNK activity in flies, Sac1 may have a similar role in mammals.  The 
mutation in VAP may affect the ability of Sac1 to regulate the JNK cascade and this is a 
potential explanation for many of the morphological changes witnessed at the 
neuromuscular junction and it may be causative for the degeneration of motor neurons. 
Results described earlier have shown that reduction in Sac1 causes an increase in the 
size of the synaptic boutons and also causes a degenerative phenotype in the Drosophila 
eye (figure 7.5).   
Sac1 directly affects the formation of PIPs and investigations into the function of 
Sac1 in yeast have shown that Sac1 primarily metabolizes PI(4)Ps that are synthesized 
by Stt4P, a PI-4-kinase.  A study by Foti et al demonstrated that the regulation of this 
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pool of PI(4)P is necessary for vacuole morphology, actin cytoskeleton organization and 
regulation of neutral lipid storage (Foti et al. 2001).  Rapid inactivation of Sac1 in yeast 
is accompanied by dramatic changes in vacuole shape and a null Sac1 mutation partially 
rescues the defects in actin cytoskeleton associated with a Stt4P null mutant.  Stt4 was 
identified as a member of the Scs2p complex adding a further link between VAP 
proteins and the production of PIPs (Gavin et al. 2002). Another study found that 
cellular membrane homeostasis is coupled with the compartmentalization of individual 
PI(4)P-dependent processes and a deficiency in site specific regulation of PI(4)P due to a 
mutation in Sac1 induced defects in endosomal trafficking (Tahirovic et al. 2005). A 
number of studies have looked at the role played by PIPs in exocytosis in mammalian 
neurons and there is evidence that they are necessary for priming of vesicles 
(Wiedemann et al. 1998). In mice the loss of Sac1 causes preimplantation lethality(Liu 
et al. 2008a).  In order to study the mammalian function of Sac1 and the cause of this 
lethality, Liu et al moved into HeLa cell culture and found that the knock down of Sac1 
by RNAi caused a severe disruption of the Golgi and mitotic spindle which leads to cell 
cycle arrest.   Whether it is a disruption of the regulation of the PI(4)P pool at the Golgi 
that is the ultimate cause of the change in its organization is a matter still to be 
confirmed. 
 In yeast, Sec14 encodes a phosphatidylinositol transfer protein (PITP) that is 
required for the formation of Golgi-derived vesicles and a mutation in Sac1 acted as a 
suppressor of a Sec14 mutant phenotype (Hama et al. 1999). This is particularly 
interesting considering that the mouse mutant, Vibrator, which has a reduced expression 
of PITPα, develops a progressive whole body action tremor with selective degeneration 
of neurons of the spinal cord, brain stem and dorsal root ganglia (Hamilton et al. 1997).  
It is not known if mammalian Sac1 also has a genetic interaction with PITP but it was 
found that expression of either of the rat homologues of Sec14 (PITPα or β) could 
rescue the mutant phenotype associated with a knock out of Sec14 in yeast (Nemoto et 
al. 2000).  They also demonstrated that rat Sac1 is the functional homologue of yeast 
Sac1p and as such it is very likely that Sac1 is functionally linked to the role of PITPs in 
mammals. 
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In yeast there is believed to be a number of pools of PIPs which are independent of one 
another.  One particular pool is at the ER and this is controlled particularly by Stt4p and 
Sac1 (Konrad et al. 2002; Tahirovic et al. 2005; Faulhammer et al. 2007; Knodler et al. 
2008).  VAP’s localisation at the ER may be key to this function and its removal may 
have serious implications on the role of Sac1 here.  Also, removal of Sac1 might have 
other affects on the ER and the disintegration of this organelle will greatly affect a 
number of proteins with roles linked here.  Considering that mutations in Fig4, another 
lipid phosphatase involved in the removal of phosphate groups from the 5th head group 
of PI(3,5)Ps, have been recently linked to cases of ALS there is a strong case for the 
further study of these lipid molecules with reference to ALS and other 
neurodegenerative disease (Chow et al. 2007). 
 
 
9.6 DVAPT48I no longer interacts with the FFAT domain protein 
CERT 
 
Research has shown that VAP is necessary for the anchoring of a number of proteins to 
the ER (Amarilio et al. 2005; Kaiser et al. 2005; Kawano et al. 2006; Peretti et al. 
2008).  This is via an interaction of the FFAT motif contained within these proteins to a 
region of positive residues in the MSP domain of VAP.  Such FFAT containing proteins 
include CERT, OSBP and Nir2.  The crystal structure of the VAP-FFAT interaction has 
been solved and the residues necessary for the interaction mapped (Kaiser et al. 2005).  
The phenylalanine within the FFAT tract has extensive Van de Waals contacts with a 
number of VAP residues which create a positive pocket. Crucial residues for this are 
Met 89 and the sidechains of Lys 45, Thr47, Lys 87 and Lys 118. Another screen in 
yeast also found the equivalent residues to be necessary for the FFAT interaction 
(Kagiwada and Hashimoto 2007).  In the rat Orp1 protein sequence, the Ala479 is also 
important interactor and binds VAP in a small hydrophobic pocket created by Val 44, 
Thr 46 and Val54 (Kaiser et al. 2005).  This is particularly of note because it is the 
Thr46 that is mutated in the new ALS 8 patients.  Both residues have hydrophobic side 
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chains but Isoleucine has an extra CH2 which can be expected to disrupt the 
configuration of the pocket.  To a similar extent with regard to the previous mutation, 
the change of the large cyclic structure of a Proline residue for a small polar Serine at 
position 56 in the sequence so close to these important residues is also likely to interrupt 
the binding domain.  These hypotheses were found to be true, at least by Co-IP, as no 
interaction was found for either DVAPP58S or DVAPT48I with DCERT whereas wt 
DVAP showed good co-immunoprecipitation (figure 8.2). In agreement with our data, 
Teuling et al found that following the P56S mutation the interaction between VAPB and 
Nir2 or a number of ORP proteins were lost as seen by pull down assays and mass 
spectrometry (Teuling et al. 2007).  Again a full understanding of the role of these 
proteins is necessary for gaining an insight into the potential problems that such a loss of 
interaction would have in relation to the disease and our model.  Luckily, experiments 
have already been carried out to investigate the effect of a knock down of VAP on the 
localisation of these proteins.  
 
9.6.1 Role of CERT, Nir2 and OSBP 
 
A study by Perretti et al found that upon removal of VAP, the localisation of CERT, 
Nir2 and OSBP at both the ER and the Golgi was affected.  These proteins, involved in 
the synthesis and trafficking of lipids, shuttle between these two organelles and the loss 
of Golgi localisation was attributed to the loss of PI(4)P which is necessary for 
anchoring the proteins via their PH domains (Peretti et al. 2008).  This is important 
considering that Sac1 is a lipid phosphatase and removes the phosphate group from 
PI(4)P.  Disruption of Sac1 is likely to affect the pool of PI(4)Ps at the Golgi and could 
in turn affect the localisation of these proteins.  Over expression of VAP in the presence 
of Nir2 has been shown to affect the arrangement of the ER and is was suggested that in 
some cases, VAP proteins act more as a receptor with the interaction inducing a 
conformational change that in turn affects the organization and positioning of the ER. 
(Amarilio et al. 2005)  The position of the ER is linked to the microtubule network and 
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previously VAP has been shown to affect the organization and stability of the 
microtubules (Pennetta et al. 2002). Amarilio et al find that the presence of Nir3 is 
necessary for the formation of microtubule bundles and it is hypothesized that this could 
act as the bridge between VAP and the microtubules that has been missing up until now.  
OSBP and CERT also have a strong link with VAP and the role at the ER.  In response 
to oxysterol binding or the depletion of cholesterol, OSBP translocates with CERT to the 
Golgi where upon SM synthesis is stimulated (Perry and Ridgway 2006).  OSBP was 
also found to be necessary for the interaction of CERT with VAP at the ER and it was 
hypothesized that both proteins could interact in a heterodimer along with the 
homodimer of VAP.  When examining the FFAT interaction, it was proposed by Kaiser 
et al that interactions formed with VAP may occur in a 2:2 complex (Kaiser et al. 2005).  
If OSBP and CERT interact they may together bind the VAP homodimer and the 
interaction of VAP and CERT is increased when sterol levels are low as sensed by 
OSBP (Perry and Ridgway 2006). 
The production of Sphingomyelin and DAG is tightly regulated at the Golgi by a 
number of negative feedback loops.  DAG is the substrate of the CDP Choline pathways 
which synthesizes PC at the Golgi membrane (Hanada et al. 2009).  Transfer of PI to the 
Golgi from the ER by Nir2 is coupled with the removal of PC to the ER.  This allows for 
the production of PI4P at the Golgi which provides a target for the PH domain of CERT 
and OSBP (Peretti et al. 2008).  OSBP activates CERT and leads to the transfer of 
Ceramide from ER to the Golgi and into the hands of SM synthase which produces SM 
and DAG (Perry and Ridgway 2006).  VAP is a key targeting protein in this system as it 
is necessary for the binding of Nir2 at the ER-Golgi membrane contact sites and upon its 
depletion, a reduction in the levels of PI4P, SM and DAG at the Golgi were all noted 
which can be attributed to a lack of binding of these three FFAT containing proteins 
(Amarilio et al. 2005; Perry and Ridgway 2006; Peretti et al. 2008).  This has an affect 
on the structure and function of the Golgi and causes a decrease in protein transport to 
the plasma membrane, endosome, lysosome and ER (Peretti et al. 2008).   
In our model little has been noted of the Golgi so this is an area of future 
research but the ER is certainly affected and looking at the roles of these proteins it is 
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possible to see how a removal of VAP might also affect the ER.  One aspect will be the 
accumulation of Ceramide at the ER and this has been shown both in Drosophila and 
mice.   Mice that have been bred as double mutants for CERT are embryonic lethal and 
die at E11.5 (Wang et al. 2009b).  Examination of the ER and mitochondria show both 
these organelles to be under stress as inferred from the engorgement and vesiculation of 
the ER and engorgement of the mitochrondria accompanied by functional abnormalities.  
The total levels of ceramide remained unchanged as compared to control animals but the 
levels within the ER and mitochondria were increased suggesting an inability of the 
Ceramide to be transported away from the ER due to a loss of CERT.  The mitochondria 
are believed to receive ceramide directly from the ER via close contact sites through a 
mechanism apparently independent of CERT.  The increased level within these two 
organelles puts them under severe stress as seen by the changes in physiology and 
function.  Despite these problems the mice survive up until E11.5 at which point the 
cause of death is from a malformation of the cardiovascular system due to an 
interruption of the cell cycle and differentiation.  Many downstream targets of the UPR 
are up regulated including eIF2-α which is involved in cell cycle arrest and protein 
translation following ER stress.  Chronic ER stress in these animals is believed to be the 
cause of the cellular disruptions which leads to the embryonic death (Wang et al. 
2009b).   
In Drosophila the knock out of DCERT has a severe effect on lifespan and males 
live between 10-20 days, females up to 30 days. Ceramide Phosphoethanolamine (CPE) 
is the Drosophila analogue of SM and in these mutant flies both the levels of CPE and 
Ceramide are decreased by about 70% (Rao et al. 2007).  This leads to a decrease in 
membrane density causing an increase in fluidity and a susceptibility to Oxygen free 
radicals which react with the membrane lipids to produce lipid peroxidation products.  
The mitochondria is also affected and believed to be under chronic stress which 
compromises function as seen by a reduction in cytochrome C Oxidase activity which is 
also evident in the mouse model (Rao et al. 2007; Wang et al. 2009b).  Such data linked 
to a reduction in CERT could also be expected from a model in which VAP has been 
removed and as such the localisation of CERT, Nir2 and OSBP affected.  The changes in 
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the ER may be both as a direct consequence of the increase in Ceramide levels in this 
organelle and also as a result of the aggregation of VAP.  Teuling et al report that the 
aggregates formed by mutant VAP consist of ER-derived tubular structures and the 
fragmentation seen in our data may indicate a similar process is occurring here (see 
figure 3.5 and 3.6) (Teuling et al. 2007)  In the mouse CERT KO model a number of 
pathways were down regulated in response to the ER stress and one such pathway was 
the JNK cascade which has been mentioned earlier in respect of the role of Sac1 (Wei et 
al. 2003a; Wang et al. 2009b).  Sac1 is a negative regulator of the JNK cascade and it 
might be imagined that following the removal of VAP, the cellular ability to compensate 
for the increase in Ceramide might further be compromised by a lack of other regulatory 
pathways also linked into the role of VAP. 
The role of lipid molecules may be further instigated in the story of ALS by the 
finding that diets high in lipid content are beneficial in ALS and delay disease 
progression (Dupuis et al. 2004; Dupuis et al. 2008).  SOD1 mouse models of ALS 
showed an increased energy expenditure causing the mice to be leaner than their wt 
littermates despite a normal rate of food consumption.  Feeding a fat enriched, high 
energy diet to these mice allowed them to gain weight and actually reversed the 
expression of some denervation markers suggesting a delay in disease progression 
(Dupuis et al. 2004).  In humans, two thirds of ALS patients have been shown to have a 
stable hyper-metabolism which is linked to survival and a number of patients also 
present with hyperlipidemia despite having a lean physique.  Such patients tend to live 
longer (Dupuis et al. 2008). Exactly why this might be the case is unknown but is 
possibly linked to the increased energy expenditure required for regeneration.  
Drosophila is a good system for modeling changes in metabolism as a number of the key 
regulatory pathways are conserved.  The Drosophila fat body can be considered as the 
equivalent to adipose tissue in humans meanwhile there are the oenocytes that have been 
described as hepatocyte-like cells (Bharucha 2009).  A study investigating the role of the 
Ceramide synthase gene named Schlank found that a reduction in the expression of this 
gene caused a reduction in the fat storage of the fat body (Bauer et al. 2009).  Similarly 
over expression caused an increase in triacylglyceride (TAG), DAG and fatty acids 
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(FA).  It could be considered that fat storage will be affected in our fly model if the 
Ceramide transport is disrupted by the loss of CERT localisation to the ER and if so this 
is another key hallmark that can be investigated in our model.  The necessity of VAP in 
the production of Ceramide, SM and other lipid molecules in the cell puts this protein 
right in the middle of this important field of research. 
 
9.7 The role of VAP as an Eph receptor ligand 
 
The extensive knowledge to be gained through a fuller understanding of the interaction 
of VAP with these lipid regulating proteins is just one part of the jigsaw puzzle that is 
ALS.  The afore mentioned interaction with Eph receptors as demonstrated by Tsuda et 
al is also of huge importance as these Tyrosine Kinase receptors and the multiple 
downstream pathways which they regulate are linked to a number of aspects of 
synaptogenesis, synaptic plasticity and axonal guidance as well as angiogenesis and 
neural crest migration (Adams et al. 2001; Klein 2001; Dearborn et al. 2002; Tsuda et 
al. 2008).  In vertebrates there are two types of Ephrin ligand. Ephrin As are membrane 
bound and anchored by glycosylphosphatidylinositol (GPI) and they are the ligand for 
Eph A receptors.  Ephrin B are phosphorylated on cytoplasmic tyrosyls following the 
binding of Eph B receptors (Chin-Sang et al. 1999).   The invertebrate C. elegans has 
only one receptor Vab-1 and four ligands. Vab2/EFN-1 is a GPI-anchored ephrin similar 
to the type A of vertebrates but in sequence they are similar to Ephrin B suggesting that 
this is a common ancestor for the two vertebrate ligands (George et al. 1998; Chin-Sang 
et al. 1999).   Tsuda et al believe the MSP domain of VAP is cleaved and released from 
cells and from evidence in C. elegans it is thought that this domain might act on Eph 
receptors in the surrounding environment.  Considering that our disease model in 
Drosophila has shown a re-organisation of the glutamate receptors postsynaptically and 
a change in the morphology of the synapse, such a role of the MSP domain is very 
exciting. The Eph receptors activate a number of down stream pathways which gives 
them control of an array of cellular mechanisms at the synapse and affect pre and 
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postsynaptically by forward signaling and reverse signaling back to the pre synaptic 
terminal from which they were released (Pasquale 2008; Lai and Ip 2009). They have 
been shown to play a key role in the clustering of AMPA and NMDA receptors in 
mammalian cells and are necessary for the motility of filopodia which precedes spine 
formation during the development of synaptic contacts (Kayser et al. 2008; Lai and Ip 
2009).  Signals sent between pre- and post- synaptic membranes is vitally important for 
the correct formation of connections and  by signaling between neurons a 
communication network is accomplished that allows for the precise pattern of neuronal 
circuitry seen in the nervous system.  If the MSP domain of VAP is cleaved and secreted 
it can be imagined how this might impact upon the formation and homeostasis the 
synapse (Tsuda et al. 2008).  If this signal is removed due to the disease mutation 
causing aggregation of the full length protein and an inability to cleave and release the 
MSP domain then this homeostatic signal would be lost.   
Synapses have a remarkable ability to compensate for the loss of neighbouring 
synapses by the sprouting and formation of new connections (Gillingwater et al. 2006).  
ALS is a late onset disease with symptoms not presenting until past the age of 50 in the 
majority of cases.  Such a pattern of disease might be attributed to a decline in the ability 
of the nervous system to compensate for stress put on the system.  A general age-related 
decline in a number of homeostatic and stress response mechanisms such as the UPR 
and synaptic sprouting may be underlying the late onset occurance of a number of 
degenerative diseases.  Here it could be hypothesized that only after many years does the 
cell become overwhelmed and unable to cope with the aggregation of VAP leading to a 
greater decline in the available wt VAP and a decrease in Eph signaling coupled with a 
build up of Ceramide in the ER. Perhaps it is the stress caused on this organelle and 
others such as the mitochondria and Golgi that overloads the system that has been under 
strain for many years previously and a fairly rapid decline is seen.  The apparent 
multiple roles of VAP proteins means that once the quality control system of the cell 
starts to fail, multiple downstream targets are affected by the loss of VAP and the ER is 
put under further stress so that a fairly rapid deteriorating cycle might occur. 
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This all makes for an interesting hypothesis but it is unlikely that this is the 
whole story and for this reason I carried out the library scale yeast two hybrid. 
 
9.8 Library Scale Yeast two Hybrid Screen 
 
  There are a number of interesting findings in the screen and overall the screen was 
working well as I repeatedly pulled out VAP which shows that I was able to find a 
positive interactor.  However there was a continual problem of finding interactors that 
were in non coding regions of a gene. After a number of repeat platings of a positive 
colony on high stringency AHLT plates, in an attempt to select only for the interacting 
clone, and then the process of extracting the DNA and amplifying it in bacteria and 
sending for sequencing often the sequence received contained only 3’UTR.  All the 
results in table 9.1 and 9.2 contain ORF but not always the whole protein and as such, 
they may be anomalies.  The kit we used was the MATCHMAKER GAL4 Two-Hybrid 
System 3 from Clontech with the Drosophila melanogaster embryo MATCHMAKER 
cDNA library as we wanted to use DVAP as the bait protein.  The average length of 
cDNA in the library was known to be 1.4kb ranging between 0.5-3kb which means that 
a lot of the cDNA is truncated which is a problem as in addition to getting false 
positives, we will also miss interactions that require the full length protein such as Sac1.  
There is now a human library available in which new SMARTTM cDNA synthesis 
technology has been used to obtain longer lengths of cDNA and this will hopefully 
prove to be better if another yeast two hybrid screen were to be undertaken (Clontech).   
 Despite the problems, a number of the results look promising and will be 
investigated in due course.  Proteins will be selected on the basis of length of the 
interacting cDNA, the knowledge about the interactor and the available tools including 
antibodies and Drosophila stocks and finally on the link between said protein and roles 
in which VAP is believed to play.  A genetic enhancer suppressor screen for the 
degenerative eye phenotype of VAP was carried out by Andrea Chai and any overlap in 
results will greatly increase the likelihood of a meaningful interactor.  Already one such 
 157
interactor is Bangles and Beads which is believed to be involved in gliogenesis due to 
the pattern of expression but there is little further information known 
(www.flybase.com).  A known co-localisation of proteins with VAP will also make an 
interaction more trustworthy, an example being FIT2, an ER localised protein that is part 
of a conserved family involved in the accumulation of lipid droplets (Kadereit et al. 
2008).  A number of proteins are being confirmed as co-localising with lipid droplets in 
Drosophila and we believe DVAP to be one of them (data not shown).  Important tools 
will include stocks containing P-element insertions or mutations that disrupt the gene of 
interest, full length cDNA to enable the cloning of the gene into Drosophila 
transformtation vectors and antibodies against the protein.  Such time saving tools would 
allow for the quick identification of important interactions and likewise the ability to 





















Chapter 10: Future Prospectives 
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Chapter 10.1: Looking to the future 
 
In order to advance our understanding of the disease pathomechanism of ALS and other 
neurodegenerative diseases it is vital that we dissect out the sequence of events that 
leads to the phenotypes observed.  Drosophila is a perfect tool for looking for genetic 
interactors that affect the disease phenotype and we have a number of well characterised 
phenotypic markers including the degeneration of the eye, larval locomotion, aggregate 
formation and ER fragmentation (Chai et al. 2008).  Already Andrea Chai has carried 
out a screen for genetic modifiers of the degenerative eye phenotype by using a kit of 
deficiency lines composed of flies carrying various P element insertions that disrupt 
various numbers of genes.  Here I have carried out a library scale yeast two hybrid in an 
attempt to find genes involved in ALS by the direct interaction with DVAP and this has 
produced a long list of proteins possibly involved in the function of DVAP.  Taking the 
list of interactions that resulted from the library yeast two-hybrid screen and 
transforming it into a comprehensive list of suitable targets for future study is the next 
step to be undertaken. By investigating the tools and knowledge available for each 
interactor a shortlist can be created that can then be used to target our attempts to 
uncover the pathways in which DVAP acts and the events that lead to degeneration.  A 
few of the genes are discussed here but there are many genes that may be worth further 
investigation, including those that have yet to be characterised. 
One of the first interacting proteins found in the screen was CHOp24.  This is a 
member of the p24 family of proteins which are type 1 integral membrane proteins 
involved in intracellular trafficking between the ER and the Golgi (Carney and Bowen 
2004).  The expression pattern for CHOp24 during larval development up until 
adulthood is ubiquitous in all tissues examined and the sub cellular localisation is at the 
ER which makes this a plausible interaction (Boltz et al. 2007).  An investigation into 
the feasibility of further researching this protein in relation to DVAP presents some 
promising data.  CHOp24 (CG3564) is present on the X chromosome at position 4C7 
and it is composed of three exons (Flybase).  The Bloomington Stock Center holds two 
available stocks that have piggybac insertions within  the 5’ UTR of CHOp24 named 
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PBac(RB)CHOp24[e04526] and PBac(RB)CHOp24[e04567].  It is possible that these 
will disrupt the gene and provide an opportunity to study the function of this protein in 
Drosophila.  There is also an RNAi line available from the Vienna Drosophila RNAi 
Centre (VDRC) termed w[1118]; P(GD3225)v7039.  I believe it would be worthwhile 
obtaining these stocks and observing the resulting phenotype from the disruption of the 
gene.  If results are promising, the creation of a UAS-CHOp24 should be undertaken in 
order to look at the effect of over expression.  It is likely that the various hallmarks of 
disease seen in our Drosophila model are due to a number of different downstream 
targets and it would be expected that the involvement of an interacting protein such as 
CHOp24 might be to contribute to subset of the phenotypic markers. 
FIT2 (CG10671) is a promising interaction by way of its proposed involvement 
in lipid storage (Kadereit et al. 2008).  Similarly to VAP it is located at the ER where it 
is believed to enhance the partitioning of trigylcerides into lipid droplets (Kadereit et al. 
2008).  FIT2 is present on the third chromosome (3L) at position 64C7 and is composed 
of 2 exons (Flybase).  There is unfortunately no P-element insertion within the open 
reading frame of this gene but there are two insertions available at the extreme 5’ UTR.  
These may be useful as they may still interfere with the translation of the gene or, if not, 
they could possibly be jumped further into the gene by a phenomenon known as local 
hopping (Zhang and Spradling 1993).  By crossing a P-element insertion line with a 
stable source of transposase the resulting mobilization of the P element occurs in the 
germline of females and this transposition tends to occur within integration sites nearby 
(0-150kb away)  Unfortunately however there is some overlap of the 5’UTR of FIT2 
with 5’UTR of a neighboring gene Aats-ala-m.  Jumping out the P-element may disrupt 
this gene so any phenotype observed will have to be rescued with the transgenic 
expression of wt FIT2 to ensure that it is not due to the disruption of Aats-ala-m, a little 
known protein believed to have alanine-tRNA ligase activity (Flybase).  There are also 
two RNAi stocks available w[1118]P(GD3580)v44435 and w[1118]; P(GD3580)v44433 
that can be used to observe the effect of silencing FIT2 expression. 
Both FIT2 and CHOp24 would certainly warrant further investigation in view of 
the localisation at the ER, an organelle so central to the VAP story.  Yorkie (Yki) on the 
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other hand is a transcription co activator that shuttles between the cytoplasm and the 
nucleus and rather than be selected for its localisation, it is its function as an anti-
apoptotic factor that makes this protein a potentially interesting interactor (Kadereit et 
al. 2008; Wang et al. 2009a). VAP may interact with Yki in the cytoplasm and 
disruption of this pathway, especially the retention of Yorkie away from the nucleus in 
aggregates, could cause cell cycle arrest and induce apoptosis. There are a number of 
Drosophila P-element insertion lines for Yki (CG4005) including PBac(WH)ykif06249  
from the Harvard stock centre and Mi(ET1)ykiMB09079 available from the Bloomington 
stock centre.   The gene is located on chromosome 2R, consisting of 5 exons and is free 
from overlap with other neighboring genes (Flybase). There are a number of UAS-Yki 
lines that have been created and are available from the Bloomington stock centre 
including UAS-Yki-GFP  and there is also an RNAi line available from the VDRC 
W[1118];P(GD11187)v40497/TM3   Finally an antibody has been raised in rabbits 
against Yki (Oh and Irvine 2008) allowing the localisation to be observed in vivo which 
will make it possible to check for the co localisation with VAP.  The availability of so 
many tools makes for a very promising project and the immediate confirmation of the 
interaction with VAP by Co-IP, GST pull down or co-localisation should be undertaken. 
As described in the results section 9.2 it was not possible to reproduce the 
interaction for DVAP with the full length cDNA for Coracle and PioPio.  However it 
may be worth pursuing these interactors as the respective roles in glutamate receptor 
anchoring and tracheal system formation make these proteins very interesting (Chen et 
al. 2005; Paul and Beitel 2005).  The tracheal system of Drosophila has been used as a 
tool for the study of angiogenesis and a link between angiogenesis and ALS has been 
found in patients (Storkebaum et al. 2004; Lambrechts et al. 2006).  Piopio is on 
Chromosome 2R and there are two available insertions from the Bloomington stock 
centre located within the 5’UTR (Flybase), w1118; PBac{WH}piof04210 and w1118; 
Mi{ET1}pioMB03570 that may themselves disrupt the gene or by jumping out by 
imprecise excision could lead to null mutants.   Again there is also an RNAi stock w1118; 
P{GD4824}v12877/TM3 that is available from VDRC.  An antibody has been raised 
against Piopio (Jazwinska et al. 2003) and if a colocalisation with VAP can be 
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confirmed this would support the continuation of this project.  Similarly an antibody is 
available against Coracle (Fehon et al. 1994) that can be used to check for a 
colocalistion with VAP prior to obtaining P element insertion lines that are available 
from Bloomington and Harvard Stock Centers and the VDRC.  Despite the lack of 
interaction of the full length protein in yeast cells an interaction should be obtainable by 
Co-IP or GST pull down and this should be attempted. 
From the library scale yeast two hybrid I had hoped to pick up OSBP as this is a 
well known interactor of VAP and CG1513, a Drosophila gene with high homology to 
the mammalian OSBP, was identified as a DVAP interactor in a genome wide yeast two-
hybrid screen (Giot et al. 2003).  Another Drosophila homolog is CG6708 which 
interacts with farinelli, a VAP homologue found only in the male testes 
(www.thebiogrid.com). The previous interaction with DVAP makes CG1513 a lucrative 
gene for further study but the genomic region is very complex as there are 15 exons and 
two other genes are present within the first two introns (Flybase).  These two genes are 
CG30008 and CG12923 and although CG12923 is only expressed in the adult testes, 
CG30008 is ubiquitously expressed and believed to have a role in fatty acid synthesis 
(Szafer-Glusman et al. 2008).  Any P elements or mutations within this region must be 
verified as causing phenotypes directly linked to the interuption of CG1513 by rescuing 
the phenotype with wt CG1513 cDNA.  As it is, there is an insertion within the third 
exon from the 3’ of CG1513 which falls within the putative Oxysterol binding domain 
(Levine and Munro 2001) so may significantly affect the function of the protein PBac 
CG1513c05643 (Minogue et al.).  There are also some P elements inserted 1.4 kb 
downstream that could be jumped into the gene by local hopping transposition 
P(lacW)l(2)k06204k06204.  Previous attempts of obtaining full length cDNA from the 
BDGP were unsuccessful so this interaction has not been confirmed as yet but as it is so 
well conserved in other organisms it should warrant some further investigation if 
possible (Wyles et al. 2002; Wyles and Ridgway 2004).  The interaction with OSBP 
occurs through the FFAT domain and the conservation of the DVAP-CERT interaction 
and the effect of the DVAPT48I mutation make this a very interesting interaction.  
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The increasing understanding that ALS is more than a disease of the motor 
neurons and actually affects a number of systems (multisystemic), means that the search 
for potential candidates involved in the disease pathomechanism widens.  Only when a 
full knowledge of the pathomechanism of disease is gained and all the contributing 
factors have been realized can there be hope of substantial advancements towards a 
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